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Today, amphibian extinction rates are rising at an alarming rate. Captive assurance
colonies have become a hedge against extinction, and often must employ assisted reproductive
technologies (ART) in species that do not readily breed in captivity. One technique that can be
utilized in assisted breeding is hormone therapy, which involves the treatment of individuals with
exogenous reproductive hormones. The primary delivery method used in most breeding
programs is intraperitoneal injection, but many institutions either lack the training necessary to
conduct this invasive procedure, or require veterinary staff to perform them, thus delaying
breeding events. Therefore, there is interest in alternate means of hormone delivery. In particular,
the use of intranasal administration. The following studies were conducted to determine the
efficacy of hormones administered via alternate delivery routes, and to investigate the pathways
taken by both intraperitoneal and intranasal delivery methods. Through these studies, we found
that intranasal administration gonadotropin releasing hormone (GnRH), is effective at eliciting
sperm production in male anurans. In order to investigate the paths taken by intraperitoneal and
intranasal GnRH, I used a treatment of hormone-conjugated quantum dot nanoparticles and
employed both in-vivo fluorescence imaging techniques and histological imaging. The evidence

presented here suggests that the route traveled by nasally-delivered GnRH is largely swallowed
and accumulates in the GI tract, but eventually diffuses into the bloodstream in large enough
concentrations to exact a reproductive response. The other hormone investigated here was
arginine vasotocin (AVT), a hormone known to elicit calling and amplexus behaviors in
amphibians. Though limited reproductive behaviors were observed in these studies, I found that
both intranasal and intraperitoneal delivery of AVT resulted in water uptake and retention in
males. Fluorescence imaging revealed that AVT, when administered nasally, is largely
swallowed, similarly to GnRH. Intraperitoneally-injected AVT, however, was found to
accumulate in large concentrations within the interrenal gland and kidney, where it likely
stimulated the observed osmoregulatory effects. This study therefore offers insight into an
effective alternate hormone delivery method (nasal) and provides compelling evidence into the
organs wherein GnRH and AVT act following two different delivery routes.

DEDICATION
I would like to dedicate this thesis to my family and friends, who have supported me
through all of the blood, sweat, and tears of this grueling but oh so rewarding process. Included
in this is my advisor, Carrie Vance, for taking a chance on a kid who wanted to go in a
completely different direction than this lab has ever been taken, and for trusting and supporting
my decisions over these many years. I also must include a dedication to Beth Roberts, who let an
enthusiastic husbandry volunteer look through her microscope and opened the door to the world
of reproductive physiology in herpetofuana. I would also like dedicate this work to my husband,
who not only cheered me on during my time in graduate school, but who kept me comforted me
through the sleepless nights and made sure I always ate and eventually slept. Finally, this
dedication would not be complete without acknowledging my father, who not only supported me
through my undergraduate degree, but also pushed me forward during this program with his
obvious pride and encouraging sense of humor. I couldn’t have made it without each and every
one of you.

ii

ACKNOWLEDGEMENTS
I would like to express my infinite gratitude again to my advisor, Carrie Vance, as well as
Andy Kouba, who saw something special in me and set me on graduate school course and career.
I would of course also like to thank the rest of my committee: Scott Willard, for his constant
support and knowledge of the inner workings of the university, Jean Feugang for introducing me
to the amazing world of nanotechnology, and David Kabelik, whose support and mentorship
helped me not just through my graduate career, but throughout my undergraduate degree.
I want to thank my fellow graduate students Kristen Counsell, Amanda Gillis, Mariana
Santos-Rivera, Qingyu Sheng, Isabella Burger, Shaina Lampert, and Devin and Li-Dunn Chen.
My experience would not have been the same without their encouragement, humor, knowledge,
and solidarity.
Finally, I would like to thank all of my laboratory assistants and undergraduate student
mentees, including Andrew House, Lauren Agcanas, Addison Hoven, Auriana Tucker, Rachael
Feeney, Rand Henderson, Mars Leon, and Norman Lewis. Their dedication to animal care and
experimental assistance has been instrumental to the completion of this dissertation, and I am
forever grateful.

iii

TABLE OF CONTENTS
DEDICATION ................................................................................................................................ ii
ACKNOWLEDGEMENTS ........................................................................................................... iii
LIST OF TABLES ......................................................................................................................... ix
LIST OF FIGURES .........................................................................................................................x
CHAPTER
I.

INTRODUCTION: NANOPARTICLES AS A GUIDING LIGHT IN AMPHIBIAN
REPRODUCTIVE PHYSIOLOGY ............................................................................................ 1

II.

LITERATURE REVIEW ............................................................................................................. 1

Amphibians........................................................................................................................1
The Anuran Families: Ranidae and Bufonidae ...........................................................1
The Amphibian Extinction Crisis and threats to amphibian species .................................3
Amphibian Extinction Crisis .......................................................................................3
Habitat loss and climate change ..................................................................................4
Disease .........................................................................................................................5
Anuran reproduction ..........................................................................................................6
Endocrinology of reproduction in anurans ..................................................................6
Females ........................................................................................................................7
Males .........................................................................................................................8
Mating strategies and seasonality ..............................................................................10
Gonadotropin releasing hormone (GnRH) ......................................................................12
Structure and synthesis ..............................................................................................12
Receptors ...................................................................................................................15
Action within the central nervous system .................................................................16
Action within the periphery .......................................................................................18
Exogenous effects ......................................................................................................19
GnIH and kisspeptins ................................................................................................20
Arginine vasotocin (AVT) ...............................................................................................22
Structure and synthesis ..............................................................................................22
Receptors ...................................................................................................................23
Action within the central nervous system .................................................................25
Action within the periphery .......................................................................................26
Oviducts and testes ....................................................................................................28
iv

Exogenous effects ......................................................................................................28
Hormone administration routes .......................................................................................29
Intraperitoneal injection.............................................................................................31
Intranasal administration ...........................................................................................31
Biological imaging ..........................................................................................................33
Nanoparticles and quantum dots .....................................................................................39
Nanoparticle structure ...............................................................................................39
Uses in medicine and science ....................................................................................39
Toxicity concerns ......................................................................................................41
Quantum dot nanoparticles ........................................................................................44
References .......................................................................................................................48
III.

UPTAKE, INTEGRATION, AND DEVELOPMENT OF AMPHIBIAN LARVAE
FOLLOWING EXPOSURE TO QUANTUM DOT NANOPARTICLES ............................... 63

Introduction .....................................................................................................................63
Materials and Methods ....................................................................................................67
Larval care .................................................................................................................67
Nanoparticle exposure ...............................................................................................68
Experiment 1: Rate of QD uptake .................................................................68
Experiment 2: Effects of QDs on fertilization rates, early
development, larval mortality, and metamorphosis ..........................69
Experiment 3: QD retention ..........................................................................71
IVIS imaging .............................................................................................................71
Histology ...................................................................................................................71
Spectral analysis ........................................................................................................72
Developmental tracking.............................................................................................72
Statistical analysis .....................................................................................................72
Experiment 1: QD uptake ..............................................................................73
Experiment 2: Larval development and survival...........................................73
Experiment 3: QD retention ..........................................................................74
Results .............................................................................................................................75
Experiment 1: Rate of uptake of QDs by larvae........................................................75
Experiment 2: Effects of integrated unconjugated and hormone-conjugated
QDs on early larval development, mortality, and metamorphosis rate .........77
Larval mortality over time .........................................................................................79
Metamorphosis by stage of exposure ........................................................................80
Juvenile weights over time across treatments ...........................................................82
Organ retention of QDs by treatment and developmental stage................................84
Discussion........................................................................................................................90
Conclusions .....................................................................................................................96
Acknowledgements .........................................................................................................96
References .......................................................................................................................97

v

IV.

NASAL ADMINISTRATION OF GONADOTROPIN RELEASING HORMONE
(GNRH) ELICITS SPERM PRODUCTION IN FOWLER’S TOAD (ANAXYRUS
FOWLERI)............................................................................................................................... 102

Introduction ...................................................................................................................102
Materials and Methods ..................................................................................................105
Animals....................................................................................................................105
Hormone treatment comparison on sperm production ............................................105
Spermic urine collection over time and sperm analysis ..........................................106
Data evaluation and statistical analysis ...................................................................106
Results ...........................................................................................................................107
Number of responders and latency to sperm production .........................................108
Sperm motility over time .........................................................................................110
Sperm concentration over time ................................................................................113
Discussion......................................................................................................................116
Conclusions ...................................................................................................................121
Acknowledgments .........................................................................................................121
References .....................................................................................................................122
V.

IN-VIVO MAPPING AND BIOACCUMULATION OF GNRH-CONJUGATED
QUANTUM DOT NANOPARTICLES IN A MODEL ANURAN SPECIES ....................... 126

Introduction ...................................................................................................................126
Materials and Methods ..................................................................................................129
Study animals ..........................................................................................................129
Hormone administration ..........................................................................................130
Quantum dot administration ....................................................................................130
Collection and analysis of spermic urine .................................................................131
IVIS imaging ...........................................................................................................131
Euthanasia and histology .........................................................................................132
Spectral analysis ......................................................................................................133
Statistical analysis ...................................................................................................133
Results ...........................................................................................................................134
Intraperitoneal vs. intranasal administration of GnRHa ..........................................134
Intraperitoneal vs. intranasal administration of GnRHa-Qdot ................................137
IVIS imaging of Qdots ............................................................................................137
Histology .................................................................................................................140
Oral vs. nasal administration of GnRHa..................................................................144
Discussion......................................................................................................................148
Conclusions ...................................................................................................................151
Acknowledgements .......................................................................................................152
References .....................................................................................................................153
VI.

NASAL ADMINISTRATION OF ARGININE VASOTOCIN (AVT) RESULTS IN
WATER UPTAKE AND RETENTION IN ANAXYRUS FOWLERI .................................. 155

vi

Introduction ...................................................................................................................155
Materials and Methods ..................................................................................................160
Study animals ..........................................................................................................160
Exogenous hormones...............................................................................................161
Experiment 1: Water retention and calling behaviors following nasal
administration of AVT ................................................................................161
Experiment 2: Rate of water uptake following intranasal administration of
AVT .............................................................................................................162
Experiment 3:Water retention following intranasal and intraperitoneal
administration of AVT ................................................................................162
Statistical analysis ...................................................................................................162
Results ...........................................................................................................................163
Experiment 1: AVT-induced water retention and calling .......................................163
Experiment 2: AVT weight retention over time ......................................................164
Experiment 3: Comparison of water retention between intranasal and
intraperitoneal routes ...................................................................................166
Discussion......................................................................................................................169
Conclusion .....................................................................................................................172
Acknowledgements .......................................................................................................173
References .....................................................................................................................174
VII.

A COMPARISON OF NASAL AND INTRAPERITONEAL AVT TREATMENT
PATHWAYS USING QUANTUM DOT NANOPARTICLES ............................................. 178

Introduction ...................................................................................................................178
Materials and methods ...................................................................................................182
Study animals ..........................................................................................................182
Experiment 1: Determination of biological effects of AVT, QD, and AVTQDs ..............................................................................................................183
Experiment 2: In-vivo tracking of QDs and AVT-QDs ..........................................184
Experiment 3: Bioaccumulation of QDs and AVT-QDs .........................................184
Statistical analysis ...................................................................................................185
Results ...........................................................................................................................186
Experiment 1: Determination of physiological effects of AVT-QDs .....................186
Experiment 2: In-vivo tracking of AVT-conjugated QDs .......................................188
Experiment 3: Bioaccumulation of AVT-conjugated QDs .....................................191
Discussion......................................................................................................................197
Determination of biological effects of AVT-conjugated QDs ................................197
In-vivo tracking of AVT-conjugated QDs ..............................................................197
Bioaccumulation of AVT-conjugated QDs .............................................................198
Conclusions ...................................................................................................................202
Acknowledgements .......................................................................................................203
References .....................................................................................................................204
VIII.

CONCLUDING REMARKS.................................................................................................... 206

vii

APPENDIX
A.

COMPARISON OF INTRANASAL GNRHA ADMINISTRATION IN A
RANID SPECIES (LITHOBATES CHIRICAHUENSIS) AND A
BUFONID SPECIES (ANAXYRUS FOWLERI) ...............................................208
Materials and Methods ..................................................................................................209
Results ...........................................................................................................................209

B.

COMPARISON OF INTRANASAL GNRHA ADMINISTRATION TO
TRADITIONAL INTRAPERITONEAL HCG AND GNRHA
COCKTAIL INJECTIONS IN LITHOBATES CHIRICHAUENSIS ...............214
Materials and Methods ..................................................................................................215

C.

EFFECTS OF WILD, SEMI-CAPTIVE, AND CAPTIVE MANAGEMENT
ON MALE REPRODUCTIVE TRAITS FROM THE THREATENED
CHIRICAHUA LEOPARD FROG (LITHOBATES CHIRICAHUENSIS)
...........................................................................................................................218
Introduction ...................................................................................................................219
Materials and Methods ..................................................................................................223
Animals....................................................................................................................223
Exogenous hormone, sperm collection, and analysis ..............................................225
Statistical analysis ...................................................................................................226
Results ...........................................................................................................................226
Discussion......................................................................................................................232
Acknowledgments .........................................................................................................236
References .....................................................................................................................238

viii

LIST OF TABLES
Table 1

Sperm characteristics for Fowler toads treated intranasally with three different
concentrations of GnRH. Data are shown as mean ± SEM. Significant
differences within columns are indicated by lettered superscripts ................108

Table 2

Average number of responders and sperm parameters following intranasal
(IN) and intraperitoneal (IP) administration of 10 µg GnRHa. Data are
shown as mean ± SEM, and significant differences are indicated by *. .......134

Table 3

Male responders and average sperm parameters following intranasal and oral
treatments of 10 µg GnRHa. Significant differences are indicated with
a *. Data are shown as mean ± SEM. ............................................................145

Table 4

Water retention following IN and IP administration of control (PBS),
unconjugated quantum dots (QD), arginine-vasotocin conjugated
quantum dots (AVT-QD) and arginine vasotocin alone (AVT). ...................187

Table 5

Quantum dot concentrations and dosage volumes by treatment and route.
Treatments included control (PBS), unconjugated quantum dots (QD
Alone), vasotocin-conjugated quantum dots (QD AVT) and vasotocin
alone (AVT). ..................................................................................................192

Table 6

Average weights and sperm parameters between ranid and bufonid species ............210

Table 7

Average weight, percentage of responders, motility and concentration between
IP and IN treatments ......................................................................................215

Table 8

Male L. chiricahuensis physiological and response parameters based on
population groups. Parameters include percentage of responders,
forward progressive sperm motility, total motility, and sperm
concentration following intraperitoneal (IP) ..................................................229

ix

LIST OF FIGURES
Figure 1

General bufonidae and ranidae physical and gametic differences. Ranid A)
anatomy; B) frog spawn, laid in clumps, C) frog sperm; note the short
head. Bufonid D) physiology, E) spawn, laid in strands, F) sperm, note
the mitochondrial vesicle (arrow; from Kouba et al. 2003). ..............................2

Figure 2

The basic hypothalamic-pituitary-gonadal (HPG) axis in amphibians.
Hormone cascades are generally stimulated through natural or external
environmental cues, but can be elicited through exogenous hormone
treatments which act at either the level of the brain or pituitary, or
directly at the gonads. ........................................................................................7

Figure 3

Visual example of handling methods for a) intranasal administration and b)
intraperitoneal injection in A. fowleri. Both methods of treatment
facilitate the targeting of the amphibain HPG axis with exogenous
hormones. .........................................................................................................33

Figure 4

The use of ultrasonography as a non-invasive method of detection for
follicular development in female amphibians. .................................................36

Figure 5

The general structure of a quantum dot nanoparticle. Quantum dot
fluorescence emission is determined by its size and subsequent
emissions wavelength. .....................................................................................46

Figure 6

Well map of tadpole treatments in experiment 1. Tapoles were placed in the
first three wells (top to bottom). The first well served as a control with
no QDs while the second two contained 1nM or 2nM of QDs. .......................69

Figure 7

Well map of tadpole treatments by Gosner stage and experiment number: 2
(A) and 3 (B-D). Numbers reflect number of eggs or larvae/treatment
in each well. .....................................................................................................70

Figure 8

Loss of fluorescence (Total flux) from wells over time normalized against
control (A) and time-lapse image of decreasing visible fluorescence
intensity in assay-wells at 0 hrs, 0.5 hrs, 1 hrs, 2 hrs, 24 hrs, and 48
hrs. (B). Well 1 contained control treatment, Well 2 contained 1 nM
treatment, and Well 3 contained 2 nM treatment. ............................................76

x

Figure 9

EVOS fluorescence imaging validation of unconjugated QD retention
following uptake from assay wells in sectioned tadpoles. Fluorescence
signal (red) detected in larval GI tracts at 2, 24, and 48 hours. .......................77

Figure 10 Total percentage of total larvae at developmental stages across treatments
following exposure at fertilization (Gosner stage 1)........................................78
Figure 11 Percentages of living larvae across treatments over time following exposure at
A) Gosner stage 1: fertilization, B) Gosner stage 19: hatch, C) Gosner
stage 25: opening of the mouth, and D) Gosner stage 30: pre-limb bud. ........80
Figure 12 Total percentage of metamorphosed juveniles from free-swimming tadpole
across both QD treatments and Gosner stages of exposure. ............................81
Figure 13 Average weight of metamorphosed juveniles by treatment following exposure
at Gosner stage 30. Data are shown as mean ± SEM.......................................83
Figure 14 Juvenile weights over time following QD treatment exposure at Gosner stage
30. Data are shown as mean ± SEM. ...............................................................84
Figure 15 Visible fluorescence signal surrounding oocytes exposed at Gosner stage 1
from A) unconjugated QDs, B ) AVT-conjugated QDs, and C) GnRHconjugated QDs ................................................................................................85
Figure 16 Visible fluorescence signal from AVT-conjugated QDs (A and B), and
GnRH-conjugated QDs (C and D) surrounding oocytes and embryos at
24 hours post-exposure (A and C) and 48 hours post-exposure (B and
D) at Gosner stage 1. ........................................................................................85
Figure 17 Fluorescence intensity within in the GI tract from GnRH QDs at T24 (A) and
T48 (C) and AVT QDs at T24 (B ) and T48 (D). .............................................86
Figure 18 Visible QD fluorescence within the GI tract in Gosner stage 30 larvae
following exposure to unconjugated QDs at T5 (A) and T24 (D); AVT
QDs at (B ) T5 and (E) T24; and GnRH QDs at (C) T5 and (F) T24. ............88
Figure 19 Presence of AVT-conjugated QDs within the kidney of larvae exposed at
Gosner stage 30 at A) five hours post-exposure and B ) twenty-four
hours post-exposure. Histological analysis was also performed on
metamorphosed juveniles post-treatments, but there was no remaining
fluorescence signal detected by metamorphosis. .............................................89
Figure 20 Fluorescence intensity in the GI tract of larvae exposed at G25 (A&B) and
G30 (C&D) to AVT (A&C) and GnRH (B&D) conjugated QDs at 24
hours.................................................................................................................90

xi

Figure 21 Percentage of males (n = 15/trt) responding to each treatment of GnRH (Panel
A). Average latency (in hours) to spermiation between treatment
groups (Panel B). Data are shown as Mean + SEM.......................................109
Figure 22 Percentage of responding males (n=15/trt), as measured through sperm
production, over time between GnRH treatment groups: 5 µg (), 10
µg (●), and 20 µg (◼). ...................................................................................110
Figure 23 Average total sperm motility over time for males (n=15/trt) between GnRH
treatment groups: 5 µg (), 10 µg (●), and 20 µg (◼). Total motility
is defined as motile (M) sperm + forward progressive motile (FPM)
sperm. Data are shown as mean + SEM. .......................................................111
Figure 24 Average sperm forward progressive motility (FPM) over time for males
(n=15/trt) between GnRH treatment groups: 5 µg (), 10 µg (●), and
20 µg (◼). Data are shown as mean + SEM. .................................................113
Figure 25 Average amount of sperm/mL produced over time by males (n=15/trt)
between GnRH treatment groups: 5 µg (), 10 µg (●), and 20 µg (◼).
Data are shown as mean + SEM. ...................................................................115
Figure 26 Average number of sperm in sample following treatment of GnRH (5, 10, and
20 µg) calculated as sperm/mL, total number of sperm, and total
motile sperm. Different letters indicate significant differences (p <
0.05) within a category. Data are shown as mean + SEM. ............................116
Figure 27 Breadloaf sectioning map ..........................................................................................132
Figure 28 Average concentration sperm released over time for male toads administered
10 µg GnRHa via IN administration (n = 15) (●), and IP injection (n =
12) (■). Data are shown as mean + SEM. .....................................................135
Figure 29 Forward progressive motility (A), and total motility (B) of sperm samples
collected from male toads given 10 µg GnRHa via IN administration
(n = 15) (●), and IP injection (n = 12) (■) over time. Data are shown
as mean + SEM. .............................................................................................136
Figure 30 In-vivo imaging of QD fluorescent signal following (A) intranasal
administration, and (B) intraperitoneal injection of GnRHa-QDs and
unconjugated QDs (Dorsal View). .................................................................138
Figure 31 In-vivo imaging following intranasal administration of (A) GnRHa-QD and
(B) unconjugated QDs prior to treatment and at 1 hour and 24 hour
post-treatment (Ventral view). .......................................................................138

xii

Figure 32 In-vivo imaging following intraperitoneal injection of (A) GnRHa-QD, and
(B) unconjugated QDs, prior to treatment and at 1 hour and 24 hour
post-treatment. ...............................................................................................139
Figure 33 Histological sectioning of toad kidney following IP injection of (A)
unconjugated QDs, and (B) GnRHa-QDs at 24 hours post-treatment.
Yellow circles indicate locations of QD concentration. ................................140
Figure 34 Pathway of bio-accumulation of GnRHa-QD conjugates following nasal
administration. GnRH-QD signal (red) was observed within the nares
(A), mouth (B), tympanum (C), and GI tract (D). .......................................141
Figure 35 Histological sectioning of toad GI tract following IN administration of GnRHa
-QDs at (A) 1 hour, and (B) 24 hours post-treatment. Histological
sections of the kidney following IP injection at (C) 1 hour and (D) 24
hours post-treatment. Yellow circles indicate locations of QD
concentration. Average fluorescence intensity within the GI tract and
the kidney following IN (GI tract) and IP (kidney) treatments (E).
Significance is indicated with *. Data are shown as mean ± SEM. ...............142
Figure 36 Average fluorescence intensity in the kidney from GnRH-QDs and
unconjugated QDs at 24 hours post-exposure. Data are shown as mean
± SEM. ...........................................................................................................144
Figure 37 Percentage of males responding to nasal (●) or oral (▲) GnRHa treatment
over time. .......................................................................................................145
Figure 38 Average concentration of sperm/mL over time following nasal (●) or oral (▲)
GnRHa treatment. Data are shown as mean ± SEM. .....................................146
Figure 39 Average percentage of motile sperm over time following nasal (●) or oral (▲)
GnRHa treatment. Data are shown as mean ± SEM. .....................................147
Figure 40 Average male weights before and after control (PBS) and arginine vasotocin
(AVT) delivered intranasally. Letters indicate significant. Data are
shown as mean ± SEM. ..................................................................................164
Figure 41 Average weight gained over time between control (PBS) and intranasal AVTtreated males over 24 hours. Data are shown as mean ± SEM. .....................166
Figure 42 Average weight change between AVT-treated males following intranasal (IN)
and intraperitoneal (IP) administration routes. Data are shown as mean
± SEM. ...........................................................................................................167
Figure 43 Average weight change over time between AVT-treated males following
intraperitoneal and intranasal administration routes over 24 hours.
Data are shown as mean ± SEM. ...................................................................168
xiii

Figure 44 Diagram of sectioned regions of toads for breadloaf imaging ...................................185
Figure 45 Average water retention across treatments. Weights collected every two hours
for 24 hours. Data shown as mean ± SEM. ....................................................188
Figure 46 IVIS imaging of AVT-conjugated quantum dot visualization over time
following (A) IN administration, and (B) IP injection. .................................189
Figure 47 IVIS imaging comparison of quantum dot movement over time following IN
administration of (A) AVT-QDs, and (B) unconjugated QDs. ......................189
Figure 48 IVIS imaging comparison of quantum dot movement over time following IP
administration of (A) AVT-QDs, and (B) unconjugated QDs. ......................190
Figure 49 Dorsal view of QD AVT IVIS signal at 1 hour and 24 hours after IN and IP
administration. ...............................................................................................190
Figure 50 AVT-conjugated quantum dot bioaccumulation across organs at 1 hour, 12
hours, and 24 hours post intranasal administration. Quantum dots
visualized in red with DAPI blue staining. ....................................................193
Figure 51 AVT-conjugated quantum dot bioaccumulation across organs at 1 hour, 12
hours, and 24 hours post intraperitoneal injection. Quantum dots
visualized in red with DAPI blue staining. ....................................................193
Figure 52 Fluorescence intensity across organs at 1 hour, 12 hours, and 24 hours of
accumulation following intraperitoneal injection. Data are shown as
mean ± SEM. .................................................................................................194
Figure 53 Fluorescence intensity across organs at 1 hour, 12 hours, and 24 hours of
accumulation following intranasal administration. There was no signal
detected from nasally-administered unconjugated QDs. Data are
shown as mean ± SEM. ..................................................................................195
Figure 54 AVT-conjugated quantum dots bioaccumulated in sections of a) the interrenal
gland, b) the kidney, and c) the testes at 12 hours post intraperitoneal
injection. Images on right, from top to bottom, were taken from
Anatomy of the Human Body (Gray, H. 1918), FertilityPedia, and
Notes on Zoology (Bhavya, S).......................................................................196
Figure 55 Demonstration of nasal administration in a) the ranid L. chiricahuensis and b)
the bufonid A. fowleri ....................................................................................210
Figure 56 Distribution of sperm motility between a bufonid species (blue) and a ranid
species (orange) .............................................................................................211

xiv

Figure 57 Concentration of sperm/mL distributions between a bufonid species (blue) and
ranid species (orange) ....................................................................................211
Figure 58 Percentage of sperm total motility between a bufonid and ranid over time ..............212
Figure 59 Concentrations of sperm/mL over time between a bufonid and ranid .......................213
Figure 60 Sperm motility distributions (A) and concentration of sperm/mL (B) between
IP and IN routes in L. chiricahuensis.............................................................216
Figure 61 Average percentage of sperm motility over time .......................................................216
Figure 62 Average concentration of sperm/mL over time between IP and IN routes of
hormone administration .................................................................................217
Figure 63 Percentage of males responding to hormone treatments over time between
wild, semi-captive and captive males ............................................................229
Figure 64 Average sperm concentration/mL (Panel A) and total sperm collected (Panel
B) across the three population groups, Captive, Semi-Captive, and
Wild, over time. Data are shown as mean ± SEM .........................................230
Figure 65 Average total sperm motility (Panel A) and forward progressive sperm (Panel
B) across the three population groups, Captive, Semi-Captive, and
Wild, over time. Data are shown as mean ± SEM. ........................................231
Figure 66 Images of population housing locations. A) Captive, The Fort Worth Zoo; B)
semi-captive, The Ladder Ranch; and C) wild, New Mexico field site .........232

xv

CHAPTER I
INTRODUCTION: NANOPARTICLES AS A GUIDING LIGHT IN AMPHIBIAN
REPRODUCTIVE PHYSIOLOGY
Over 40% of all amphibian species in our world today are considered threatened or
endangered, predominantly due to anthropogenic effects (Stuart et al. 2004). However, while
human influence has negatively impacted these species, it can also have a positive effect.
Through the use of assisted reproductive technologies (ART), we can slow the decline of
amphibian species on the brink of extinction. These technologies include the implementation of
captive breeding programs, reintroduction of captive-produced offspring, genome banking, and
the use of hormone therapies for maximizing reproductive output of breeding animals. Hormone
therapy is perhaps one of the most valuable tools in the ART toolbox, as it is required for both
breeding and gamete storage and cryopreservation. New hormones and routes of administration
are being investigated every year to increase breeding performance and fill cryobanks with
gametes. However, before implementation of new forms of hormone therapies, it is critical that
we understand the safety and mechanisms of action of the hormones and treatment routes.
One means by which these hormone routes and receptors could be investigated is through
imaging experiments. Unfortunately, most methods of imaging do not allow for easy
visualization in live animals, as many fluorescent probes are not visible in deep tissue or research
methods require the euthanasia of test subjects for in-vitro imaging. In order to combat this
limitation, researchers have turned to fluorescent nanoparticles such as quantum dots (QDs).
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Nanoparticles are becoming an increasingly popular tool for in-vivo live animal imaging in the
areas of diagnostics and research for their visibility in deep tissue and resistance to
photobleaching. Nanoparticles, including QDs, can be conjugated to a wide variety of
biomolecules such as hormones. Once conjugated, they provide a means by which to visualize
real-time hormone pathways over multiple time points. This is a major advantage over traditional
imaging methods which often require animal sacrifice at each time point for in-vitro
visualization of hormone movement and binding.
By binding hormones to QDs, we can follow the pathways of reproductive hormones of
interest to ART and differentiate their pathways by type of hormone and route of administration
to better determine the efficacy and usefulness/convenience of novel treatments. However,
before QDs and other nanoparticles can be recommended as a new standard for imaging, it is
crucial to evaluate their effects on living animal systems. Therefore, this dissertation seeks to:
Chapter III: investigate the developmental stages at which amphibian larvae uptake quantum
dot nanoparticles and the potential of QDs to affect subsequent larval development as a way to
better understand a) the potential toxic effects of nanoparticles on developing larvae and b) the
aggregation of reproductive hormones on developing larval systems.
Chapter IV: determine whether or not a novel, minimally invasive intranasal hormone delivery
route is effective at eliciting spermiation in male Anaxyrus fowleri and whether or not sperm
parameters are comparable to those elicited by traditional intraperitoneal injections.
Chapter V: investigate the differences in intranasal and intraperitoneal treatment routes of
GnRHa using quantum dot nanoparticles as a means to inform
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Chapter VI: determine the potential use of arginine vasotocin (AVT) in anuran assisted
reproduction through the investigation of intranasal administrations of exogenous AVT in male
Anaxyrus fowleri.
Chapter VII: differentiate the pathways of intranasal and intraperitoneal routes of AVT
treatment using QDs.
This research serves to expand our knowledge of current assisted reproductive techniques and to
contribute to our understanding of amphibian reproductive biology in an attempt to increase
reproductive output while mitigating the dangers of hormone treatments.
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CHAPTER II
LITERATURE REVIEW
Amphibians
Amphibians are semi-aquatic, ectothermic vertebrates that begin life in a larval state in
water, then metamorphose into an adult following completion of development. Evolutionarily,
amphibians are considered an early and primitive vertebrate species, with their closest related
ancestor being fish. The class amphibia consists of anura, or frogs and toads, caudata, or
salamanders, and gymnophiona, or caecilians. In 2018, the AmphibiaWeb database contained
7,799 species of amphibian, with over 88% of these species classified as anurans. Anuran species
are not only numerous, but are also diverse.
The Anuran Families: Ranidae and Bufonidae
The two primary families of anurans are ranidae, or true frogs, and bufonidae, or true
toads. Ranids are characterized by their smooth, moist skin and powerful back legs for
swimming and jumping. They are also typically localized near water. Bufonids, conversely,
generally have bumpy, dry skin with paratoid glands on their heads which secrete toxins for
defense. They are more terrestrial than ranids, and do not typically have the powerful hindlimbs
of true frogs. There are also differences in the reproduction of each family, most notably gamete
characteristics. For example, ranid eggs are generally larger and laid in clumps of a few hundred,
while bufonid females tend to lay thousands of smaller eggs in interconnected strands (Kouba et
al. 2012). Sperm between the two families also differs. Most notably, bufonid sperm has a more
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narrow head and contains what is known as a mitochondria vesicle. Mitochondrial vesicles are
extracellular vesicles containing mitochondria, which supplies the sperm with energy for
motility. Spermatozoa with non-intact mitochondrial vesicles have been observed to lose motility
(Kouba et al. 2004). Ranid sperm has shorter heads and lacks the mitochondrial vesicle (Fig. 1).
These are, of course, only general differences; there are numerous species-specific differences
within these families as well.

Figure 1

General bufonidae and ranidae physical and gametic differences. Ranid A)
anatomy; B) frog spawn, laid in clumps, C) frog sperm; note the short head.
Bufonid D) physiology, E) spawn, laid in strands, F) sperm, note the mitochondrial
vesicle (arrow; from Kouba et al. 2003).

It is important to note that there are also observed differences in responses to assisted
reproductive technologies between ranidae and bufonidae, and these differences impact ART
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strategies. During in-vitro fertilization, oocytes are often expressed manually from the female. In
ranidae species, the females are unlikely to oviposit without assistance, and eggs can be steadily
expressed. In bufonid females, however, oviposition is often rapid and independent of manual
expression (Kouba et al. 2012). Additionally, the strands in which bufonid females lay are
delicate, and require careful manipulation. Pulling on the strands to express eggs can risk damage
to the eggs and the occurrence of autoactivation. Autoactivation is a process by which oocytes
are artificially activated into development, either by chemical or mechanical means and prevents
fertilization by applied sperm (Toro and Michael 2004). In males, the greatest consideration
during assisted reproduction is perhaps the difference in timing of spermiation responses
between ranidae and bufonidae. In male anurans, treatments of exogenous reproductive
hormones such as human chorionic gonadotropin (hCG) and gonadotropin releasing hormone
(GnRH) result in sperm production and release. In ranid males, sperm production typically
begins at thirty to sixty minutes post-treatment and declines by three hours. Bufonid males,
however, do not begin to produce sperm until between three to five hours, on average, and
continue to produce until approximately eight hours post-treatment (Kouba et al. 2012). Again, it
is important to note that there are species-specific differences in these trends.
The Amphibian Extinction Crisis and threats to amphibian species
Amphibian Extinction Crisis
Today, amphibians are most threatened taxa in the world (Bishop et al. 2012). Since the
1500s, between 0.48% and 3.4% of amphibians have likely become extinct, with the majority of
these having occurred since the 1980s, demonstrating an alarmingly rapid acceleration in
extinction rates (McCallum 2007). Today, over 1/3rd of all amphibian species are considered
threatened with extinction (Stuart et al. 2004). As of 2019, the International Union for
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Conservation of Nature and Natural Resources (IUCN) listed approximately 43% of amphibians
as threatened. There are a number of factors that have been cited as contributing to these
declines, with the majority of them likely man-made, or at the very least, heavily impacted by
human contributions (Velasco et al. 2021). Three of the greatest threats to amphibians today are
habitat loss, climate change, and disease (Stuart et al. 2004; Walpole et al. 2010; Bishop et al.
2012).
Habitat loss and climate change
Habitat loss has also had a substantial deleterious effect on amphibian populations.
Chanson et al. (2008) estimated that 63% of amphibians are affected by habitat loss. The reliance
on clean water sources and specific temperature and soil conditions by amphibians creates a
dependency on niche microhabitats that can be drastically affected following minor
perturbations. Thus, land clearances for farming and human housing can cripple amphibian
habitats and breeding capabilities. Because amphibians are both aquatic and terrestrial, they face
negative effects of habitat loss on more than one front. While adult animals can survive
restrictions in available clean water sources, the loss of clean standing water prevents breeding
events and offspring development, crippling species propagation. The effects of habitat loss are
further exacerbated by the effects of climate change (Bishop et al. 2012). Climate change leads
to events such as changes in weather patterns, which further impede successful breeding and can
have deleterious effects on successful hibernation and food availability. Finally, amphibians are
highly susceptible to biological contaminants. A mentioned, skin is extremely sensitive due to
their ability to breathe and absorb water through it (Bishop et al. 2012). Additionally, their
reliance on aquatic environments for living and reproducing, as well as their external fertilization
methods expose both their gametes and offspring to the external environment (Burlibasa and
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Gavrila 2011). Because they develop in water for extended periods of time, amphibian larvae are
exposed to aquatic contaminants far more than adult animals and these contaminants can cause
serious defects during development such as skeletal deformities and delayed metamorphosis
(Sparling et al. 2005; Lefcort et al. 1998).
Animals have also been removed from the wild for the international pet trade and for
scientific use. While this causes genetic loss from the removal of animals from wild populations,
it has also caused the transfer of disease both into and out of wild habitats. The most devastating
of these has been the chytrid fungus.
Disease
After habitat loss, disease is likely the greatest threat to amphibian species. While there
are numerous diseases that are detrimental to amphibian health, the most virulent and deadly is
likely chytridiomycosis (Skerratt et al. 2007). Chytridiomycosis is a deadly disease caused by the
chytrid fungus, Batrachochytrium dendrobatidis, commonly referred to as Bd. The spread of B.
dendrobatidis has largely been due to human actions. Weldon et al. (2004) claims that Bd had
was first transferred from Africa to non-native international environments by the spread of
Xenopus laevis. In the 1930s, X. laevis were shipped worldwide in the thousands as a human
pregnancy test. From there, many were released or introduced into the pet trade, where Bd has
been able to spread to different species worldwide (Weldon et al. 2004). Chytridiomycosis
infects keratinized areas of the body, such as the skin, and impedes proper osmoregulation and
dermal gas exchange, eventually leading to death (Berger et al. 1998). While chytridiomycosis
is, for the most part, only fatal to adult amphibians, it can be transferred by larval amphibians by
infecting their keratinized mouth parts (Berger et al. 1998). This can make the disease hard to
detect in larval populations, leading to further pathogen dispersal and infection. The rapid
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infection rate and high percentages of mortality of B. dendrobatidis has had crippling effects on
amphibian populations worldwide.
Anuran reproduction
Endocrinology of reproduction in anurans
As in all vertebrate species, anuran brains contain a hypothalamus and a pituitary,
forming the hypothalamic-pituitary-gonadal (HPG) axis which mediates reproductive functions
(Licht, Porter and Millar 1987). Neuroendocrine reproductive pathways are most frequently
defined as the interconnection of the hypothalamic pituitary gonadal axis to the gonads and other
related peripheral organs. These essential structures and pathways are retained across all
vertebrate species. Basic neuroendocrine reproduction pathways begin with stimulation of the
hypothalamus to synthesize and release gonadotropin releasing hormone (GnRH), which signals
the anterior pituitary to secrete the two gonadotropins (GTHs): luteinizing hormone (LH) and
follicle stimulating hormone (FSH). These GTHs are then released into the bloodstream to
various organs in the body, particularly the gonads, where they mediate steroid hormone
synthesis and gametogenesis (Norris and Carr 2013). There are several forms of GnRH across
vertebrate species, with most species exhibiting 3 types of GnRH (Millar et al. 2004). Anurans
are no exception to this finding. Fernald and White in their 1999 study determined that anurans
contain at least two forms. Form one, GnRH1, is mostly found in the POA-hypothalamic area of
the brain and acts on the pituitary to control GTH release. The second form, GnRH2, is found
predominantly within the midbrain to act as a neurotransmitter/neuromodulator. In anurans,
GnRH 1 is presumed to function as the main mediator of gonadotropin control from the pituitary
(Fig. 2). Unlike mammalian gonadotropins, the exact classification of the anuran gonadotropins
has not been determined. It has been established, however, that the two gonadotropins are similar
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to LH and FSH in both structure and function and will be referred to as such for simplicity for
the remainder of this dissertation (Licht, Porter and Millar 1987). In males and females, GnRH
has similar actions in the brain pertaining to gonadotropin release, but subsequent downstream
effects of the released gonadotropins in anurans do, however, differ between sexes.

Figure 2

The basic hypothalamic-pituitary-gonadal (HPG) axis in amphibians. Hormone
cascades are generally stimulated through natural or external environmental cues,
but can be elicited through exogenous hormone treatments which act at either the
level of the brain or pituitary, or directly at the gonads.

Females
In females, gonadotropins target the ovaries. Initial oocyte development and final oocyte
maturation are mediated by FSH and LH, respectively (Vu and Trudeau 2016), by stimulating
the release of estrogens. Within the ovaries, estrogens such as estradiol cause the ovary to grow
and develop through follicular recruitment the initiation of follicular development (Norris and
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Carr 2013). In females, when gametogenesis is nearly complete, LH stimulates the synthesis of
progesterone, which in turn stimulates final oocyte maturation. It also triggers ovulation. Hours
before ovulation, LH and FSH levels spike. Progesterone also increases prior to ovulation. This
increase in progesterone is required for the surge of LH that leads to ovulation to occur. This
happens as a result of the fall of estrogen levels as progesterone increases. Progesterone then
stimulates the release of the ovulatory spike in LH, and LH further stimulates more progesterone
increases (Ottinger and Bakst 1995).
In the liver, estrogens stimulate the synthesis of vitellogenin within the liver (Wallace and
Bergink 1974). Vitellogenin is then incorporated into the ovary and developing oocyte, wherein
is it converted to yolk proteins (Wallace and Bergink 1974; Ho 1987; Norris and Carr 2013).
Both vitellogenesis and follicular growth are dependent upon GTHs. Decreases in GTH levels
lead to a decrease in circulating steroid hormones and subsequent decrease in follicle and oocyte
maturation (Norris and Carr 2013). When estrogen levels decline following breeding, the ovaries
and oviducts regress (Norris and Carr 2013). High levels of estradiol and progesterone also
mediate breeding receptivity in females (Norris and Lopez 2011). In Bufo japonicas (Itoh and
Ishii 1990), high levels of progesterone have been detected prior to ovulation that then decline
after breeding and oviposition. It is likely that this progesterone peak also contributes to the LH
surge for ovulation (Ottinger and Bakst 1995).
Males
In males, FSH mediates the process of spermatogenesis in the Sertoli cells while LH
stimulates Leydig cells within the testes to produce testosterone and dihydrotestosterone (DHT)
and stimulates release of mature sperm (Norris and Carr 2013). Under the influence of LH,
testosterone production increases, which stimulates spermatogenesis (Vu and Trudeau 2016). In
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some species, such as birds, expression of male behavior occurs when testosterone is converted
to estradiol by aromatase in the central nervous system to elicit singing and aggression (Ottinger
and Bakst 1995; Balthazart et al. 1983). In anurans, this rise in testosterone similarly stimulates
calling behavior (Norris and Lopez 2011). Circulating steroid hormones then feedback to the
hypothalamus and pituitary to stimulate mating behaviors or to inhibit further gonadotropin
release (Norris and Lopez 2011). In Bufo marinus, circulating levels of androgens are increased
following sexual stimuli. During amplexus, androgen levels increase, implying that mating
behaviors increase androgen levels-androgens do not increase mating behaviors. This is likely
due to rising GnRH and gonadotropins levels following sexual cues, which then cause a release
of androgens. (Licht, Porter and Millar 1987). Females also see a rise in estradiol during sexual
activity.
A recently discovered additional hormone of the HPG axis merits discussion here as
well. Gonadotropin inhibiting hormone (GnIH) is a related hypothalamic hormone that inhibits
the release and synthesis of gonadotropins. It acts directly on the pituitary following release from
the hypothalamus or indirectly by inhibiting GnRH neuron activity. GnIH has recently been
discovered in anuran brains (Jadhao et al. 2016). In birds, melatonin also influences the release
and production of GnIH. This implies that GnIH, once influenced by melatonin, impacts the
daily fluctuations of gonadotropin release. It is also possible that in unsatisfactory conditions
such as food shortages, extreme temperatures, or lack of mates, GnIH impedes the release of
gonadotropins for energy conservation (Ubuka, Bentley and Tsuitui 2013). The inhibition of
gonadotropin synthesis and release then inhibits gametogenesis and steroid hormone synthesis
(Jadhao et al. 2016). Another relatively new neural factor that can affect the release of
gonadotropins are peptides known as kisspeptins. In rodents, kisspeptin neurons project from the
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anteroventral periventricular area to act on GnRH neurons to promote the release of GnRH
(Norris and Carr 2013). Xenopus laevis have been found to contain genes for kisspeptins (Felip
et al. 2009; Kim et al. 2012). Dopamine also directly inhibits the release of gonadotropins from
the pituitary (Norris and Carr 2013) in anurans.
An additional mediator of anuran reproduction is arginine vasotocin (AVT), a
neuropeptide that is not present in mammals. Vasotocin is the ancestral form of vasopressin and
oxytocin, which are found in mammals. As such, vasotocin fulfils both the roles of vasopressin
such as osmoregulation and smooth muscle contraction (Norris and Carr 2013). In anurans,
vasotocin also mediates a variety of reproductive behaviors, such as amplectic clasping during
breeding (Norris and Carr 2013). In both anurans and in birds, vasotocin influences calling
behaviors in males and phonotaxic response to calling in female anurans (Norris and Carr 2013).
During oviposition, vasotocin stimulates water retention and causes contractions of the oviducts
(Norris and Carr 2013).
Mating strategies and seasonality
Amphibian breeding behaviors are heavily reliant on environmental cues such as
rainfall, food availability, and temperatures (Browne and Zippel 2014). They are also influenced
by social stimuli, such as mate calling and the presence of conspecifics (Browne and Zippel
2014). Following environmental or social stimuli, the hypothalamus releases GnRH, which
stimulates the release of two gonadotropins from the pituitary. Reliance on environmental cues is
what makes anurans seasonal breeders. Anurans can exhibit either associated or dissociated
reproduction patterns. Associated reproductive patterns lead to mating occurring during peak
gonadal activity, while in a dissociated reproductive pattern, mating occurs when gonadal
activity is low (Norris and Carr 2013). For example, in temperate species, spermatogenesis &
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ovarian follicular development start in fall then animals “hibernate” until breeding occurs (Norris
and Carr 2013).
In most vertebrates, differentiation between seasons is mediated by melatonin. The
relationships between photoperiod, seasonality and melatonin secretion from the pineal have
been well-documented in other vertebrate classes, though it is understudied in anurans. The
anuran pineal gland secretes melatonin as a result of signaling from the retina in a rhythmic
fashion, indicating effects of season (Norris and Carr 2013). In other vertebrate species,
melatonin then stimulates an increase in gonadotropin releasing hormone (GnRH), which in turn
increases gametogenesis and steroid hormone production (Dunn and Sharp 1999; Kang et al.,
2006). There is evidence in the seabass that GnRH, in turn, modulates the release of melatonin as
a feedback loop (Servili et al. 2010). However, unlike other classes of vertebrates such as birds,
no consistent effects of pineal regulation on reproduction have been found in anurans. One study
on the tree frog has shown an increase in gonad development following pinealectomy (Norris
and Carr 2013; Trudeau 2016), and ovulation has been inhibited in Rana pipiens by melatonin in
vitro (Norris and Carr 2013). Beyond these studies, little work has been done on the study of
pineal activity and the effects of melatonin in amphibians, though as seasonal breeders, it is
likely that melatonin affects reproduction in a similar fashion.
Unlike in mammals and birds, it is common for all anuran reproductive activity such as
courtship, fertilization, and oviposition to occur at once (Norris and Lopez 2011). During the
breeding season, anurans gather at night near water sources. Males will then begin to call in
order to demonstrate his superior fitness to other males and earn a mate. Lynch and Wilczynski
(2008) demonstrated that estradiol levels in female anurans rise following the influence of male
calling. If interested, females respond to male calls by seeking out the male, known as a
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phonotaxic response. The pair will then enter the water and the male will climb onto the female’s
back and clasp her under the forelimbs in a position called “amplexus” (Moore, Boyd and Kelley
2005). The male will squeeze the female in order to help stimulate oviposition. Anurans are
external fertilizers, so as the female releases her eggs, the male releases sperm onto the eggs
(Moore, Boyd and Kelley 2005). The combination of direct release onto the eggs and amplexus
helps ensure that no other males fertilize the eggs. Once the eggs enter the water, the egg jelly
surrounding the eggs begins to harden to prevent polyspermy and damage to the eggs.
Gonadotropin releasing hormone (GnRH)
Structure and synthesis
Gonadotropin releasing hormone, or GnRH, is an evolutionarily well-conserved hormone
which is synthesized in the hypothalamus and acts as the control center for neuroendocrine
reproduction in vertebrates. It is thought to have been present within the evolutionary record for
over 500 million years. As its name implies, it mediates the release of gonadotropins from the
pituitary. In the majority of vertebrates, these refer to luteinizing releasing hormone (LH) and
follicle stimulating hormone (FSH), or unnamed analogs (Norris and Carr 2013). GnRH was first
isolated in mammals in (Schally et al., 1971). During early discovery, however, GnRH was
referred to “luteinizing hormone releasing hormone” (LHRH) due to the belief that it controlled
only the release of LH. For many years, it would be referred to as LHRH until it was discovered
that it also mediated the release of FSH (Schally et al. 1971). When purchasing GnRH for work
in the areas of assisted reproduction, it is still common for commercial organization to sell it
under the name of LHRH (Kouba et al. 2012).
Early in its evolution, GnRH likely started as primitive sexual communication with the
gonads, as evidenced by the location of GnRH receptors on the gonads of the majority of
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vertebrate species, despite little current evidence of direct GnRH binding in the gonads. It is
likely that the response to external cues, its neuroendocrine role, and its relationship to the
pituitary evolved much later (Millar 2004). In vertebrates today, GnRH mediates the
neuroendocrine control of reproduction in vertebrates as part of a system with the pituitary and
gonads, referred to as the hypothalamic-pituitary-gonadal (HPG) axis. GnRH is both synthesized
and stored within the hypothalamus in specialized neurons. Projections of these neurons pass
through the median eminence to release GnRH into the pituitary. From there, it stimulates the
release of the gonadotropins LH and FSH from the anterior pituitary. Following release, the
gonadotropins enter the blood stream to act on the gonads. The gonads, in response to
gonadotropin stimulation, release steroid hormones such as androgens and estrogens (Fink
1988).
In mammals and birds, the release of GnRH has been found to be pulsatile, as continued
release of GnRH can desensitize and downregulate receptors, which prevent further
gonadotropin and steroid hormone release (Fink et al 1988; Smith & Vale 1983). In anurans,
however, GnRH release seem to be continuous, and pulsatile release actually decreases HPG axis
function (Licht, Porter and Millar 1987). During breeding seasons, these patterns of secretion
change in order to stimulating breeding behaviors and gametogenesis (Norris and Carr 2013). In
order to stimulate gametogenesis, FSH stimulates the synthesis and secretion of estrogens and
initiates follicular development and stimulates androgen release and spermatogenesis in males.
Oocytes maturation and ovulation and testosterone production and sperm release is mediated by
LH (Norris and Carr 2013).
In mammals, GnRH is the guiding hormone behind puberty, though it likely plays a role
in sexual differentiation in the brain during early development as well (Norris and Carr 2013). At
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the onset of puberty, GnRH will increase pulsatile secretion, which in turn activates the
production of sex steroids, leading to development of secondary sex characteristics and
gametogenesis. What remains understudied, however, is the precise “on switch” that generates
GnRH pulse increases. Some theories postulate that GnRH is dormant throughout adolescence,
while others assume there is an inhibition that occurs prior to the onset of puberty (Ebling 2005).
The inhibition is thought to come from low levels of androgens and estrogens secreted from prepubertal gonads, which negatively feedback on the HPG axis (Ebling 2005). While it is well
known that many other factors play a role in the onset of puberty, such as fat stores and light
cycles, but the exact mechanism and its relationship to GnRH remains a source of investigation.
Investigations into GnRH and its relationship to puberty are of a particular interest at present as
the number of transgender youths seeking the suppression of puberty increase. In order to
suppress puberty and the development of secondary sexual characteristics, GnRH analogues are
prescribed (Olson et al. 2014). The potential issue, however, is that the precise role of GnRH in
puberty is still relatively unknown, which could impact the efficacy of GnRH as a suppressor of
puberty. In addition, further understanding of the mechanism behind the start of puberty could
provide new methods for delaying its effects.
At its first discovery, GnRH was assumed to only be a mammalian hormone, but
investigation over the years has revealed over 15 GnRH forms which have been isolated in a
variety of vertebrate animals (Millar et al. 2004). The majority of vertebrates have at least two
forms, while some species have three forms (Millar et al., 2004). Amphibians, for example,
express three forms of GnRH: GnRH 1, the mammalian form, GnRH 2 (Miyamoto et al., 1984),
the chicken form, and a third, salmonid form, though little is known about the third form. The
first form is primarily found within the hypothalamus, in the preoptic area-a sexually dimorphous
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region associated with sexual behaviors such as calling in anurans (Moore, Boyd and Kelley
2005). The first GnRH form controls the hypophyseal system, stimulating the release of
gonadotropins from the pituitary and subsequent synthesis and release of steroid hormones,
while the precise roles of GnRH 2 and GnRH 3 are still under investigation (Norris and Carr
2013).
Receptors
There are three receptors for GnRH that are located throughout the amphibian brain:
GnRH1R, GnRH2R, and GnRH3R (Millar 2004). Each of these types of GnRH have their own
receptor types that are located in various areas of the brain, similar to the distributions of their
ligands. For example, the majority of receptors for GnRH1 are located within the pituitary,
where GnRH binds to stimulate gonadotropin release. Receptors for GnRH2 and GnRH3,
however, are mostly distributed in other areas of the brain. There is, however, a degree of
overlap between GnRH receptors. Both type 1 and type 2 GnRH receptors have been found on
gonadotropic cells, suggesting that both GnRH 1 and GnRH 2 play a role in hypophyseal activity
(Millar 2003). Previous studies on GnRH 2 found that GnRH 2 had a greater effect on FSHrelease from the pituitary than GnRH 1 in chickens, suggesting that GnRH 2 may also play a role
in gonadotropin release along with GnRH 1. The type 2 GnRH receptors are the highly selective
cognate receptors of GnRH 2, and GnRH 2 has been found to have a lower binding affinity to
type 1 receptors than GnRH 1 (Millar 2002). Chen and Fernald (2008) determined that GnRH
receptors are promiscuous, with all receptor forms having high affinities for GnRH2.
GnRH forms are decapeptides, containing only ten amino acids: Glu-His-Trp-Ser-TyrGly-Leu-Arg-Pro-Gly.NH2. While each form differs slightly in amino acid sequence, each form
includes and NH2-terminus and COOH-terminus that are critical to receptor binding and
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activation and the eighth amino acid in the decapeptide sequence seems to determine receptor
sensitivity (Millar et al. 2004). During binding, GnRH folds at the glycine amino acid location to
bind its terminal ends to the GnRH receptor (Sealfon et al. 1997; Karten and Rivier 1986). The
NH2 terminus is responsible for receptor activation (Sealfon et al. 1997). The GnRH receptor
was first discovered by Tsutumi et al. (1992) using a cloned mouse pituitary, but GnRH
receptors have subsequently been cloned in several fish, mammals including humans, anurans
and chickens (Millar 2004).
Following binding, the NH2 terminus controls receptor activation (Sealfon et al. 1997).
During binding, the COOH tail is critical for phosphorylation and internalization (Finch et al.
2009). Previous studies have shown that the non-mammalian GnRHRs tend to have a
dissociation rate of approximately 0.2 ± 0.02 koff (min-1) and internalize within 60 to 120
minutes. (Nederpelt et al. 2016; Hashizume et al. 2001; Hislop et al. 2000; Vrecl et al. 1998).
The mammalian form, on the other hand, is much slower with Hislop and colleagues (2000)
finding only 25% of internalized radioligands after 60 minutes. It does so by binding β-arrestin,
which both desensitizes the receptor and marks it for internalization. The GnRH1R is also known
as the mammalian type. It is unique amongst the three receptors in that it lacks the COOH tails of
the other two receptors. This causes slow desensitization and internalization from the plasma
membrane (Finch 2009; Hislop et al. 2000). The other two GnRHRs are non-mammalian forms
that contain COOH tails and thus undergo rapid desensitization and internalization.
Action within the central nervous system
The mammalian form, GnRH 1, is primarily found within the hypothalamus. In
particular, within the preoptic area of the hypothalamus (POA). The POA is a sexually
dimorphous region that is associated with a variety of sexual behaviors, such as calling in anuran
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amphibians (Moore, Boyd and Kelley 2005). The fibers of GnRH 1 neurons extend down the
median eminence to mediate the pituitary release of gonadotropins (Norris and Carr 2013). A
peptide called galanin is also contained in GnRH 1 neurons. Its release and effects are not well
studied. It stimulates the release of LH, but not FSH (Norris and Carr 2013). It is possible that
this colocalization of galanin with GnRH is what lead to the initial assumption that GnRH only
controlled LH release.
The chicken form, GnRH 2, is found throughout many areas of the central and peripheral
nervous system (Millar 2004). Across vertebrate species, GnRH 2 is the most abundant and
considered the earliest evolved form (Licht, Porter and Millar. 2004). Despite this abundance,
there is still little evidence supporting any one particular role. While the effects of GnRH 1 are
well documented as mediating the hypothalamic-pituitary gonadal (HPG) axis, the roles of
GnRH 2 are variable and studies are sporadic. Millar (2004) postulated a role in reproductive
behaviors of GnRH 2. This is supported by a study by Maney, Richardson and Wingfield (1997)
which found that exogenous GnRH 2 enhanced responses to mate calling in female sparrows,
and a study by Battisti and colleagues (1997) found changes in GnRH 2 cell populations over the
course of breeding seasons. In newts, GnRH 2 neuronal cell populations have shown changes
across the breeding seasons (Maney, Richardson and Wingfield 1997; Battisti et al. 1997).
In a study on mice, GnRH 2 re-instated breeding behaviors in female mice that had
previously been deprived of food (Kauffman and Rissman 2004). This effect was also found in
female musk shrews (Temple, Millar and Rissman 2003). These effects were, however, only
found in food-deprived females, indicating a potential relationship between energetic status and
reproductive behaviors in respect to GnRH 2 influence. In addition, melatonin secretion has been
shown to be affected by GnRH 2 in the sea bass pineal (Servili et al. 2010). This points to a
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potential relationship to GnRH 2 and the effects of photoperiod. In birds, the secretion of
melatonin stimulates GnRH 1 release (Chowdury et al. 2013). Taken together, this could indicate
an overlap of function between GnRH 1 and GnRH 2. Because the receptors for various GnRHs
are promiscuous, this can make determining precise binding areas and pathway stimulation for
one particular form difficult. Future studies are required to determine the functions and networks
of both GnRH 2 and GnRH 3.
Even less is known about GnRH 3. The vast majority of studies on GnRH 3 have been
performed in fish, where it has been linked to parental behavior such as nest building
(Yamamoto et al., 1999), aggressive and sexual behaviors (Volkoff & Peter 1999). One of the
most interesting aspects of GnRH 3 is that it has been linked to sensory systems, with receptors
being found within the retina (Servili et al. 2012). None of these precise pathways or
mechanisms have been determined, however. Interestingly, all the GnRH receptors have been
found to be promiscuous; therefore, administration of exogenous GnRH or its agonists could
bind to the receptors of any of these GnRH types.
Action within the periphery
While GnRH 1 and GnRH 2 overlap in various areas of the brain, GnRH 2 is found in
high concentrations in areas without GnRH 1 and, in particular, in areas outside of the brain
(Ehlers and Halvorson 2013). Both GnRH 1 and GnRH 2 have been shown to exhibit autocrine
and paracrine effects on tissues outside of the brain, where GnRH 2 receptors have been
localized in areas such as the gonads, mammary glands, prostate and kidney (Ramakrishnappa et
al 2005; Ehlers and Halvorson 2013). The direct effects of GnRH 2 on these areas may include
steroid hormone synthesis and reproductive behavior mediation (Ramakrishnappa et al. 2005),
though there are likely non-reproductive functions of GnRH 2 as well.
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Millar (2004) postulates that GnRH initially acted directly on the gonads early in its
evolution, and current receptors are a remnant of that. Receptors for GnRH have also been found
on other reproductive tissues such as the placenta, endometrium, mammary glands and prostate,
as well as reproductive tissue carcinomas (Ramakrishnappa et al. 2005). Precise functions of
GnRH within these tissues are, however, not known. Anjum et al. (2013) found that the testicular
concentration of GnRH receptors differed over the lifespan of mice and correlated with
fluctuations in testosterone, and higher concentrations of GnRH receptors were found with
higher testosterone levels.
Exogenous effects
Due to the gonadotropin and steroid hormone-regulating abilities of GnRH, it has found
popularity in fertility treatments of both humans and animals. In humans, both agonists and
antagonists have been used in treatments of fertility (Padula 2005). In particular, they are used to
control the timing of ovulation prior to artificial insemination procedures. Agonists are used to
overstimulate the pituitary to release higher gonadotropin levels than normal, which then causes
gonadotropin release to stop. Antagonists simply block GnRH binding to the pituitary, which
also prevents gonadotropin release (Padula 2005). In both cases, a lack of gonadotropins leads to
a lack of steroid hormones, which stops ovulation. Ovulation can then be restarted at the precise
moment of desired fertilization.
In assisted reproductive technologies (ART) in animals, GnRH is frequently administered
to elicit or enhance breeding behaviors or gametogenesis. In amphibians, for example, and
analog of GnRH is used to elicit a natural cascade of gonadotropins by directly activating the
HPG axis. This leads to the increased production and expulsion of sperm in males and follicular
development and ovulation in females (Browne et al. 2006; Kouba et al. 2012). The
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concentrations administered, however, must be carefully monitored, as large doses of GnRH can
actually desensitize GnRH receptors and impede the secretion of both gonadotropins and steroid
hormones (Emons and Schally, 1994). A study by Julien et al. (2019) found that nasal
administration results in spermiation responses from male Anaxyrus fowleri, providing evidence
that nasal GnRH causes an increase in neural activity which promotes the release of
gonadotropins from the pituitary. It may also be acting directly on the pituitary to stimulate
gonadotropin release. It could also be result of direct binding to the gonads directly. This is
potentially the path that traditional intraperitoneal injections of GnRH agonists have taken.
Various studies on artificial reproduction in anuran have found that intraperitoneal injections of
GnRH also elicit spermiation in males (Brown & Zippel 2007; Kouba et al. 2012). When binding
to GnRH receptors in the testes, GnRH causes increases in testosterone levels (Anjum et al.
2013). Due to the proximity of injection points and the gonads, it is likely that a large volume of
injected solutions resulted in greater, more direct binding on the gonads.
GnIH and kisspeptins
Much of the downstream function of GnRH 1 has been studied, but the actions upstream
of GnRH 1 that mediate its release are a relatively recent area of investigation. There are a
variety of GnRH 1 modulators, ranging from endocannabanoids (Meccariello et al. 2008) to
dopamine, but two of primary interest here are gonadotropin-inhibitory hormone (GnIH) and
kisspeptins. GnIH is an additional hypothalamic hormone that, as its name suggests, inhibits the
release of gonadotropins. As with GnRH, GnIH also acts through a g-protein coupled receptor
(Jadhao 2017). Following various cues, GnIH is directly released onto the pituitary from the
hypothalamus, though it has also been shown to directly inhibit GnRH neuron activity (Jadhao et
al. 2016). In the brains of birds, GnIH has been shown to synapse directly onto GnRH neurons
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and effects the actions of GnRH in both the hypothalamus and pituitary (Bentley et al. 2003,
2006). This has also been shown to be the case in mammals (Kriegsfeld et al. 2006) and anurans
(Jadhao and Pinelli et al. 2017). Ubuka, Bentley and Tsuitui (2013) have hypothesized that
GnIH may inhibit the release of GnRH and gonadotropins outside of breeding seasons, or when
resources do not favor breeding, implying modulation through environmental cues. There is also
some evidence that there are both GnRH and GnIH receptors located on the gonads for direct
mediation of gonadal activity, such as gametogenesis or steroid hormone synthesis (Anjum et al.
2013; Ubuka, Bentley and Tsuitui 2013). The gonads contain receptors for GnRH as well at
concentrations of GnIH and kisspeptins. During senescence, mice testes show a decrease in
GnRH receptor concentration with an increase in GnIH synthesis, implying that GnIH may play
a role in suppressing GnRH during senescence (Anjum et al. 2013). The localization of GnIH
within amphibian brains is relatively recent, and considering other gaps in the current
understanding of inhibitory effects on GnRH in anurans, the study of GnIH pathways and
activation are of interest.
While GnIH acts in an inhibitory fashion on the GnRH system, kisspeptins act as
stimulators of GnRH activity (Kelly et al. 2013). Kisspeptin-secreting neurons project from the
anteroventral periventricular area (AVPV) and arcuate nucleus (AN) in rodents, which act on
GnRH neurons to stimulate release of GnRH and subsequent gonadotropin release (Norris and
Carr 2013; Yeo and Herbison 2011). Genes coding for kisspeptins have been found mammals,
birds, and amphibians (Felip et al 2009; Kim et al. 2012; Norris and Carr 2013). Although
environmental cues are likely to cause kisspeptin release, the precise cues and pathways which
stimulate kisspeptin release have not been fully explored. Recent studies, however, have put
forth evidence that kisspeptins transmit social signals from the anteroventral periventricular area
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(AVPV) to GnRH neurons for activation (Norris and Carr 2013). Kisspeptins, by and large, are
still not well understood and are a growing contemporary area of research today. For example,
there is a great interest in the role of kisspeptin in the reception and transmission of
environmental cues to signal breeding (Norris and Carr 2013). While kisspeptins and GnIH
provide more clues into the control of the GnRH system, there is still much to be determined
regarding the regulation of GnRH neurons and synthesis of GnRH itself.

Arginine vasotocin (AVT)
Structure and synthesis
Arginine vasotocin is the likely ancestral form of the neuro nonapeptide neuropeptide
family of vasopressin/oxytocin (Mahlmann et al. 1994). Arginine vasotocin (AVT), along with
mesotocin (MET) and isotocin (ITO), act as homologs to the mammalian oxytocin and
vasopressin. In mammals, oxytocin mediates pair bonding, lactation and smooth muscle
contraction while vasopressin mediates osmoregulation, smooth muscle contraction, and pair
bonding (Norris and Carr 2013; Altura and Altura 1977). In amphibians, AVT and MET regulate
these processes, but with significant overlap. In males urodeles and male anurans, for example,
AVT has been shown to influence amplectic clasping and calling behaviors, respectively (Moore,
Boyd and Kelley 2005; Norris and Carr 2013). The purpose of calling behaviors from males are
to attract mates. The release of AVT, like GnRH, is largely influenced by environmental or
social cues, such as the calls of conspecifics.
Females generally vocalize only to signal that they are not interested in a male. Thus, in
males, AVT stimulates calling behaviors while in females it inhibits vocalizations of unreceptive
females while also increasing phonotaxic responses to male calls (Moore, Boyd and Kelley 2005;
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Boyd 2006). In birds, vasotocin also controls calling and singing behaviors. In urodeles, AVT
has slightly different effects. An increase of AVT can increase the clasping propensity of male
urodeles (Moore, Boyd and Kelley 2005). Thus far, reports of AVT influencing clasping
behavior has only been seen in urodeles, not in anurans (Moore et al. 2005). AVT is frequently
found in the preoptic area of the hypothalamus and released from the posterior pituitary (Boyd
2006). As previously mentioned, the preoptic area is largely sexually dimorphic. As such, AVT
populations are also sexually dimorphic and sensitive to changes in steroid hormone levels
(Gonzalez and Smeets 1992). In addition, AVT can also influence steroid hormone levels. A
2006 study by Do-Rego and colleagues found that AVT stimulates neurosteroid synthesis in frog
brains. During sexual activity, such as amplectic clasping, testosterone levels rise. The rise in
testosterone subsequently causes a rise in AVT release and calling behavior (Norris and Lopez
2011).
Cells secreting AVT extend from the basal forebrain to the hypothalamus through the
preoptic area from the amygdala and nucleus accumbens (Wilczynski et al. 2017). From the
hypothalamus AVT is secreted through the posterior pituitary and other areas of the brain and
limbic system (Wilczynski et al. 2017). Fibers of AVT, however, occur from the olfactory bulb
to the spinal cord, with locations in the forebrain, midbrain, and hindbrain such as the torus
semicircularis and pretrigeminal nucleus, which are involved in calling behaviors (Boyd 1997).
Receptors
There are three types of receptors for AVT, and they are located in a variety of areas
inside and out of the brain. In amphibians, three different G-protein coupled AVT receptor
subtypes have been found (Acharjee et al. 2004). Of these, the VT1aR receptor bears similarities
to the mammalian vasopressin receptor V1a, while the VT2R receptor seems closely related to
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the mammalian V2R. Finally, the third AVT receptor type, VT1bR is similar in sequence to the
V1b receptor in mammals. All of these receptors are preferential to AVT, but will also bind with
oxytocin, mesotocin, and vasopressin. The presence of multiple AVT receptors within amphibian
brains is, however, debated. While some studies have reported the presence of multiple AVT
receptor subtypes, Boyd (2006) states that there may be only one subtype, VT1aR, within anuran
brains. Receptors are also found along the brainstem and into the spinal cord. This led to the
theory that AVT may act more generally within the brainstem and stimulate numerous behaviors
(Boyd 2006).
Kohno et al. (2003) determined that anuran AVT receptors bear close similarity to the
mammalian vasopression VT2 receptor. However, Boyd (2006) stated that only VT1a receptors
have been located within anuran brains, particularly within the pituitary. The reason for this
discrepancy, however, may be that Kohno and colleagues tested only one species of anuran. An
additional study by Acharjee and colleagues (2004) localized one AVT receptor within anuran
brains and peripheral tissue, as well as one form of mesotocin receptor (MTR). Therefore, it is
highly possible that is only one form of AVTR within the anuran brain, and only one form of
MTR, or that the VTRs are extremely similar. In the 2004 Acharjee study, VTRs were localized
within the forebrain, hypothalamus, distal lobe of the pituitary, heart, and adrenal gland, kidney,
and oviduct. Receptors for MT were found in the forebrain, hypothalamus, pituitary, adrenal
gland, kidneys and testes. Due to preferential binding of AVT to AVTR over MTR, it can be
assumed that nasal administration would target AVTRs.
As mentioned, AVT receptors are of the G-protein coupled receptor (GPCR) family. As
such, the mechanisms of binding and internalization bear certain similarities. For example, due
perhaps to the inclusion of a COOH tail like the non-mammalian GnRHRs (Gimpl, Fahrenholz
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and Gene 2001), the internalization rates are similar. Oxytocin receptors, for example, undergo
75% internalization within one hour (Smith et al. 2006). Due to the homologous nature of
oxytocin and AVT, it is likely that internalization kinetics are similar between receptor types. A
study by Conti et al. (2009) described OXTR and V2 receptor recycling and return to cell
surfaces within four hours post-internalization. In terms of additional timing, Gazis (1987)
reported that the dissociation rate of from receptors in the rat was 1.1koff(min-1). Following
binding, both the AVT ligand and receptor are internalized into the cell and then recycled back to
the cell membrane (Kim, Summer and Schrier 1994). In addition, the receptor desensitization
and internalizations are frequently described as rapid processes (Conti et al. 2009).
Internalization occurs between 60 and 120 minutes of binding (Hashizume et al. 2001; Hislop et
al. 2000; Vrecl et al. 1998; Smith et al. 2006).
Action within the central nervous system
In both birds and anurans, AVT exerts powerful influence over calling behaviors
(Choleris, Pfaff and Kavaliers 2013). In the brain, AVT-producing cells are most numerous
within the amygdala, preoptic area, and pretrigeminal nucleus, all of which control calling
behaviors (Boyd 1997). Goodson and Bass (2000) found that administration of AVT into the
preoptic area of fish also affects vocal output. The general calling pathway mediated by AVT in
male anurans seems to be initiated by social cues such as conspecific calling, which are
processed within the thalamus, amygdala, and preoptic area of the hypothalamus. From there,
signals are sent to the reticular nuclei, which coordinates calling and breathing, and the pretrigeminal nucleus (PTN) which generates vocal patterns which are sent to the motor nucleus and
finally, to the larynx via cranial nerve 10 (Boyd 1997).

25

In addition to eliciting calling, AVT may also affect the auditory processing of
conspecific calls. Penna and colleagues (1992) found that AVT can change auditory processing
within the torus semicircularis in tree frogs. In females, it has been postulated that exogenous
AVT administrations may act on the torus semicircularis to control phonotaxic responses to
calling (Boyd 1997). Aggressive calls between males, however, are also affected by AVT,
though these seem to be context dependent and steroid hormone-dependent (Marler et al. 1995).
Depending in the binding location, exogenous AVT may affect different aspects of calling. If
AVT binds in the amygdala, it may affect sensory processing, while in the pretrigeminal nucleus
(PTN), it may alter motor output (Boyd 2006).
Action within the periphery
Within the periphery, AVT elicits numerous effects on various organs. The most notable
of these include the kidney, heart, liver, interrenal gland, oviducts and testes. In one case, the
presence of AVT was also found in the GI tract of chickens (Robinzon et al. 1988), thought there
has been little additional evidence for this. In the heart, AVT has been found to slow heart rate or
increase it, depending on the type of receptors located on the heart (Boyd 2006). In the liver of
mammals, vasopressin stimulates glycogenolysis; in amphibians, AVT fills this role (Ade,
Segner and Hanke 1995).
Corticosteroid release is also stimulated by AVT (Burmeister, Somes and Wilczynski
2001). The relationship between corticosteroids and anuran reproductive behavior is sometimes
contradictory and not well understood; for example, rises in corticosterone in males anurans will
not cause males in amplexus to cease clasping, but it will prevent males that are not in amplexus
from clasping females (Norris and Carr 2013). It has been shown that AVT effects the release of
corticosteroids from the interrenal gland, the amphibian equivalent of the adrenal gland (Gupta
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and Hanke 1994). In both mammals and anurans, the adrenal or interrenal glands lie against the
kidneys and produce catecholamines and steroid hormones: predominantly aldosterone, and
corticosterone (Hanke 1978; Milano and Accordi 1983; Gupta and Hanke 1994). In anurans, the
kidneys and interrenal glands share an interconnected blood supply which differs from
mammalian kidney and adrenal gland connections (Hanke 1978). In response to stressful stimuli,
AVT is secreted from the posterior pituitary and subsequently binds to V2 receptors, stimulating
the release of catecholamines from chromaffin cells within the interrenal glands (Larcher et al.
1998; Larcher et al. 1992).
Within the kidneys, AVT plays a prominent role in osmoregulation (Boyd 2006). In the
kidney, AVT has an anti-diuretic effect, increasing water retention and decreasing filtration
(Warburg 1995). Within the glomerulus and renal tubules, AVT stimulates water retention
(Henderson et al. 1972; Pang et al. 1982). In the trout, AVT was shown to reduce the filtration of
glomeruli for an antidiuretic effect (Amer and Brown 1995). These effects are all achieved
through aquaporin expression. Aquaporins are water channel proteins. Aquaporins are located on
the membranes of epithelial cells and facilitate the movement of water across cell membranes.
Anurans contain several types, expressed within the urinary bladder, kidney, and skin (Suzuki
and Tanaka 2010). Depending on their organ and function, aquaporins are located on either the
basolateral or apical membrane side. Aquaporins located in the kidney, skin, and urinary bladder
become expressed on the apical membrane from the cyotoplasm of the cell following vasotocin
binding (Suzuki and Tanaka 2010). The relationship between aquaporins and vasotocin is also
responsible for mediating water absorption in the skin. Absorption of water is also mediated by
AVT via VT2 receptors in the skin (Ogushi et al. 2010). When vasopressin binds to V2 receptors
in the collecting ducts of the kidney, it increases aquaporin expression, which in turn increases
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permeability to water within in the collecting ducts and leads to water retention (Verbalis 2002;
Goldsmith and Gheorghiade 2005).
Amphibians are also heavily reliant on aquaporin-mediated water regulation in their skin,
as they do not drink water from their mouths, but rely on skin absorption for hydration. Anurans
have a section of ventral pelvic skin known as the pelvic patch or drink pouch which has a higher
water permeability than other areas of the skin to better facilitate fluid regulation (Hasegawa et
al. 2003). The permeability of this area of skin is increased by AVT-induced aquaporin
translocation, as in the kidney and urinary bladder.
Oviducts and testes
In females, in addition to phonotaxic responses, AVT controls oviduct constriction much
like its mammalian cousin stimulates uterine contractions (Coleris, Pfaff and Kavaliers 2013;
Norris and Carr 2013) and aids in oviposition (Boyd 2006). As with other effects of steroid
hormones on AVT, increased steroid hormone circulation can increase the stimulation of oviduct
contractions by AVT (Boyd 2006). Combining both osmoregulatory effects and reproductive
effects, AVT stimulates water retention during oviposition in female anurans (Norris and Carr
2013). In the testes, the presence of V1 receptors, the homolog of vasotocin, binding sites have
been reported in the Leydig cells (Maggi et al. 1989). Following vasopressin binding in rat
Leydig cells, steroidogenesis is inhibited (Meidan and Hsueh 1985).
Exogenous effects
Rowlison et al. (unpublished) found that intraperitoneal administrations of AVT resulted
in calling and amplexus behaviors in Anaxyrus fowleri. Boyd (1994) demonstrated that
intracranial administrations of AVT into the laryngeal motor nucleus increased calling in male
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anurans, however, the elicited calls were shorter. Though there have been many studies across
anuran species citing different effects of AVT on calling, a consistent theme is that AVT
increases call frequency (Choleris, Pfaff and Kavaliers 2013). In females, AVT seems to have
the opposite effect, decreasing release calls from females (Boyd, Tyler and de Vries 1992).
Taken together, it would seem that AVT increases mating behaviors. Aggressive calls between
males, however, are also affected by AVT, though these seem to be context dependent and
steroid hormone-dependent (Marler et al. 1995).
In addition to reproductive functions, exogenous AVT affects other physiological
functions. Exogenous AVT was found to increase diastolic and systolic blood pressure in the
trout, likely as a result of binding to V1 type receptors (Le Mevel et al. 1993). Jenssens et al.
(1985) reported an increase in glycogen breakdown and glucose release in excised axolotl liver
sections. Within the interrenal glands, the amphibian equivalent of the adrenal glands, AVT has
been shown to elicit the release of corticosteroids and catecholamines in response to stressful
stimuli (Larcher et al. 1989). As mentioned, receptors for AVT in the skin stimulate water
absorption and this has been stimulated by exogenous administrations of AVT both in the
periphery and intracerebroventricular injection (Uchiyama and Konno 2006; Maejima et al.
2015), indicating both direct peripheral control of water absorption and neuromodulatory control
of water absorption. While in females water absorption is necessary for oviposition (Norris and
Carr 2013), in males, excessive water absorption is undesirable and may impede amplectic
clasping.
Hormone administration routes
In human and veterinary medicine, common methods of drug delivery involve injections.
Depending on the type of drug or the use, the type of injection differs. Intravenous injection is
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the method of injection of a deliverable directly into the vein. Due to its delivery into the vein, it
is quickly distributed throughout the body by the circulatory system for fast action (Jin et al.
2015). Intramuscular injection is an injection directly into the musculature. Musculature has
many veins, which increases the speed at which injectables can be absorbed (Jin et al. 2015). For
a slower route absorption, subcutaneous injection can be considered. This is when an injection is
made under the outer layer of skin, but above the inner dermal layer. This causes a slow
absorption rate, which is preferable for some medications. When delivering exogenous hormones
to amphibians, these methods are not often possible due to their size. Therefore, the most
commonly employed method for hormone treatment in amphibians is intraperitoneal injection
(Kouba et al. 2012; della Togna 2020). All forms of injection, while minimally invasive, carry
risks. Therefore, there is interest in non-invasive methods of administration as well.
Some of the most common forms of minimally invasive or non-invasive methods are oral
administration, skin absorption, and intranasal administration. Rowson et al. (2001) compared
oral administration and topical application of GnRHa, a synthetic GnRH, into two species of
toad. While both methods did induce spermiation, oral administration was sporadic in its success.
Topical application was more successful than oral administration, and elicited a response in 70%
of tested toads. However, the hormones were applied with 40% DMSO in order to facilitate
absorption, which can be difficult to obtain and possibly pose health risks. An additional noninvasive method that has been explored is intranasal administration, or direct administration of
hormones into the nasal cavity. Intranasal administration was recently found successful in
eliciting sperm from Fowler’s toads (Julien et al. 2019), as well as from the Houston toad, Puerto
Rican crested toad, and Chiricahua leopard frog.
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Intraperitoneal injection
The current accepted form of exogenous hormone administration in assisted reproductive
technologies is an intraperitoneal injection. Intraperitoneal injection is injection into the
peritoneal cavity, or body cavity/abdominal cavity (Fig. 3b). From here, hormones enter the
bloodstream and are dispersed throughout the body. Injections can, however, be dangerous when
used on amphibians, as they are small and very energetic. In addition, the slippery skin of many
frogs and toads can make handling them difficult and the potential of inadvertent damage with an
injection needle possible. In such small animals, any deviation from the proper point of injection
can be dangerous and potentially life threatening. In the case of an endangered species, this can
be particularly devastating. In order to minimize the danger of injections, the majority of
breeding facilities allow only trained professionals or licensed veterinarians to perform them.
Acquiring the proper personnel to perform hormone injections can be a costly and timeconsuming effort. Due to the time constraints of veterinary staff and limitations in funding for
professional personnel, this can limit the number of animals being bred or even impede the
process all-together, leading to fewer offspring being reproduced for population increases and
release. Because of this, the development of effective minimally invasive administration
techniques is of interest. In addition to the dangers of needles, intraperitoneal injection also
requires larger concentrations and volumes of hormones. The currently used reproductive
hormones are expensive, and there is growing concern that large hormone dosages can be
dangerous.
Intranasal administration
With nasal administration, there is no danger of inadvertent damage to the animals with
any needles. During nasal administration, hormones are administered directly into the nares
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using a pipette, not a needle (Fig. 3a). As such, professionally licensed or trained personnel are
not required. This speeds up both the number of animals that can be hormonally stimulated and
the time required for hormone administration. The lower level of invasiveness of nasal
administration may also reduce the handling stress and pain of experimental animals. Overall,
nasal administration has the potential to result in less stressed animals and potentially more
animals bred.
Previous research has provided evidence for both intracellular and extracellular pathways of
substances from nasal passages that bypass the blood-brain barrier and are able to rapidly enter
the brain (Thorne et al. 2004). Within the nasal cavity of anurans there are both ciliated sensory
neurons non-sensory neurons that extend to the internal nares and onto the olfactory bulb
(Lockhead and Thorne 2012). From there, olfactory sensory signals can be transmitted to various
other areas such as the septum, striatum, and onto the amygdala (Lockhead and Thorne 2012).
For exogenous substances administered into the nares, there are three main pathways
through which entry into the brain is possible. The first is a passive route, wherein molecules
diffuse across the olfactory mucosa through gaps between nerves and into the subarachnoid
space and cerebrospinal fluid, where they can travel to various brain areas (Lockhead and Thorne
2012). The second method is the active method, where molecules bind to olfactory receptors and
are transported along neurons to target areas. The third route involves traveling of the exogenous
hormone along the trigeminal nerve (Lockhead and Thorne 2012). If hormone administrations
take an active route through the brain, the first receptors activated may be those located within
the olfactory bulb or amygdala. Following the passive route, however, hormones may bind in
various areas of the brain and activate different receptors depending on location. There is also a
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chance that the administrations will instead enter the pituitary or the periphery, bypassing the
brain entirely. These different pathways can result in different receptor activations.

Figure 3

Visual example of handling methods for a) intranasal administration and b)
intraperitoneal injection in A. fowleri. Both methods of treatment facilitate the
targeting of the amphibain HPG axis with exogenous hormones.

Biological imaging
The first recorded instance of fluorescence was made by Sir Frederik William Herschel in
1845, when he observed blue fluorescence coming off of a quinine solution following excitation
by the ultraviolet light of sunlight (Herschel 1845; Renz 2013). The potential for the use of lightemitting samples in biological imaging was later expanded upon by Helmholtz (1874). The first
fluorescent microscopes were invented by Carl Zeiss and Carl Reichert in the early 1900s; the
products of which are still well known today in the Zeiss company (Renz 2013). Fluorescent
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antibodies for the labeling of thicker tissue and samples was developed in the 1940s by Coons et
al. (1940).
In 1961, Marvin Minsky developed the imaging system for better resolution of
fluorescence imaging that would later lead to the development of the confocal microscope, one
of the primary types of microscopes used in fluorescence imaging today (Renz 2013). One of the
key differences between general microscopy and confocal microscopy is the ability to view
multiple depth layers of a given sample to reconstruct a three-dimensional image, whereas
general microscopy is limited to samples at a particular depth. Samples that are too thick often
appear dark or blurry under regular microscopes, while confocal microscopes can focus in on
various depths. Confocal microscopy utilizes an aperture such as a pinhole in order to filter out
scattered and off-axis light, which is called spatial filtering (Prasad 2003). The effect of this
spatial filtering is the removal of out-of-focus images, because the out of focus areas are not
included in the field of view of the pinhole (Prasad 2003). The focus areas are scanned across the
entire sample at various focal planes, and a 3-D image is recreated by piecing together the
focused images on each focal plane (Prasad 2003). During fluorescence confocal microscopy, a
fluorescent excitation light is shined on the sample through the objective lens. In order to
separate the excitation light from the fluorescent light, a beam splitter is used to reflect the
shorter wavelength excitation light and transmit the longer wavelength light (Prasad 2003).
Confocal microscopy functions through single photon excitation. There are however, now twophoton excitation methods wherein, as the name suggests, two photons are excited and interact to
produce twice as many electron energy transitions as single-photon excitation (Renz 2013).
Unlike confocal imaging, no pinhole to prevent light scattering is needed, as two-photon
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excitation only produces fluorescent signal at the areas of interest with high photon densities
(Renz 2013).
In-vivo imaging is useful for numerous procedures and has many benefits. One benefit is
that in-vivo imaging can be used to view imaging changes in a live animal over numerous time
points, whereas in-vitro methods require the sacrifice of animals at various time points to build a
complete time course picture. The use of multiple animals is not only expensive and invasive,
but the sacrifice of numerous animals at various time points increases the chances of individual
animal effects that can skew data, as it is not possible to image individual animals at numerous
time points for a full view of treatment interactions. In addition, animals used in non-fatal
experiments can potentially be used again in future replicates or experiments. There are now
numerous forms of in-vivo imaging in research and diagnostic fields today.
In-vivo imaging began with radiography, a process by which a form of ionizing radiation
“X rays” is used to penetrate materials, such as tissue, and subsequently project an image of what
is within the material, like organs and bone (Filler 2009; Studwell and Kotton 2011). In
computed tomography (CT) imaging, X-rays re used to take multiple image sections of a subject,
which are then used to create a three-dimensional structure for greater internal detail than
tradition X-ray radiography (Studewell and Kotton 2011). Magnetic resonance imaging (MRI) is
another popular diagnostic imaging tool, which, instead of ionizing radiation technologies,
utilizes radiofrequency fields to stimulate and visualize the movement of water molecules
through detection of changes in their magnetic fields in various tissues (Lauterbur 1974). This
creates an image. Another non-invasive method of imaging is ultrasonography. During
ultrasonography, an electronic current is generate through the transducer probe as its applied to a
subject (Kremkow 1998). These currents cause vibrations, which create an image contrasting
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“hyperechoic”, or bright, and “hypoechoic”, or dark, aspects of the body, such as tissue and
fluid. Although primarily used in diagnostics, it has also been used for reproductive imaging
purposes. In amphibians, ultrasonography is often used in order to determine sex in sexually
monomorphic species, determine internal testicular maturation, and oocyte development for use
in assisted reproduction (Fig. 4; Graham et al. 2018). Positron-emission tomography, or PET, is
a process which uses gamma rays to detect injected substance radiotracers in living systems,
such as targeted dyes (Studwell and Kotton 2011).

Figure 4

The use of ultrasonography as a non-invasive method of detection for follicular
development in female amphibians.

Two photon imaging is a form of optical in-vivo imaging (OI). OI is a relatively new
form of in-vivo imaging which visualizes bioluminescence or fluorescence signal within cells or
tissue, making it useful for both in-vitro or in-vivo imaging practices (Studwell and Kotton
2011). This allows real-time whole body imaging in small animals. While OI is a very useful
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technology, it requires careful selection of bioluminescent or fluorescent probes, as these probes
need to be a) excited and b) visualized in deep, living tissue.
There are two primary types of light-emitting probes used in OI. The first is
bioluminescence and the second is fluorescence. Bioluminescence refers to a type of light
produced through a reaction between an enzyme and substrate (Wilson and Hastings 1998). The
most common of these in use today is the enzyme luciferase and its substrate luciferin, produced
from the firefly (Studwell and Kotton 2011). While bioluminescent probes therefore produce
their own light, fluorescent probes must be excited with an external light source, known as an
excitation wavelength. Photons are then released from the excited fluorophore, which is then
visible (Studwell and Kotton 2011). This is known as the “emission” wavelength. Fluorescent
fluorophores come in many forms, such as dyes, proteins, and nanoparticles. One of the first
fluorescent proteins isolated for research use was the green fluorescent protein (GFP) (Chalfie et
al. 1994) which is still used today.
When an excitation light source is shone on a fluorescent molecule, or fluorophore, the
electron is excited, and transfers energy to a nearby molecule. The energy is released as a
photon, and the electron returns to its unexcited, or ground state. The emitted number of photons
from a fluorophore divided by the number absorbed is the quantum yield. The light absorbed by
a fluorophore is the molar extinction coefficient. The product of the molar extinction coefficient
and the quantum yield determines the brightness of a given fluorophore. Excitation and emission
wavelengths are unique to fluorophore types and determine their colors; for example, shorter
wavelengths of emission result in blues and greens, while longer wavelengths emit in the reds.
The Stokes shift refers to the distance between excitation and emission wavlenghts. Greater the
Stokes shift, easier to distinguish from excitation. (Cazes 2001). For use in vivo, fluorophores are
37

often covalently linked to a molecule or substrate that can bind to sites of interest within the
body for labeling purposes.
Though much of fluorescent imaging is used for qualitative purposes, that is, the
visualization of fluorophores, there is sometimes the desire for the quantification of fluorescence.
This may be desired when comparing fluorescence intensity in regions of interest for areas such
as receptor binding detection. This is typically achieved through various imaging software.
Regions of interest are identified and selected, either through pre-determined programs with predetermined sizes, or drawn manually in areas where fluorescence is visualized. Measurements
are then taken by the program of photons or fluorescence intensity (arbitrary units). Background
measurements are then taken; background signal is natural signal that occurs in samples and
images and contributes to the overall fluorescence intensity detected. It is important to subtract
this intensity from the measured fluorescence intensity to control for background influence and
be sure measurements are for the fluorophore only.
There are difficulties with fluorescent imaging. For example, most living tissue produces
autofluorescence, which is a form of background signal of naturally-produced light that can
interfere with fluorophore imaging and cause fluorophore quantification difficulties. In addition,
because fluorescent probes require an external excitation source, this can make it difficult to
visualize probes that are in deep or darker tissue that is not readily penetrated by excitation light.
This is especially true of probes with short wavelengths, such as those on the green or blue
spectrum. Reds and near-infrared sources, which have longer wavelengths, are more easily able
to penetrate deep tissue without being wholly absorbed by surrounding tissue and hemoglobin
(Studwell and Kotton 2011). One solution to this issue is the use of nanoparticle fluorophores;
particularly, quantum dot nanoparticles.
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Nanoparticles and quantum dots
Nanoparticle structure
Nanoparticles are commonly described as any material on a nanometer scale.
Nanoparticles used in research are therefore made from a diverse range of materials, such as
silicon. The most common tend to have a heavy metal or noble metal core.
Uses in medicine and science
Nanoparticles can be useful for a variety of diagnostics, such as locating blood clots in
patients to quickly deliver pharmaceuticals or provide early preventative treatment. In addition, it
can be used to visualize blood flow in a living patient to diagnose cardiovascular issues or
changes in blood pressure. A study by Gao et al. (2004) demonstrated in-vivo prostate cancer
cell growth imaging in mice by conjugating tumor-targeting ligands to polyethylene glycol
coated quantum dots. The ability to view tumor location and growth in a living system is
extremely valuable, particularly in cases where tumors may be small or in areas that are hard to
reach with other imaging technology. Finding tumors is also the first step to treating tumors,
which nanotechnology is being applied to. Many nanoparticles have been explored for drug
delivery either into organs or directly into cells for applications such as tumor treatments.
Endocytosis is a critical function of cells; a process wherein receptor-ligand complexes are
delivered, degraded, and recycled into the membrane. Quantum dots have also been observed to
be endocytosed by cells. Barasso (2011) reported that quantum dots can be endocytosed via
clathrin meditiation. Tekle et al. (2008) found that transferrin can be conjugated to quantum dots,
which bind to clathrin and facilitate clathrin-mediated endocytosis. Quantum dots have been
integrated as far as the nucleus (Clift and Stone 2012). By being able to enter cells, quantum dots
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could be tailored to deliver pharmaceuticals for detection and treatment of diseases such as
cancers.
One particular area of medical and diagnostic research that remains challenging is
the brain. The homeostatic balance of the brain is extremely sensitive to perturbations, thus
making attempts at invasive imaging or treatment very dangerous. Unfortunately, the brain is
still susceptible to disease and injury such as Alzheimer’s, Parkinson’s Disease, and cancer, as
well as injuries such as blood clots or traumatic brain injury (TBI). Treatments at the level of the
brain are difficult for all of these, but may be possible through the use of nanoparticles. Methods
for delivery of nanoparticles across the restrictive blood brain barrier (BBB) which generally
restricts large or exogenous substances from entry are already being investigated (Wiley et al.
2013). If nanoparticles can safely enter and move throughout the brain, then it opens up the
possibility of everything from vasculature imaging to direct treatment of neurodegenerative
diseases.
Additional nanoparticles that are common in research colloidal gold and silver
nanoparticles. Gold and silver nanoparticles are of interest due to their unique optical properties
which can cause visible color changes or light scattering when the particles aggregate or interact
with particular wavelengths of light (Sun et al. 2016; Evanoff and Chumanov 2006). In a more
recent study by Singh and colleagues’ (2008), silver nanoparticles were used to kill bacteria.
Drug resistant bacteria are a growing concern to public health. By utilizing a non-antibiotic
method to target and eradicate bacterial infections, antibiotic resistance can potentially be
avoided. In the 2008 study, silver nanoparticles in the study penetrated bacterial cell walls to
modulate their cellular signaling and disrupt basic cell functions, possibly by deactivating the
thiol groups of critical bacterial enzymes. The results offer applications of silver nanoparticles in
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treatment of bacterial infections and aiding in wound healing. Gold nanoparticles are also being
applied to medicinal areas. Nucleolin-conjugated gold nanoparticles have been used to target
cancer cells and were found to enter cancer cells to a point close to the nucleus, where they
caused cell deformations (Dam et al. 2012).
A growing area of nanoparticle application in diagnostics is the use of nanoparticles
as biosensors to detect particular biological compounds. In one study, gold nanoparticles
conjugated to fluorescent probes were used to detect the presence of particular proteins in human
plasma (De Paoli Lacerda et al. 2009). These techniques could be used to detect not only
proteins, but also other signifiers of disease for fast diagnoses of a variety of ailments. For
example, nanoparticles could be conjugated to detect changes in oxygen imbalances in the blood
of patients.
Toxicity concerns
The use of nanoparticles in research has been growing at a rapid pace as more
applications are found and the nanoparticles themselves become more commercially available.
The use of nanoparticles for in-vivo work has, however, proceeded at a cautious rate. While the
use of nanoparticles in-vitro or in non-biological systems has been successful and demonstrated
little cause for medical concern, the toxicity of nanoparticles in living systems is a barrier to the
ethical expansion of nanoparticles use into in-vivo diagnostics and medicine. With each type of
nanoparticle comes new concerns of their toxicity to living systems. The main source of toxicity
concerns for nanoparticles lies in their composition.
One of the most common nanoparticles in both research and consumer products are silver
nanoparticles (Project on Emerging Nanotechnologies). Silver, however, can be toxic. Silver
nanoparticles have been shown deform cells, disrupt cellular proliferation, and even lead to cell
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death upon exposure (Zanette et al.2011). While Singh and colleagues’ 2008 study demonstrated
that silver nanoparticles can be used to kill bacteria, and recommended further investigation into
their antibacterial properties, the toxic effects of silver should not be ignored. Additional risks to
in-vivo silver nanoparticle use are potential damages to native bacteria cultures that are essential
to the metabolism and immune defenses of living systems.
The final caution in the use of nanoparticles in-vivo stems from their potential to
aggregate and be retained in systems. In diagnostic uses of dyes in living patients, the dyes are
excreted following imaging. Nanoparticles are being considered as a replacement or an
improvement on many dyes and other imaging methods, but their potential for retention is not
well studied.
In a study by Gao et al. (2004), nanoparticles were used to target tumors in-vivo in rats.
The researchers did not, however, report clearance of the nanoparticles from the animals
following imaging. The researchers also admitted that polymer coated nanoparticles are unlikely
to undergo enzymatic degradation. It is very possible that lack of excretion and degradation can
lead to aggregation or retention of nanoparticles within living systems or cells. Gold and silver
nanoparticles as well as magnetic nanoparticles are particularly susceptible to aggregation.

Cadmium, which is the heavy metal core found in many quantum dot nanoparticles, gives
the nanoparticle its fluorescence, but it is toxic to living organisms (Gao et al. 2005). The
international Agency for Cancer Research classifies cadmium as a type 1 carcinogen meaning
there is ample evidence for its carcinogenic effects in humans (IACR 1999). In most
applications, the cadmium core is capped with a zinc-sulfide shell to prevent the escape of
cadmium. In order for cadmium-zinc quantum dots to fluoresce, they need to be excited by an
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external source of UV light. UV illumination, under extended exposure, oxidizes and dissolves
the zinc-sulfide coating around the cadmium (Derfus, Chan and Bhatia 2004). Thus, even though
the cadmium is initially kept safely within a shell, prolonged exposure to UV light during
imaging can result in the release of cadmium into subject that is being imaged. This demonstrates
that while capping the core can reduce the toxicity of cadmium, it does not eliminate it. In-vivo,
this presents concerning cytotoxicity issues.
When cadmium is exposed to a living system, it exhibits a toxic effect through a variety
of methods. A study by Oh and Lim (2006) demonstrated that cadmium induces apoptosis by
rapidly activating caspase-8, which plays a primary role in apoptosis. In addition, cadmium also
acts on the mitochondria to inhibit oxidative phosphorylation and acts as a catalyst to generate
oxygen free radicals with hydrogen peroxide (Fu et al. 2014). Reactive oxygen species can also
be generated through immune responses to nanoparticles when they are administered into living
cells (Fu et al. 2014). Cadmium can also deplete antioxidant glutathione levels, which reduces
the buffering effect against the buildup of reactive oxygen species (Clift and Stone, 2012).
Because some nanoparticles can enter cells, they run the risk of both extracellular and
intracellular free radical formation. Oxidative stress and reactive oxygen species can kill cells,
damage proteins and even damage or cause DNA mutations, which can lead the development of
cancer (Nel et al. 2006).
As indicated here, there are a variety of ways in which nanoparticles can exhibit
toxic effects on living systems. However, this also demonstrates the need for further study in
living systems. Recent advances, however, have developed solutions for issues of toxicity and
biocompatibility while expanding the possible applications of nanoparticle use in areas of
research, diagnostics, and therapeutics. There are three main types of nanoparticles that are
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currently popular in medical research: quantum dot nanoparticles, gold nanoparticles, and silver
nanoparticles. Each has unique properties that make them ideal for use in various areas of
medicine. The medicinal and diagnostic uses for nanoparticles continue to expand, with new
applications being developed at a rapid pace. There is still the potential issue of toxicity, but this
is particle-specific and solutions are being found every day. In 2012, L. Zhang and colleagues
reported that there were 24 types of nanotechnology-based therapeutics on the market for clinical
use, demonstrating that many nanotechnology toxicity issues have been resolved. Nanoparticles
have the potential to be cheaper, faster, and more effective than current medicinal tools and
should be examined fully. Certain nanoparticles have even been utilized to view embryo
development in-vivo, in real time (Dubertret et al. 2002). One of these types of nanoparticles
with great promise for in-vivo imaging is the quantum dot.
Quantum dot nanoparticles
Quantum dots are small man-made, light-emitting semiconductors on a nanometer scale,
ranging from two to several hundred nanometers (Gao et al., 2011). Quantum dots were invented
in 1984 by L. E. Brus, though they did not earn the name “quantum dot” until 1988 by Mark
Reed. However, it is only within the last decade or so quantum dots have been considered for invivo imaging. As mentioned above, most fluorescent proteins and organic dyes are not sufficient
for detection in-vivo due to limitations in their visibility in deep tissue. Quantum dots, on the
other hand, do not share these limitations. They are much brighter and longer-lasting than other
dyes and probes due primarily to their unique structures and versatility (Gao et al., 2011). Most
commonly, quantum dots consist of a highly fluorescent semiconductor core, followed by a shell
of zinc sulfide, and a final outer shell of nonpolar organic material. For in-vivo purposes,
external biomolecules are then applied for biocompatibility. The most common semiconductor
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cores in quantum dots are silicon, cadmium selenide, cadmium sulfide, or indium arsenide (Gao
et al., 2011). Of these, cadmium is perhaps the most common. Heavy metals such as cadmium
are, however, toxic. The zinc-sulfide caps therefore prevent the exposure of cadmium to living
cells. Further caps facilitate biocompatibility and ease of conjugation. For this reason, quantum
dots fall under an area of technology known as “biomimicry”, or the process of technology
mimicking biological functions.
Quantum dots come in a variety of colors and sizes, depending on their intended purpose.
Quantum dot color emissions are determined by their size. The wavelength of emitted light
increases as the size of the quantum dot increases, meaning reds are produced by the larger
quantum dots, while greens and blues are from the smaller sizes (Owen et al. 2008; Fig 5). In
order to emit fluorescence, quantum dots are excited by external sources of illumination. These
two wavelengths are known as the excitation and emission wavelengths. Quantum dots and other
fluorescence dyes are categorized by these wavelengths. At exposure, or excitation, the electrons
within the metal atoms absorb energy and excite to higher energy bands. These are known as
valance bands. Once the electrons return to their ground states on lower energy bands, the energy
absorbed from the excitation source is released in the form of light (Norris and Bawendi 1996).
Smaller quantum dots with shorter wavelengths require higher energy levels to excite the
electrons to their valence band, while large quantum dots require less energy.
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Figure 5

The general structure of a quantum dot nanoparticle. Quantum dot fluorescence
emission is determined by its size and subsequent emissions wavelength.

In in-vivo biological imaging, an amphiphilic polymer is added to the outside of the
quantum dot, thus making it hydrophilic and water soluble (Gao et al. 2011). Quantum dots are
further disguised from the body’s defenses, such as macrophages, with additional polymer layers
(Xing et al. 2008). Then, biomolecular components can be added through a process known as
bioconjugation. This allows the quantum dot to be used for a wide variety of applications, from
cellular imaging to tumor localization and pharmaceutical delivery. Most uniquely to quantum
dots, though, is still their use in in-vivo imaging.

Today, the vast majority of research into internal amphibian physiological processes
and pathways is invasive and necessitates animal euthanasia. With a growing number of
amphibian species becoming threatened or endangered, any amphibian death should be avoided
unless absolutely necessary and steps to reduce invasive studies or those with an endpoint of
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euthanasia should be reduced. Fluorescent quantum dot nanoparticles may be a way to vastly
reduce the use of invasive research into amphibian anatomy and biological processes.
With the use of quantum dots to image living amphibians, fewer captive animals
would be euthanized, meaning that fewer wild animals would need to be used in experimental
procedures. In addition, the knowledge gained from these studies could be used in everything
from increasing our understanding of reproductive or neurological processes, metabolism, or
disease progression. Quantum dots can be conjugated to a wide variety of molecules and
structures, making their application to in-vivo studies limitless. In addition, the ability to view
movement of conjugated or unconjugated quantum dots through a living system created the
possibility of consolidating several studies into one; many studies of physiological pathways can
only look at one location at a time due to the frequent need to euthanize animals to determine
results. This, also, could drastically reduce the number of animals required in scientific work.
Quantum dots can also be used as a model for contaminant retention in amphibians,
both larval an adult. With growing interest in the effects of pollution and endocrine disruptors in
amphibians, studies such as this could be instrumental in determining the effects of various
contaminants on wild amphibian populations, and thus prevent further contamination.
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CHAPTER III
UPTAKE, INTEGRATION, AND DEVELOPMENT OF AMPHIBIAN LARVAE
FOLLOWING EXPOSURE TO QUANTUM DOT NANOPARTICLES
Introduction
Amphibians are often considered to be biological indicators owing to the reliance on their
skins for respiration and osmoregulation (Romer 1972; Bishop et al. 2012). In addition,
amphibians reproduce externally, exposing their gametes and offspringing to the external
environment (Burlibasa and Gavrila 2010). They are therefore heavily reliant on clean water
sources and are highly sensitive to environmental contaminants. In 1998, Welsh and Ollivier
found that significantly fewer amphibians inhabited streams impacted by increased sediment
concentrations following a storm in the Redwood National Park in California, leading to the
conclusion that amphibian density can predict stream contaminant conditions. However, while
natural environmental contaminants can periodically affect amphibian health and habitat
preference, man-made pollutants are of growing concern. Nanoparticles, defined as particles
between 1 and 100 nanometers in size, are found in large amounts in the environment. There are
numerous sources of nanoparticles in nature, produced by such events as volcanic eruptions or
erosions. These can cause numerous detrimental effects on amphibians and their larvae. For
example, exposure of southern leopard frog larvae to sediments containing increasing
concentrations of lead impacts developmental rates and led to skeletal malformations (Sparling et
al. 2006), and heavy metal (lead, zinc, and cadmium) soil contamination from mining in Silver
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Valley, ID, led to delayed metamorphosis and decreased predator-induced fear responses in
spotted frog tadpoles (Lefcort et al. 1998). In recent years, however, areas of electronics,
industry, skin-care and medicine have increased their production and use of man-made
microplastics and nanoparticles (Kessler 2011). Unfortunately, this expansion in micro and
nanomaterial use increases the potential for environmental contamination.
Numerous studies have found evidence of nanoparticle contamination in water systems.
Large deposits of microplastics have been found in the Mediterranean Sea, as well as the
estuaries and lagoons surrounding it (Martellini et al. 2019). Tiede et al. 2015 found that
engineered nanoparticles composed of metal, metal oxide and organic materials have the
potential to contaminate both raw and treated drinking water. Peters et al. 2018 investigated the
prevalence of gold, cerium (IV) oxide, titanium oxide microparticles and nanoparticles in two
rivers in the Netherlands and found that both rivers had nanoparticle contamination consistent
with industrial and commercial product pollution. Wang et al. 2020 found that engineered
titanium oxide particles are also found in urban water runoff. Zinc and organic carbon
nanoparticle contamination is not only caused by man-made urban water runoff, but also, and in
greatly increased concentrations, caused by storm rain (Characklis and Wiesner 1997).
Therefore, engineered micro- and nanoparticles have the potential to contaminate both urban and
non-urban aquatic environments.
Once inside of the body, nanoparticles can circulate to and throughout organs and
systems freely aggregating and causing disruptions in a variety of cell and organ functions such
as cytotoxic effects. Silver nanoparticles can cause cellular deformities and inhibit cell
proliferation (Zanette et al. 2011). Cadmium, a common heavy metal core, can lead to buildup of

64

free radicals and increase the number of reactive oxygen species (ROS) (Clift and Stone, 2012;
Fu et al. 2014).
In humans and other mammals, the skin prevents most contamination from environmental
nanoparticle exposure and most nanoparticles that are required are either ingested or inhaled.
Amphibians, however, with their comparatively permeable skin are much more susceptible to
passive uptake of nanoparticles from the environment. Larval amphibians in particular are more
susceptible to nanoparticles due to the extended time developing in aquatic environments. In
fact, their potential for exposure begins even prior to hatching because amphibian eggs do not
have hard shells to exclude environmental contaminants (Burlibasa and Gavrila 2010). Spence et
al. (2016) found that zinc oxide nanoparticles increased mortality in the rough-skinned newt
when eggs, larvae, and adults were exposed. Toxic effects of these nanoparticles included earlier
hatch rates, decreased larval sizes, and gill degradation. A review by do Amaral et al. (2019)
found that the most common factors that influenced effects of nanomaterials on amphibian larvae
depended on the behavior of the nanomaterial in the environment and the developmental stage of
the larvae investigated. For example, gastrulation and neurulation stages in Xenopus laevis
embryos appear particularly sensitive to contamination by nanodiamond nanoparticles (Marcon
et al. 2010). Nanomaterials most commonly affected amphibian larvae by increasing the
production of reactive oxygen species (ROS) and genotoxicity (do Amaral et al. 2019).
Despite their potential toxic effects, nanoparticles are becoming increasingly important in
research and diagnostics. For example, quantum dot nanoparticles have matured swiftly in their
structure and use as an imaging tool in the past decade. Quantum dots (QDs) are small (≤ 25nm
in diameter), light-emitting semiconductors that are gaining popularity in biochemical research
for in vivo imaging, endocrine mapping, drug delivery and investigation of physiological
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systems. This is largely due to the flexibility in their size, structure, and function. They can also
be seen in deep tissue, making them ideal for in-vivo diagnostic fields (Gao et al., 2011). The
potential of contamination from nanoparticles and their increasing popularity necessitates
investigation into their negative physiological effects. Amphibian larvae are an ideal model for
assessing toxicity because of their sensitivity to environmental contaminants and rapid and easily
observable developmental stages
In addition to the question of toxicity, there is interest in whether or not QDs themselves
can be used to investigate larval amphibian physiology. Because of the unique imaging
capabilities of QDs, they could be a potentially valuable tool in the study of larval amphibian
endocrinology through the use of hormone conjugation. For example, tumor-targeting
nanoparticles were not readily excreted from treated rats (Gao et al. 2004). Thus, unconjugated
and conjugated QDs could interact differently, impacting larval development based on conjugate
size and type.
To test the effects of hormone-conjugated and unconjugated QDs in larval amphibians,
we tested two hormones: arginine vasotocin (AVT) and gonadotropin-releasing hormone
(GnRH). In adult anuran amphibians, AVT is responsible for numerous physiological functions
such as osmoregulation and reproductive behaviors like mate calling and clasping behavior
during breeding (Moore, Boyd and Kelley 2005; Boyd 2006). In larval anurans, AVT systems do
not develop until larvae are close to metamorphosis, though some development of AVT
responses has been reported in early stages of limb development (Mathieson 1996). Hyodo
(1999) reported the presence of AVT after limb development in bullfrog tadpoles and theorized
that in bullfrogs, AVT systems begin to develop at stages closer to metamorphosis, when
osmoregulatory systems begin to change for terrestrial life. This observation may be species
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specific, as Mathieson (1996) reported that wood frog tadpoles develop AVT systems later than
bullfrog tadpoles. Exogenous treatments of AVT into tadpoles with limb development was
shown to inhibit locomotor activity, increase sodium uptake, and increase weight gain, a
response that is more exaggerated in older larval stages (Boyd 1991; Alvarado and Johnson
1966).
There are fewer reports of the effects of GnRH in anuran larvae. In adults, GnRH is
secreted by the hypothalamus, which stimulates the pituitary to release the gonadotropins
follicle-releasing hormone (FSH) and leutenizing hormone (LH). These subsequently cause the
gonads to produce and release steroid hormones and gametes (Norris and Carr 2013). Sherwood
et al. (1986) reported the presence of a form of GnRH in tadpole brains. McCreery and Licht
(1984), however, found bullfrog tadpoles to be unresponsive to exogenous GnRH, as measured
by increases in FSH and LH, unless pre-treated with androgens.
Here, we used Anaxyrus fowleri tadpoles to investigate uptake and integration of unconjugated
and hormone-conjugated QDs into larvae and the possible deleterious effects on their growth and
development. In this study, we hypothesized that amphibian larvae would uptake quantum dots
and these QDs would impact larval development. Our objectives were to: 1) measure the rate of
uptake of QDs by larvae, 2) determine the effects of integrated unconjugated and hormoneconjugated QDs on the rates of early larval development, mortality, and metamorphosis, and 3)
establish organ retention of QDs by treatment and developmental stage.
Materials and Methods
Larval care
In this study, Anaxyrus fowleri larvae were created from in-vitro fertilization (IVF).
Quantum dot integration into larvae was conducted at the following developmental stages:
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Gosner stages 1: fertilization, 19: hatch, 25: mouth opening, and 30: beginning of hind limb
development. Larvae exposed at Gosner stages 1, 19, and 25 all resulted from the same IVF in
May 2020, while Gosner stage 30 larvae were created in a separate IVF in June 2020. All larvae
were kept in groups of between 10 and 30 tadpoles and housed in plastic tanks of approximately
1 liter of aged tap water. All larvae were fed a diet of blended fish flakes, potato flakes, dried
shrimp, and blood worms. Water changes were performed daily in which 20-50% of the water
volume was replaced with clean water. Following hind and forelimb development, larvae were
moved to plastic dishes tipped at an angle of ~ 30º to create sufficient terrestrial space for
tadpoles to undergo metamorphosis. Terrestrial substrate was provided consisting of coconut
fiber and organic soil cultured with springtails (Collembola). Following metamorphosis, pinhead
crickets were provided every other day and water was provided ad libitum.
Nanoparticle exposure
Experiment 1: Rate of QD uptake
In a 24-well plate, 3 wells were filled with 1mL of aged tap water. Unconjugated
quantum dot nanoparticles (QDTracker655, Invitrogen, Carlsbag, CA) in concentrations of 1nM
and 2nM were added to each of the 3 wells, with the remaining well left as a control with only
water (Fig. 6). Five tadpoles at Gosner stage 25 were then added to each of the 4 wells and
monitored for absorbance of nanoparticles. Fluorescence integration into larvae was validated
through histological analysis.
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Figure 6

Well map of tadpole treatments in experiment 1. Tapoles were placed in the first
three wells (top to bottom). The first well served as a control with no QDs while the
second two contained 1nM or 2nM of QDs.

Experiment 2: Effects of QDs on fertilization rates, early development, larval mortality, and
metamorphosis
Larvae were placed into one well plate/exposure stage (4 wells total) with aged tap water.
For exposure at Gosner stage 1, unfertilized eggs were placed into 4 well plates containing 1mL
of aged tap water. Treatments of 10nM unconjugated, AVT-conjugated, and GnRH-conjugated
quantum dots (Qtracker® 655 (Invitrogen) and a phosphate-buffered saline (PBS) control were
then applied to spermic urine samples obtained from male toads and directly deposited, with the
sperm, to the eggs (Figure 7a). A selection of fertilized eggs and larvae exposed at fertilization
were removed at 48, 72, and 240 hours for histology to determine QD integration and
localization. Larvae were then monitored until hatch (~G19), and then moved to housing tubs
until development.
Larger tadpoles exposed to QDs between Gosner stage 19-30 were treated in 6 well
plates. Unconjugated, AVT-conjugated, and GnRH-conjugated quantum dots were added at a
concentration of 1nM/1mL water in each treatment. Phosphate-buffered saline (PBS) was added
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to control groups (Figure 7b-d). Larvae were exposed to QDs for approximately 24 hours. From
each group, on tadpole was removed at 24 hours post-exposure for histological analysis. An
additional tadpole was removed from each well of tadpoles exposed at G30. All remaining
tadpoles in each group were then removed from well plates and placed into housing tubs for
developmental monitoring.

Figure 7

Well map of tadpole treatments by Gosner stage and experiment number: 2 (A) and
3 (B-D). Numbers reflect number of eggs or larvae/treatment in each well.

70

Experiment 3: QD retention
IVIS imaging
Assay plates containing larvae from Experiment 2 were placed into the In Vivo Imaging
system (IVIS). Fluorescence mages were taken with the IVIS imaging system at time 0 (directly
after addition of nanoparticles and tadpoles), 0hr, 0.5hr, 1hr, 2hr, 24hr, and 48hr at an excitation
range between 485-525 nm. On each image, an ROI tool was used to select and measure total
fluorescence intensity in each well. After each imaging, a subset of tadpoles were removed and
fixed for further histopathology examination. The remaining living tadpoles were set aside and
monitored through development, in order to observe effects of nanoparticles on development in
vivo.
Histology
Following IVIS imaging, subsets of larvae from experiments 1, 2, 3, and 4 were
euthanized with MS-222 and preserved in paraformaldehyde. Larvae were then fixed into
paraffin wax and cut in 5 µm sections consecutively to be fit to slides. Larvae were sectioned
whole, which limited control of the orientation of whole-larvae sectioning. Sectioned larvae were
placed onto slides for analysis. Sections were deparaffinized and coverslipped. Briefly, slides
were deparaffinized in 100% xylenes and subsequently dehydrated in dilutions of ethanol. Slides
were then coverslipped following the application of a DAPI mounting medium (Vectashield) and
incubated in a darkened room for 24 hours prior to imaging.

71

Spectral analysis
Fluorescence detection and analyses of sectioned tadpoles for experiment 1 was
conducted using an EVOS inverted fluorescence microscope (Thermo Fisher Scientific). In
experiments 2 and 3, imaging was conducted using a Nikon 80i. Photos were taken with an
excitation between 485-585 nm. Five photos from each slide were taken at 20x. Image analysis
was completed with ImageJ. Areas of fluorescence intensity were selected and measured in
replicates of five per image. Background measurements of intensity were taken and removed
from each replicate intensity measurement. Subtracted intensities were then averaged per
developmental stage and organ to assess bioaccumulation.
Developmental tracking
Larvae in all exposure groups were monitored for mortality and metamorphosis. Weekly
counts were taken of tadpoles across experiments and treatments until all larvae had either
metamorphosed or died, with dates of metamorphosis recorded. Metamorphic juveniles that had
been exposed to QDs at Gosner stage 30 were further monitored for changes in weight over time
between treatments. Juveniles were weighed weekly to the nearest 0.001 g for seven weeks postmetamorphosis.
Statistical analysis
Prior to further statistical analysis, all data were tested for normality using a Shapiro
Wilke’s test, and for homogeneity of variance with a Levene’s test. All data were analyzed using
SAS version 9.4 for Windows. Significance levels were set at alpha = 0.05.
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Experiment 1: QD uptake
Fluorescence intensity uptake between controls and unconjugated quantum dot groups
was analyzed by ANOVA, followed by student’s LSD test. The rate of QD uptake by tadpoles is
described by the equation where t1/2 is the half-life of QD remaining in solution.)
𝑦 = 𝐶 + 𝐴o∗ 2 ^ (−𝑥 / 𝑡1/2)

(1)

Experiment 2: Larval development and survival
Following experiment 1, early tadpole development data was run as a one-way ANOVA
to determine the effects of developmental stage on tadpole development progression. A mixed
models analysis (PROC MIXED) was then run to determine the interaction effects of quantum
dot treatment (PBS control, unconjugated quantum dots, AVT-conjugated quantum dots, and
GnRH-conjugated quantum dots) and developmental stage (cleavage, neurula, hatch, and
metamorphosis).
The percentages of surviving larvae were recorded weekly. A repeated measures analysis
was performed to determine the percentage of surviving tadpoles by treatment across seven
weeks, with class set as treatment and the model set as week 1-7. An additional generalized
linear mixed models (PROC GLIMMIX) was then performed to determine the interaction effects
of both treatment (PBS control, unconjugated QDs, AVT-QDs, and GnRH-QDs) and
developmental stage of exposure (Gosner stage 1, 19, 25, and 30) on mortality rates. Treatment
and developmental stage were set as fixed effects, and week was set as a random effect.
Because individual juveniles could not be identified, total percentages of metamorphosed
juveniles by treatment and stage of exposure were run as a mixed model for the effects of
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treatment (PBS, unconjugated QD, AVT QD, and GnRH QD), exposure stage (Gosner stage 1,
19, 25, and 30), and their interactions. A second analysis was conducted using a two-way
ANOVA, with the model set for treatment, stage, and treatment by stage interactions.
As mentioned, individual juveniles could not be identified. Thus, juvenile weights were
analyzed using both an ANOVA in the PROC GLM function and a mixed model to model the
effects of treatment (water control, PBS control, unconjugated QD, AVT QD, and GnRH QD),
week, and treatment by week.
Experiment 3: QD retention
Finally, fluorescence intensity from internalized QDs was compared across the larval GI
tracts where signal was detected. Comparisons were made between 1) AVT-conjugated QDs
between 24 hours and 48 hours post-exposures at Gosner stage 25, 2) between AVT-and GnRHconjugated QDs between 24 hours and 48 hours post Gosner stage 25 exposure, 3) between
unconjugated, AVT, and GnRH QDs at 24 hours post-exposure at Gosner stage 30, 4) between
AVT and GnRH QDs at both 5 hours and 24 hours post-exposure at Gosner stage 30, and 5)
between AVT and GnRH QDs 24 hours post-exposure at Gosner stages 25 and 30.
A Student’s T Test was performed on fluorescence data between 24 hours and 48 hours
of AVT QD exposure to larvae at Gosner stage 25. To compare these data to that of GnRH QDs
across 24 and 48 hours, a two-way ANOVA was performed with a model for treatment, time,
and treatment by time interactions.
Fluorescence intensity was compared between unconjugated, AVT, and GnRH QDs at 24
hours post-exposure at Gosner stage 30 using a 1-way ANOVA for differences due to treatment.
AVT and GnRH QD fluorescence intensity between 5 hours and 24 hours post exposure at
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Gosner stage 30 using a mixed models test for treatment by time interactions. An additional 2way ANOVA with a model of treatment, time, and treatment by time.
A final comparison was made between AVT and GnRH QDs at 24 hours post-exposure at
both Gosner stage 25 and 30 using a generalized linear mixed models procedure (PROC
GLIMMIX) with exposure stage, treatment, and interactions between stage and treatment
modeled.

Results
Experiment 1: Rate of uptake of QDs by larvae
In-vivo imaging of assay wells containing larvae and unconjugated QDs revealed a rapid
decrease of fluorescence intensity from the wells (and subsequent uptake by larvae) within onehour post-exposure, and appeared dose and time dependent (Figure 8). The loss of fluorescence
intensity (total flux) from wells over time was representative of tadpole uptake. The half-life of
total flux in solution was 20.75 hours (R2=0.92) for 1 nM and 2.54 hours (R2=0.96) for 2nM QD.
Approximately 94% of QD are taken up within 72 hours post-exposure and within 12 hours in
the 1nM group and 2nm group, respectively. Histological analysis revealed fluorescence
intensity from quantum dot aggregation within the lumen of the intestines within an hour
following exposure, validating QD uptake from assay wells (Figure 9). No QD signal was
detected in the control group.
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Figure 8

Loss of fluorescence (Total flux) from wells over time normalized against control
(A) and time-lapse image of decreasing visible fluorescence intensity in assay-wells
at 0 hrs, 0.5 hrs, 1 hrs, 2 hrs, 24 hrs, and 48 hrs. (B). Well 1 contained control
treatment, Well 2 contained 1 nM treatment, and Well 3 contained 2 nM treatment.
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Figure 9

EVOS fluorescence imaging validation of unconjugated QD retention following
uptake from assay wells in sectioned tadpoles. Fluorescence signal (red) detected in
larval GI tracts at 2, 24, and 48 hours.

Experiment 2: Effects of integrated unconjugated and hormone-conjugated QDs on early
larval development, mortality, and metamorphosis rate
When larvae were exposed to QDs at fertilization (Gosner stage 1), cleavage rates were
high, ranging from 65% to 82% across treatments, with the lowest rate found in AVT conjugated
QDs, and the highest in unconjugated and GnRH conjugated QDs (Figure 10). Rates of neurula,
however, decreased significantly from cleavage rates across all groups, with the lowest
percentage found in PBS control treatment groups. Development rates saw a further decrease
through metamorphosis. Final percentages of metamorphosis were 1%, 1%, 9%, and 5% of total
eggs in treatment groups exposed to PBS, unconjugated QDs, AVT conjugated QDs, and GnRH
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conjugated QDs, respectively (Figure 10). There were no significant effects (p > 0.05; F = 0.01)
of treatment on percentages of larval development. Stage did affect larval development.
Significantly more (p < 0.01; F=294.9) oocytes underwent cleavage than those that progressed to
neurula, hatched, or metamorphosed. Following cleavage, however, there were no significant
differences (p>0.05) on larval development progression between neurula, hatch, and
metamorphosis.

Figure 10

Total percentage of total larvae at developmental stages across treatments following
exposure at fertilization (Gosner stage 1).
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Larval mortality over time
Similarly, the percentages of surviving larvae over time was not significantly affected (p
= 0.07; F= 0.38) by treatment or over time by week (p = 0.77; F = 0.38). The stage of exposure,
however, significantly impacted overall larval survivability (p < 0.01; F= 17.91). There was no
significant interaction effect between treatment and stage (p = 0.19; F = 1.43), meaning that no
QD treatment was more or less significantly beneficial or hamful to larval development. Over
time, survival across treatments following exposure at Gosner stages 1, 19, and 30 remained high
until weeks 5 to 7, when large die-offs occurred in all treatments. Exposure at Gosner stage 25
had the fastest rate of larval mortality, with an average loss of 78% of all larvae across treatments
by week 4 (Figure 10).
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Figure 11

Percentages of living larvae across treatments over time following exposure at A)
Gosner stage 1: fertilization, B) Gosner stage 19: hatch, C) Gosner stage 25:
opening of the mouth, and D) Gosner stage 30: pre-limb bud.

Metamorphosis by stage of exposure
Across stages of exposure, the highest percentages of hatched larvae that underwent
metamorphosis were in groups exposed to QDs at Gosner stage 30, with 62.5% of PBS-exposed
larvae, 100% of unconjugated QD and AVT conjugated QD exposed larvae, and 87.5% of GnRH
conjugated QD exposed larvae undergoing metamorphosis (Figure 11). Exposure at Gosner
stage 1 also resulted in metamorphosis across all treatments, with the lowest percentage in
unconjugated QD groups (33%), and the highest in AVT conjugated QDs (48%). Larvae exposed
to PBS and GnRH conjugated QDs resulted in 33% and 41% of metamorphosed larvae,
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respectively. Neither unconjugated QD nor GnRH conjugated QDs produced metamorphic
larvae when exposed at Gosner stage 19. In larvae exposed to PBS and AVT conjugated QDs,
metamorphosis occurred in 33% and 13% of larvae. There were, however, no significant
differences between percentages of metamorphosed larvae as a result of treatment, stage of
exposure, or an interaction between stage and treatment (p = 0.6950; F = 0.50). Larvae treated at
Gosner stage G25 did not results in any metamorphic larvae due to improper husbandry and were
excluded from analysis.

Figure 12

Total percentage of metamorphosed juveniles from free-swimming tadpole across
both QD treatments and Gosner stages of exposure.
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Juvenile weights over time across treatments
Larvae exposed at Gosner stage 30 were monitored for changes in weight in
metamorphosed juveniles. The lowest average weights were from larvae exposed to PBS at
0.188 ± 0.009 g. The second lowest weights resulted from unconjugated QDs (0.201 ± 0.022 g),
then AVT conjugated QDs (0.211 ± 0.009 g), and finally GnRH conjugated QDs (0.241 ± 0.012
g) (Figure 12). Overall, only larvae exposed to GnRH-conjugated QDs and unconjugated QDs
significantly differed, with larvae exposed to GnRH-QDs having significantly higher (p =
0.0002; Chi-square=22.13) average juvenile weights. Predictably, time also had a significant
effect on weights across all treatments with weights increasing significantly by each week (p <
0.001; (Figure 13).
Both time and treatment affected juvenile weights. During week 1, juveniles exposed to
AVT-QDs at Gosner stage 30 weighed significantly more (p = 0.0012; t = 3.35) than juveniles
exposed to unconjugated QDs (Figure 13). This was seen again at week 6 (p = 0.0278; t = 2.24). Similarly, GnRH-QD exposed juveniles weighed significantly more than both
unconjugated QD (p < 0.01; t = 4.54) and PBS exposed (p = 0.0099; t = 2.64) juveniles at during
week 1. At weeks 4 (p = 0.044; t = 2.05) and 6 (p = 0.0115; t = 2.59), GnRH-QD exposed
juveniles again weighed significantly more than juveniles exposed to PBS. Juveniles exposed to
PBS, at both weeks 6 and 7, weighed significantly less (p < 0.01) than juveniles exposed to
unconjugated QDs.
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Figure 13

Average weight of metamorphosed juveniles by treatment following exposure at
Gosner stage 30. Data are shown as mean ± SEM.
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Figure 14

Juvenile weights over time following QD treatment exposure at Gosner stage 30.
Data are shown as mean ± SEM.

Organ retention of QDs by treatment and developmental stage
As shown in Figure 14, neither unconjugated QDs, AVT-conjugated QDs, nor GnRHconjugated QDs were able to integrate into freshly fertilized oocytes at Gosner stage 1 when
exposed for over 24 hours. After 48 hours (an additional 24 hours post-QD exposure), integration
had still not occurred (Figure 15). All QD signal appeared around the oocytes and developing
embryos, but did not permeate the membranes and appeared incapable of permeating the egg
jelly coating around the embryos.
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Figure 15

Visible fluorescence signal surrounding oocytes exposed at Gosner stage 1 from A)
unconjugated QDs, B ) AVT-conjugated QDs, and C) GnRH-conjugated QDs

Figure 16

Visible fluorescence signal from AVT-conjugated QDs (A and B), and GnRHconjugated QDs (C and D) surrounding oocytes and embryos at 24 hours postexposure (A and C) and 48 hours post-exposure (B and D) at Gosner stage 1.
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Exposure at Gosner stage 19 did not result in any QD integration. The first stage of
exposure that resulted in QD integration was stage 25. Aggregation of QDs was found in the
gastrointestinal (GI) tracts of larvae exposed to both GnRH-conjugated QDs and AVTconjugated QDs at 24 and 48 hours post-exposure (Figure 16). While there were no treatment by
time interaction effects, the average fluorescence intensity found in larval GI tracts was higher (p
< 0.01; F = 39.5) for both treatments at 24 hours post-exposure than at 48 hours. There were no
significant differences between the fluorescence intensity of aggregated AVT-QD and GnRHQD exposure over time. Due to an error during histological processing, larvae exposed to
unconjugated QDs at this stage were not able to be assessed and are thus not included here.

Figure 17

Fluorescence intensity within in the GI tract from GnRH QDs at T24 (A) and T48
(C) and AVT QDs at T24 (B ) and T48 (D).

Following exposure at Gosner stage 30, measurable fluorescence intensity was observed
within the GI tracts of larvae exposed to unconjugated QDs, AVT-, and GnRH-conjugated QDs
at 24 hours. Larvae treated with AVT-conjugated QDs exhibited significantly higher (p < 0.01; F
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= 16.9) fluorescence intensity than both unconjugated and GnRH-conjugated QDs. There was no
significant difference in fluorescence intensity within the GI tract between GnRH-conjugated
and unconjugated QDs.
Measurements were also taken at 5 hours post-exposure and signal was detected in the GI
tract in AVT and GnRH-conjugated QD treated larvae, though not in unconjugated QD treated
larvae. As in exposure at Gosner stage 25, AVT-conjugated QDs resulted in a significantly
higher (p < 0.01) average fluorescence intensity than GnRH-conjugated QDs. In addition, both
treatments had signficiantly higher (p < 0.01; F = 23.64) fluorescence intensity measurements at
5 hours post-exposure than at 24 hours (Figure 17). The only additional organ to retain QD
fluorescence intensity was the kidney following treatment with AVT-conjugated QDs at Gosner
stage 30. Signal was observed at five hours post-exposure but was not detected at 24 hours
(Figure 18).
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Figure 18

Visible QD fluorescence within the GI tract in Gosner stage 30 larvae following
exposure to unconjugated QDs at T5 (A) and T24 (D); AVT QDs at (B ) T5 and (E)
T24; and GnRH QDs at (C) T5 and (F) T24.

88

Figure 19

Presence of AVT-conjugated QDs within the kidney of larvae exposed at Gosner
stage 30 at A) five hours post-exposure and B ) twenty-four hours post-exposure.
Histological analysis was also performed on metamorphosed juveniles posttreatments, but there was no remaining fluorescence signal detected by
metamorphosis.

A final comparison of the fluorescence intensity retained in larval GI tracts was made
between exposure at Gosner stage 25 and 30 at twenty-four hours post-exposure. When
combined across both development stages, there was no difference (p = 0.152; F= 2.15) in
fluorescence intensity between AVT-QD and GnRH-QD treatment. There was, however,
significantly greater (p < 0.01; F = 18.06) fluorescence intensity measured between exposure
stages, with higher intensity measured in larvae exposed at Gosner stage 25 than 30 (Figure 19).
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Figure 20

Fluorescence intensity in the GI tract of larvae exposed at G25 (A&B) and G30
(C&D) to AVT (A&C) and GnRH (B&D) conjugated QDs at 24 hours

Discussion
In-vivo imaging revealed a rapid decrease of quantum dot nanoparticles from water
containing toad larvae. In experiment 1, a dose and time dependent decrease in fluorescence is
seen in all groups other than the control. Signal was nearly entirely lost after 48 hours postexposure. Signal was not observed again within the wells even after 72 hours. This could be due
to various factors. One, is that the signal was simply being quenched over time, or nanoparticles
breakdown over time. This, however, is unlikely due to the fact that QDs are frequently
suspended in aqueous solutions for long-term storage and one their key characteristics is their
fluorescence longevity. The other possibility is that the tadpoles readily took up QDs following
exposure. Further evidence that supports this theory is that once the fluorescence disappears from
the wells, it was not observed returning in up to 72 hours. This suggest that the tadpoles are
retaining the nanoparticles that they are absorbing. This was then validated through histological
analysis, which showed that QDs aggregated within exposed larvae.
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In this study, larvae approximately at Gosner stages 1, 19, 25, and 30 were exposed to QDs. At
stages 25 and 30, the mouth has developed and opened, and the GI tract is functional, which
allows larvae to begin free-feeding (Gosner 1960). When larvae were exposed to QDs at stages 1
and 19, prior to the development of functional mouth parts and initiation of feeding, QD
retention was not observed. In larvae exposed to QDs at stages 25 and 30, fluorescent signal was
observed around the mouth parts of larvae. Taken together, we surmise that the primary mode of
integration of QDs into larval systems is by the mouth. Experiment one demonstrated that this
can be achieved as quickly as one-hour post-exposure. Oocytes exposed at fertilization and
larvae exposed at stage 19 show no integration even after 24 hours, by contrast.
However, while QDs were not able to integrate into the fertilized oocytes and pre-hatch
embryos, some images revealed QD fluorescence within the protective egg jelly surrounding the
embryos. Therefore, appears that QDs are capable of getting through this protective layer, but are
not capable of entering the embryos. Egg jelly is a gelatinous glycoprotein layer surrounding the
eggs of numerous aquatic and amphibious species (Jego et al. 1980). It both protects the egg
from outside contaminants and facilitates fertilization through interactions with sperm and
subsequent capacitation (Carey and Bryant 1985; Jego et al. 1980). Three layers, composed of
separate proteins, have been identified in anuran egg jelly capsules, which implies differences in
both function and permeability. It is not well known what means of protection egg jelly layers
confer; whether it is mechanical or has other, anti-pathogenic means of defense. (Carey and
Bryant 1995).
Egg jelly layers around amphibian embryos have previously been shown to reduce
embryo mortality by contamination of hydrocarbons compared to embryos lacking this
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protective layer (Marquis et al. 2006). In addition, Brinkmann et al. (2021) reported that titanium
dioxide nanoparticles do not enter the oocyte of zebrafish due to their jelly-like coating following
24 hours of exposure post-fertilization. Thus, egg jelly likely provides protection against QD
nanoparticle contamination as well. It is possible, however, that nanoparticles can be indirectly
toxic to developing embryos. Duan et al. (2020) found that nanoplastics can reduce gas transfer
through zebrafish egg jelly, causing embryonic distress and decreased hatch rates.
In this study, embryos were only exposed to QDs for twenty-four hours. It may be
possible that longer durations of exposure may allow passive integration into oocytes or early
embryos. However, as amphibian larvae progress through developmental stages rapidly within
the first 24 to 72 hours of fertilization (Gosner 1960), it would be difficult to assess how long
QDs would require to diffuse into early-stage embryos. The information here therefore supports
that QDs are not capable of entering developing larval systems until mouth parts are developed
and the gastrointestinal system is functional. This would mean that amphibian embryos may be
“safe” from QD contamination potentially until several days post-fertilization. This is valuable
information that could be applied to protecting developing amphibian larvae in the wild in areas
of known or potential contamination by informing practictioners of amphibian conservton with a
window of time in which embryos must be removed from contaminant sources.
All the larvae in this study were produced following in-vitro fertilization (IVF) with fresh
sperm. Burger et al. (unpublished) reported an average cleavage rate following IVF in the same
species (Anaxyrus fowleri) as 86 ± 8%. This is consistent with the average of cleavage rates
between 62-82% across treatments in the current study. Quantum dots were applied to oocytes in
spermic urine during fertilization, implying that QDs do not appear to negatively impact
fertilization. However neurula and hatch rates were low, even though there was no difference in
92

rate of development between larvae treated with the control and the three QD treatments.
Neurulation frequency was only 6% in PBS control groups, and ranged between 13% and 25%
across QD treatments. Hatch rates were similar, with only 3% of PBS-treated cleaved oocytes
hatching, and only 6-19% of QD-treated larvae hatching. This is much lower than the neurulation
and hatch rates found by Burger et al. (unpublished), which reported an average neurulation and
hatch rate of 70 ± 11% and 52 ± 10%, of cleaved oocytes respectively. Within the current study,
however, control and QD treatments did not have any significant differences in larval
development progression in neurula, hatch, and metamorphosis stages. The greatest predictor of
larval progression through later development stages would appear to be the degree of successful
development to neurulation. While we report a large difference in the treatment effect on the
number of cleaved embryos that undergo neurulation, subsequent embryonic development to
hatch and metamorphosis stages was not significantly different. Quantum dot exposure may
result in autoactivation of amphibian oocytes, a process wherein the first division is instigated by
a source that is not fertilization.
As mentioned, QDs in each treatment group and concentration accumulated within larval
systems following exposure at Gosner stages 25 and 30. Upon histological analysis, aggregation
of quantum dots was observed in the gastrointestinal (GI) tracts of the larvae after 1, 24, and 48
hours and quantified after 24 and 48 hours in experiments two and three. The potential for QD
aggregation in living systems has been previously reported. Habeebu and colleagues (1998)
noted that cadmium nanoparticles aggregate within the liver. While aggregation was not found in
the liver in this study, the occurrence of aggregation in the GI tract is unsurprising. Oral
integration is further evidenced by QD signal surrounding larvae mouth parts.
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Of all larvae treated at Gosner stage 25, regardless of treatment, 78% died by the fourth
week of observation. In addition, larvae exposed to GnRH-conjugated QDs at stage 19
experienced an early loss of 80% of treated larvae. Unfortunately, improper husbandry is likely a
factor in both of these cases, which makes assumptions regarding toxicity by stage difficult to
assess in these treatment groups. Despite this challenge, we observed accumulation of QDs
within the GI tract that was significantly higher in both GnRH-conjugated and AVT-conjugated
groups when exposed to larvae at Gosner stage 25 than stage 30. Because both the mouth parts
and GI tract development is more advanced at Gosner stage 30 than stage 25, this retention is
likely due to the faster excretion rates of QDs by the more developed GI tract of stage 30. This
longer retention of QDs within the GI tract could lead to toxic effects. However, due to the
mortalities of larvae treated with the PBS control in this group as well and the aforementioned
husbandry failures, conclusions are difficult to draw from these data.

In all exposure treatments presented here, fluorescence intensity of accumulated QDs was
higher at early time points. Following exposure at Gosner stage 25, fluorescence intensity was
greater at 24 hours than at 48 hours, and exposure at Gosner stage 30 resulted in greater
fluorescence intensity at 5 hours post exposure than 24 hours. Taken together with the results
from experiment 1 which demonstrated that larvae uptake QDs rapidly within hours, it appears
that QDs accumulate quickly within larval systems and are slowly excreted over time. While
excretion rates were not quantified in the present study, histological analysis was also performed
on metamorphosed juveniles. No fluorescence was detected at this stage. Larvae metamorphosed
at approximately one-month post-QD exposure, which implies that QDs were excreted at some
point during development over that time period.
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Interestingly, GnRH- and AVT-conjugated QDs resulted in greater fluorescence intensity
in QD aggregates than unconjugated QDs. Hormone-conjugated QDs may be binding to
receptors within the GI tract of the larvae, which could account for the greater abundance of
conjugated QD aggregation compared to unconjugated QDs. However, conjugated QD
localization was primarily found within the GI tract and not within organs containing receptors
for these hormones. The exception was that AVT-conjugated QDs were found in small
concentrations in the kidneys of GS 30 larvae at five hours post-exposure. They were no longer
detected at 24 hours post-exposure, or detected in larvae exposed at Gosner stage 25.

Unconjugated QDs used in this study were between 10 and 20 nM, while hormoneconjugated QDs may be larger due to the additional conjugate coatings surrounding them, which
can increase their sizes (Barteneva and Vorob'ev 2010). Smaller QDs were likely excreted more
readily, while large QDs could become trapped within organs for longer periods and not as
readily excreted. Choi et al. (2007) found that the increase in size of quantum dots caused by
additional coatings prevented efficient renal excretion from the body of rats. Thus this may lead
to the higher fluorescence intensities found in organs over time from conjugated nanoparticles
compared to unconjugated QDs. For diagnostic and therapeutic effects, entry into a cell by
nanoparticles can be beneficial. However, it is preferred that the nanoparticles are then safely
exocytosed from the cell. Tekle et al. (2008) demonstrated the endocytosis of bioconjugated
quantum dots into living cells, but their exocytosis was delayed, indicating a potential disruption
in cell function.
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Conclusions
As their potential for in vivo imaging and disease therapy grows, and with it their
potential for contaminating environmental systems, it is crucial to determine how QDs interact
within living organisms and the potential toxic effects they may have on living cells and systems.
In this study we have shown that a) amphibian larvae uptake QDs from aqueous environments in
both a dose and stage dependent manner, b) that QDs aggregate within the GI tracts of larval
amphibians and are not full excreted within forty-eight hours, and c) that QDs do not appear to
largely affect larval development. These results should be considered for the use of quantum dots
in-vivo and for potential contamination of quantum dots into the environment. Further study is
needed, however, to determine the potential of stage-specific toxicity and integration of QDs in
developing larval systems.
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CHAPTER IV
NASAL ADMINISTRATION OF GONADOTROPIN RELEASING HORMONE (GNRH)
ELICITS SPERM PRODUCTION IN FOWLER’S TOAD (ANAXYRUS FOWLERI)
Introduction
Like most vertebrates, the neuroendocrine hormone gonadotropin releasing hormone
(GnRH) in amphibians mediates gamete production through the hypothalamic-pituitary-gonadal
(HPG) axis. Upon onset of favorable environmental conditions, GnRH is released by the
hypothalamus to stimulate the anterior pituitary, which then secretes the gonadotropins
luteinizing hormone (LH) and follicle- stimulating hormone (FSH). These gonadotropins then
travel through the bloodstream to the gonads, where they mediate steroid hormone synthesis and
gametogenesis [1, 2, 3]. Exogenous GnRH treatment has become a powerful tool in stimulating
gamete production from a variety of species. For example, GnRH receptor agonists have been
successful in inducing spawning for commercial fish farming in species such as snook [4] and
bream [5]. In amphibians, GnRH has been found to cause upregulation of GnRH receptors [6],
increased production and release of sperm in males [3, 7, 8], and follicular development and
ovulation in females [9]. Uteshev et al. [10] found that the effects of exogenous GnRH on
amphibian spermiation was similar to that found using pituitary extract, leading to the theory that
exogenous GnRH stimulates a natural gonadotropin-release cascade.
The successful stimulation of reproductive behaviors and physiological processes in
amphibians by exogenous GnRH has led to extensive use of the hormone as a tool for assisted
breeding of threatened and endangered species. This is especially the case for species with poor
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reproductive output where sustainability of the captive collection is at risk. For successful
breeding in many amphibians, abiotic and biotic cues are necessary triggers for reproduction and
include changes in photoperiod, barometric pressure, humidity, temperature, or food availability,
which are sometimes difficult to mimic in a captive environment. Although some threatened
amphibian species breed well in captivity (e.g. Panamanian golden frogs, V. Poole, pers.
comm.), a large number of captive breeding programs utilize assisted reproductive technologies
(ART), such as hormone therapy using GnRH or other exogenous reproductive hormones, to
produce animals needed for reintroduction and recovery programs [3, 11].
At present, the most common method of GnRH administration in amphibian ART is an
injection near the gonads into the peritoneal cavity [3, 12] or subcutaneously [13]. While
intraperitoneal (IP) injections of GnRH and its agonists are known to cause sperm production,
there is still some question as to the degree that the hormone acts directly at the level of the testis
or indirectly through the anterior pituitary by initiating the endogenous cascade of LH or FSH.
Receptors for GnRH in anurans are distributed throughout the body, most notably within the
brain, anterior pituitary [14, 15, 16], and the gonads [17]. Within the brain and pituitary, there are
multiple GnRH receptor types corresponding to multiple GnRH isoforms. The physiological
effects of GnRH are thought to be mediated by the location of its receptors as well as the form of
the GnRH [18]. Fernald and White [19] determined that anurans express at least two isoforms:
GnRH 1 and 2, which are secreted by various GnRH neurons distributed throughout parts of the
brain such as the hypothalamus, midbrain, and limbic areas; their release is mediated by
environmental cues such as light or moisture [15, 20]. Isoform GnRH 1 mediates hypophyseal
function, while the precise function of GnRH 2 remains poorly understood [3, 21].
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Exogenous substances administered into the nares of an animal can enter the cranial
cavity or reach the pituitary by passive diffusion across the olfactory mucosa through gaps
between nerves and into the subarachnoid space and cerebrospinal fluid [22]. From here,
possible diffusion into the ventricular or perivascular spaces could circulate the administered
substances to various areas of the brain, or around the blood brain barrier to reach the pituitary
[23, 24]. In rats, olfactory sensory neuron dendrites are exposed in the nasal passage, and their
axons project through the cribriform plate to the olfactory bulb, thus providing a pathway from
the external environment directly into the central nervous system [25]. Substances can also
actively bind to olfactory receptors and be transported along or within neurons [26, 27]. Within
the nasal cavity of amphibians and fish there are both ciliated sensory and non-sensory neurons
that extend to the internal nares and onto the olfactory bulb, wherein GnRH receptors are located
[22, 28]. For example, in tiger salamanders, GnRH agonists have been found to bind in the
epithelium of the nasal cavity and the vomeronasal organ [29]. Indeed, various studies have
found that large concentrations of exogenous substances administered nasally bind at the level of
the olfactory bulb [23, 24]. However, exogenous substances administered through the nares may
also work their way into the throat and could be swallowed; thus, entering the bloodstream via a
different route. Hence, multiple intracellular and extracellular pathways from the vertebrate nasal
cavity into the cranial cavity, cerebrospinal fluid, or bloodstream are present whereby exogenous
hormones could rapidly reach the anterior pituitary, or even bypass the blood-brain barrier and
reach other areas of the brain (e.g. hypothalamus) that contain GnRH receptors [25].
In this study, we hypothesized that small concentrations of nasally-administered GnRH
would be successful in eliciting spermiation in male Fowler’s toads (Anaxyrus fowleri) due to the
close proximity of nasal entry routes to neuroendocrine pathways mediating gamete production
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and development. To test this hypothesis, we administered four different concentrations of a
GnRHa intranasally and monitored quantity and quality of sperm produced over eight hours,
compared to controls. Here, we show that male toads nasally administered GnRH produce sperm
within a relatively rapid time frame and at motilities and concentrations suitable for in-vitro
fertilization.
Materials and Methods
Animals
Sexually mature male A. fowleri toads were collected from Oktibbeha County in
Mississippi during the breeding season from April-July 2016 and 2017 (Permit #0728161); all
experiments were conducted within the breeding season. Toads were collected from the wild as
adults, so it was not possible to assign age classes. Animals were housed in groups of four to six
in ventilated polycarbonate tanks (30 cm H x 46 cm W x 66 cm L). Average temperatures were
maintained at 21° C and animals were kept at 12 hour night/day cycles. Crickets and mealworms
were provided three times a week, and water was provided ad libitum. Insects were gut-loaded
with Repashy SuperLoad® (Repashy Ventures Inc., CA, USA) and dusted with a vitamin D
supplement prior to feeding. Toads were housed in accordance with IACUC protocols at
Mississippi State University (IACUC #16-406 and 19-345).
Hormone treatment comparison on sperm production
In the present study, a commercial GnRH analog with the trade name luteinizing
hormone releasing hormone analog (LHRHa; Sigma-Aldrich, Product #L4513) was used for all
hormone treatments. Toads (n = 15/treatment) were intranasally administered four treatment
concentrations of GnRH (1, 5, 10, or 20 µg) or phosphate buffered saline (PBS) as a control.
Hormone was suspended in PBS to achieve the desired concentration in 20 µl, with 10 µl
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administered to each nare via pipette. Due to very small concentrations of hormone and volumes
delivered into the nares, males were given a fixed amount of GnRH per treatment group rather
than adjusting the GnRH amount on a per gram body weight basis. Average male weight was
24.0 ± 0.8 grams.
Spermic urine collection over time and sperm analysis
Hormone treatment is designated as time zero (T0). Urine collections were conducted
immediately prior to T0 and every hour afterwards for eight hours. Urine was collected at each
time point by gently suspending the males above a petri dish. Using a thumb and index finger,
the hind limbs were spread until urination occurred (≤ 1 minute) into the dish. The samples were
then collected and placed in 1.5 mL Eppendorf tubes for immediate analysis. If sperm was
observed in the urine, samples were categorized as a response and spermic urine samples were
evaluated for volume, motility parameters and concentration. Sperm motility was further divided
into the categories of forward progressive motile sperm (FPM; sperm exhibiting flagellar
movement and progressing forward), non-progressively motile sperm (NPM; sperm exhibiting
flagellar movement, but not progressing forward), and non-motile sperm (NM; sperm with no
flagellar movement). Motility (M) was calculated as the sum of FPM and NPM. We also used
motility, concentration, and total volume to calculate motile sperm/mL, total sperm produced,
and total motile sperm in a given sample.
Data evaluation and statistical analysis
If a male did not release sperm in a urine sample at a given time point, that male was not
included in the analysis of that time point. Responders to each treatment group were analyzed
with a chi-squared test. Males were considered “responders” if they released sperm following
GnRH administration. All data were assessed for normality and homogeneity of variance using
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the Shapiro-Wilke’s test and Levene’s test, respectively. Percentage data were arcsine
transformed prior to analysis. Data that did not meet the parameters for normality or
homogeneity of variances (latency to spermiation, total motility, forward progressive motility,
concentration, total sperm and total motile sperm) were analyzed using a Kruskal-Wallis oneway analysis of variance followed by the Dwass, Steel, Critchlow-Fligner method for multiple
comparison analysis. In order to determine interaction effects between time and treatment we
performed a generalized linear mixed models procedure for each sperm parameter. Statistical
analyses were performed in SAS version 9.4 (Cary, North Carolina, USA). Values are expressed
as mean ± SEM and differences were considered to be significant at p ≤ 0.05.
Results
Treatment with 1 µg of GnRH did not elicit sperm production in any male and was
therefore not included in further analyses of treatments. In addition, control males, administered
phosphate-buffered saline (PBS), did not produce sperm, nor were any animals producing sperm
prior to hormone administration at T0. The average sample volume (mL), sperm concentration
(sperm/mL), total sperm, percent motility (M), percent forward progresssive motility (FPM), and
total motile sperm of each treatment group is summarized in Table 1.
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Table 1

Sperm characteristics for Fowler toads treated intranasally with three different
concentrations of GnRH. Data are shown as mean ± SEM. Significant differences
within columns are indicated by lettered superscripts
Mean Sperm Characteristics

GnRHa
(μg)

5
10
20

Responding Spermic Concentration
Urine
Males
Sperm/mL
Volume
(x105)
(mL)
0.25 ±
9
2.39 ± 0.67a
0.03
0.30 ±
14
5.68 ± 0.80b
0.04
0.42 ±
12
3.33 ± 0.64ab
0.05

Total
Sperm
(x 105)

Motility
(%)

0.94 ±
0.34a
2.41 ±
0.49b
1.66 ±
0.45ab

72.0 ±
4.0a
63.0 ±
3.6a
49.0 ±
4.0b

Forward
Progressive
Motility
(%)
48.0 ± 4.5a
35.0 ± 3.4b
29.0 ± 3.5b

Number of responders and latency to sperm production
Figure 21 shows the percentage of males responding to hormone treatment over time and
the average latencies to sperm release. Following nasal administration of GnRH, 60% of males
responded to 5 µg treatments, 93% of males responded to 10 µg treatments, and 80% of males
responded to 20 µg treatments (Figure 21A). There was no significant difference (p = 0.17) in
the number of males responding to the three treatments. On average, 5 µg of GnRH resulted in
spermiation within 2.3 hours, while 10 and 20 µg treatments of GnRH resulted in spermiation
within 2.8 hours and 1.5 hours, respectively (Figure 21B). Across all treatment groups, nearly
50% of the males began producing sperm by the one hour collection period and 73% of the
males were producing sperm by the three hour collection period (Figure 22). There was no
significant difference (p = 0.32) in latency to sperm production between treatment groups.
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Figure 21

Percentage of males (n = 15/trt) responding to each treatment of GnRH (Panel A).
Average latency (in hours) to spermiation between treatment groups (Panel B). Data
are shown as Mean + SEM.
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Figure 22

Percentage of responding males (n=15/trt), as measured through sperm production,
over time between GnRH treatment groups: 5 µg (), 10 µg (●), and 20 µg (◼).

Sperm motility over time
Figure 3 shows the sperm motility over time for the three responding treatments and the
variation that occurs between animals and across time points. Peak sperm motility for the 5 µg
treatment (92%) and the 10 µg treatment (81%) occurred within one hour, in contrast to the 20
µg treatment (82%) which peaked at eight hours (Figure 23).
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Figure 23

Average total sperm motility over time for males (n=15/trt) between GnRH
treatment groups: 5 µg (), 10 µg (●), and 20 µg (◼). Total motility is defined as
motile (M) sperm + forward progressive motile (FPM) sperm. Data are shown as
mean + SEM.

The generalized linear mixed models analysis showed there was a significant effect of
hormone treatment (p < 0.01) on motility, but no significant effect of time (p > 0.05) or treatment
x time interaction (p > 0.05). Sperm motility across time points averaged 72%, 63%, and 49% for
the 5, 10 and 20 µg groups, respectively. Average sperm motility was significantly higher with
the 5 µg (p < 0.01) and 10 µg (p < 0.04) treatmentes compared to the 20 µg GnRHa (Table 1;
Figure 23). Otherwise, sperm motility induced by 5 µg verses 10 µg GnRHa was not different (p
= 0.07).
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We also analyzed separately the FPM of sperm samples as an additional metric for
quality of sperm. The average FPM of sperm in the 5 µg treatment was 50%, which was
significantly higher (p < 0.05) than the 10 and 20 µg treatments of GnRH at 35% and 33% FPM,
respectively (Table 1). Figure 4 shows the variation in FPM over time for the three treatment
groups. The generalized linear mixed models analysis showed there was a significant effect of
time (p < 0.01) but not treatment (p > 0.05) on sperm FPM, nor was there a treatment x time
interaction (p > 0.05). The highest FPM occurred at the last 8 hour time point collection for all
three treatment groups (Figure 24) in contrast to the highest total motility, which occurreed much
earlier (Figure 24). These data indicate that a higher proportion of non-progressive motile sperm
are produced earlier and that quality of the sperm collections may increase over time to an
unknown point before declining again.
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Figure 24

Average sperm forward progressive motility (FPM) over time for males (n=15/trt)
between GnRH treatment groups: 5 µg (), 10 µg (●), and 20 µg (◼). Data are
shown as mean + SEM.

Sperm concentration over time
Males administered 10 µg of GnRH produced significantly greater (p < 0.01) average
sperm concentrations than males administered 5 µg GnRH, though concentration was not
different between the 5 and 20 µg (p = 0.07) or between the 10 and 20 µg GnRH groups (p =
0.06) (Table 1). Figure 25 shows the average sperm concentration (sperm/mL) over time for the
three responding treatments and the variation that occurs across animals and time points. The
generalized linear mixed models analysis showed there was a significant effect of hormone
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treatment (p < 0.01) on sperm concentration (sperm/mL), but no significant effect of time (p >
0.05) or treatment x time interaction (p > 0.05). However, peak sperm concentration (sperm/mL)
occurred at one hour following 10 µg (7.64 x 105 sperm/mL) of GnRH administration, whereas 5
µg (5.14 x 105 sperm/mL) and 20 µg (6.91 x 105 sperm/mL) treatments had peak sperm
concentration four and five hours following hormone administration, respectively (Figure 25).
We also calculated total sperm in a sample and subsequently the total number of motile sperm,
with samples averaged across treatment groups (Table 1; Figure 26). Overall, more animals
(93%) produced sperm in response to the 10 µg GnRH treatment group and had a higher
concentration of sperm.
The highest sperm/mL (5.68 x 105), total sperm (2.41 x 105), and total motile sperm
concentration (1.66 x 105) resulted from treatment with 10 µg of GnRH (Figure 26). Because
percent motility was typically between 50-70%, total motile sperm concentration may be a more
valuable reflection of the quality of a sample and its fertilization potential than total sperm/mL.
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Figure 25

Average amount of sperm/mL produced over time by males (n=15/trt) between
GnRH treatment groups: 5 µg (), 10 µg (●), and 20 µg (◼). Data are shown as
mean + SEM.
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Figure 26

Average number of sperm in sample following treatment of GnRH (5, 10, and 20
µg) calculated as sperm/mL, total number of sperm, and total motile sperm.
Different letters indicate significant differences (p < 0.05) within a category. Data
are shown as mean + SEM.

Discussion
To the author’s knowledge, this is the first time intranasal GnRH administration has been
used to elicit spermiation in an anuran. Of the five treatments tested, GnRH concentrations of 520 µg resulted in sperm production for 60-93% of the animals. The lowest concentration of
GnRH we used, 1 µg, was not effective at stimulating sperm production and may indicate that
the concentration of hormone was too low to adequately trigger a downstream cascade of
gonadotropin signaling. We found that spermiation occurred within 2 hours of hormone
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treatment and sperm quantity and quality remained elevated for up to 8 hours, allowing for
multiple collections of sperm from individuals. Moreover, the use of a pipette to administer
hormone intranasally, compared to traditional methods of IP injections, is a novel, minimally
invasive delivery method that should be easily transferable to captive breeding programs. We
speculate that, given its proximity and route of transfer, nasal administration of GnRH targeted
its receptors within the pituitary to modulate LH/FSH secretion and subsequent steroidogenesis
and gamete production in the testes.
For amphibians, the most common hormone delivery method to stimulate gamete
production is intraperitoneal (IP) injections; thus, we know much more about the physiological
responses of animals receiving hormones via this delivery route. We surmise that IP injections of
GnRH may act systemically on GnRH receptors located throughout the body including on the
gonads and pituitary; thus, diluting the overall effect on the HPG axis. Bambino, Schreiber and
Hsueh [30] found that treatments of GnRH in rats decreased testicular LH receptors as a result of
repeated exposure, thereby reducing modulation of testicular function by pituitary-released
gonadotropins resulting in a decrease in spermatogenesis. We suggest that nasal administration
of GnRH would target receptors within the pituitary or brain, thereby directing and reducing the
amount of exogenous hormone needed compared to IP injections, reducing the risk of receptor
downregulation. There are three receptors for GnRH that are located throughout the amphibian
brain and pituitary: GnRH1R, GnRH2R, and GnRH3R [21]. Various forms of GnRH bind to
these different types of receptors with differential affinity and likely play different roles in
reproductive functions [31]. For example, GnRH 2 is thought to primarily act as a
neuromodulator within the midbrain while GnRH 1 is suggested to control gonadotropin release
[33, 34]. Hence, our nasal administration of GnRHa, a homolog of GnRH 1, and subsequent
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sperm production in the toads is likely acting through GnRH 1 receptors in the anterior pituitary,
although there may be other receptor binding occurring as well.
Kouba et al. [8] reported that in Anaxyrus americanus, IP injections of GnRH (1-32 µg)
resulted in only 35% of the males producing sperm. In comparison, the current study showed an
increased number of males (maximum 93%) produced sperm following nasally administered
GnRHa treatments. While both A. fowleri and A. americanus are from the same family
bufonidae, species differences may impact the efficiancy of hormone treatments, regardless of
administrative route. Moreover, the study by Kouba et al. [8] was performed outside of the
breeding season for A. americanus, while the current study was performed within the breeding
season of A. fowleri. Comparing the effectiveness of intranasally administered GnRH in eliciting
spermiation outside of the breeding season in A. fowleri would give insight into the dependence
of spermatogenesis on abiotic factors.
Here, we report a sperm motility over time ranging between 49-72%, depending on
GnRH concentration, which is slightly lower than other studies using IP injections of GnRH. In
Atelopus zeteki, average motility was approximately 85% for treatments of 1-4 µg per gram of
toad body weight [35] while in Anaxyrus americanus, GnRH treatments resulted in an average
motility of approximately 80% [12]. Peak sperm production, where sperm/mL concentration and
motility coincide, was observed at one hour post-administration of 10 µg of GnRH in the current
study. The other two treatments did not generate a discernable peak in sperm production. In A.
americanus, a clear peak in combined optimal sperm motility and concentration was not
observed across 24 hours post GnRH IP injection [12]. Initial sperm production in A. americanus
was observed at three hours post-hormone treatment [12], which is delayed compared to the
average latency (2.2 hours) of all three responding GnRHa treatments reported in this study. It
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should be noted, however, that in the A. americanus study, sperm collections did not begin until
hour three, which makes a direct comparison of latency to sperm production with the current
study difficult. In the bufonid A. zeteki, peak sperm production following IP GnRH
administration was found at 3.5 hours post-treatment [35], although sperm presence was first
observed at 1.5 hours, which is a closer latency time to what we found with nasal administration
in A. fowleri. In this study, we ceased spermic urine collections after eight hours, and did not
perform a 24-hour collection. Previous studies in bufonids have shown a high amount of
variability in the duration of sperm release, with spermic urine production ranging from 3 hours
to up to 24-hours post-hormone adminstration [12, 34]. However, sperm concentrations began to
significantly decline by 9 hours post-administration, and reached negligible concentration by 24hours. Therefore, sperm collected within the first 8 – 9 hours post-administration would likely be
of the highest quality and concentration for in-vitro fertilization.
In the study of A. americanus, Kouba et al. [12] also tested the effectiveness of human
chorionic gonadotropin (hCG) on sperm production. Unlike the hypophyseal functions of GnRH,
hCG mimics the downstream effects of luteinizing hormone (LH) and acts directly on either the
testes [9, 36] or the ovaries [9, 37] to induce gamete maturation and release. Following the
highest treatment of hCG (300 IU), 100% of males produced sperm with a peak of 12 x 106
sperm/mL. While the concentration achieved from hCG was higher than in the current study,
motilities ranged from 40-80%, similar to motilities reported here. Compared to GnRH, however,
hCG is more expensive, must be used at higher concentrations, and stock availability can
fluctuate. Therefore, despite its increased ability to produce higher concentrations of sperm, the
relative cost and comparable motilities may make nasally administered GnRH a viable substitute
for IP-administered hCG, especially for small amphibians that are difficult to inject.
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In order for nasal administration of exogenous hormone to be considered a useful tool for
assisted reproductive technologies (ART), it is imperative that sperm be collected in
concentrations that are useful for in-vitro fertilization (IVF) or cryopreservation. To achieve high
rates of fertilization in anurans, sperm concentrations (sperm/mL) should be between 1 and 8 x
105 [11, Langhorne et al., unpublished]. As noted in Table 1, each treatment group of GnRH
above 1 µg resulted in an average sperm/mL concentration of 2.6 x 105 or above, though the 10
µg treatment group resulted in the highest sperm concentrations overall. Adequate concentrations
of sperm could be collected over time by pooling samples across eight hours (or longer), helping
to meet the criteria for IVF of a useful tool for amphibian ART [11, Langhorne et al.,
unpublished]. As previously mentioned, the 10 µg treatment groups also elicited the highest
sperm concentrations overall compared to the other two treatment groups. Taken together, these
data suggest that administrations of 10 µg of GnRH could be used to collect high enough
amounts of sperm for assisted breeding following nasal hormone administration for this species.
The implementation of nasal hormone stimulation in captive amphibian breeding may
have several advantages over IP injections. For example, IP injections require larger hormone
concentrations calculated on a per gram body weight basis, which can be expensive or pose a
risk to animal health and reproductive output. By contrast, nasal administration uses lower
concentrations of hormone, smaller volumes of delivery vehicle, and is less invasive than IP
injections. In addition, many zoological institutions require trained veterinarians to administer
injections to animals in collections, whereas non-invasive hormone treatment by pipetting
through the nares would not require this level of expertise. Furthermore, eliminating the need for
IP injections increases the safety factor for animals that are too small to safely inject with a
needle. Thus, nasal administration is a viable alternative hormone delivery route, owing to its
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similarity in sperm production variables to that of previously published results from IP injections
of GnRH.
Conclusions
This study demonstrates for the first time that exogenous GnRH can be delivered
intranasally in an anuran species to stimulate a downstream physiological effects of gamete
production and release. Moreover, GnRH concentrations between 5-20 µg successfully elicited
sperm production in up to 93% of male Anaxyrus fowleri and across at least 8 hours. The results
of these experiments demonstrate that non-invasive nasal administration of hormone is a viable
substitute for IP injections, which may be particularly helpful in other, smaller amphibians.
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CHAPTER V
IN-VIVO MAPPING AND BIOACCUMULATION OF GNRH-CONJUGATED QUANTUM
DOT NANOPARTICLES IN A MODEL ANURAN SPECIES
Introduction
The field of assisted reproduction in amphibians employs numerous techniques to
enhance reproductive output. One of the most common methods is the use of exogenous
hormone therapies. Hormones of interest are those which have been proven to stimulate both
reproductive behaviors as well as gamete development. One of the most common of these used
in breeding institutions today is gonadotropin releasing hormone (GnRH), a neuromodulatory
hormone that acts on the brain to activate a cascade of hormones for gamete release (Kouba et al
2009). Natural breeding behaviors in anurans are heavily seasonal and rely on environmental
cues such as rainfall, food availability, and temperatures (Browne and Zippel 2014). Following
these cues, GnRH is released from the hypothalamus to stimulate the release of two
gonadotropins, follicle stimulating hormone (FSH) and luteinizing hormone (LH) from the
pituitary. In males, both gonadotropins act on cells within the testes; FSH stimulates the
secretion of androgens such as testosterone and dihydrotestosterone (DHT) by Leydig cells and
mediates the process of spermatogenesis, while LH stimulates Sertoli cells that control sperm
maturation and release (Norris and Carr 2013). Circulating steroid hormones either stimulate the
hypothalamus and pituitary to initiate mating behaviors, or inhibit further gonadotropin release
(Norris and Lopez 2011). Synthetic GnRH, often referred to as GnRHa or LHRHa, can also
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stimulate the hypothalamic-pituitary-gonadal (HPG) axis to induce reproductive functions (Licht,
Porter and Millar 1987) when environmental cures are limited or absent.

Many institutions have been unable to breed endangered anuran species as a result of the
limits of captive environments to mimic needed environmental stimuli. It is in these cases that
assisted reproductive technologies (ART) are needed. The most common ART procedures use
hormone therapy, which can facilitate natural breeding or induce gamete release for in-vitro
fertilization (IVF), wherein gametes are collected from each male and female and combined
externally. The most common delivery method of hormone treatment is intraperitoneal (IP)
injection, in which hormones enter the bloodstream and circulate to other organs such as the
brain and pituitary (Kouba et al. 2003; Kouba et al. 2012; Trudeau 2016). There is some concern
regarding the relative safety and level of invasiveness of hormone administration using syringes
and needles, especially in small animals. In some cases, IP injections are only permitted to be
given by approved veterinary staff, a requirement that has both slowed and limited the number of
institutions and staff that have adopted hormone administration for enhanced breeding output of
their threatened or endangered amphibians. Due to the critical conservation status of over 30% of
amphibian species today, an alternative safe and easily-applicable delivery method for
exogenous GnRHa to stimulate breeding..
A study by Julien et al. (2019) found that intranasal administration (IN) of exogenous
GnRHa is capable of eliciting sperm production in male Anaxyrus fowleri toads. Not only does
this delivery method not require injections with needles, but it is also relatively fast and simple.
While IN delivery of GnRH has been shown to be successful at eliciting spermiation, it is
unknown if the response rate and sperm parameters are comparable to those obtained by
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administering GnRHa using IP injection. Differences in the efficacy of GnRHa delivered through
IN and IP administration could depend on the pathway GnRHa takes to reach the brain and
pituitary. Determining the differences of the IN and IP pathways could dictate the optimal
hormone delivery method in terms of both the level of invasiveness and physiological outcome.
While comparisons of spermiation response can readily be made between administration routes
(nasal and intraperitoneal) by analyzing differences in male responsiveness and sperm
parameters, identifying the localized GnRH receptors that bind GnRHa must be accomplished
with tissue analysis. .
Despite the primary receptors of GnRH being localized within the brain and pituitary,
receptors for GnRH have also been found on the gonads of several vertebrates (Huhtaniemi et al.
1985; Ban et al. 1990; Millar 2004), however, therecise function of GnRH within these tissues is
not well-known. Intraperitoneal injection, by virtue of the route’s proximity to the gonads, may
enable GnRHa to exert stronger action on the testes through direct binding than solely through its
action on the pituitary, while nasal administration may enable GnRHa to act predominantly on
the pituitary by directly accessing it through nasal pathways..
The difficulty in investigating precise hormone pathways and functions lies in the limited
availability of live in-vivo and real-time observational methodologies. These procedures often
require the sacrifice of numerous animals for removal of the tissue or organs for in-vitro analysis.
Some non-fatal methods of investigation employ x-ray or positron emission tomography (PET)like imaging technologies. One such system is the In-Vivo Imaging System (IVIS; company)
which can function like a PET-scan while also having the capacity for fluorescence dye detection
and x-ray imaging. In contrast to traditional fluorescent dyes and proteins, quantum dot
nanoparticles (Qdots) exhibit bright and long lasting fluorescence that can be detected in living
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tissue. Moreover, quantum dots are incredibly versatile in function, application, color, and
intensity (Burbach et al. 1995) and when covalently linked to complex biomolecules such as
peptides, proteins, and nucleic acids they are ideal for targeting specific tissues for in-vivo
imaging(Xing and Rao, 2008; Gao et al., 2011).
In the current study, GnRHa-conjugated Qdots were delivered to male toads (Anaxyrus
fowleri) by either intranasal administration or intraperitoneal injection in order to investigate
the respective pathways of each delivery method. IVIS imaging was performed to visualize QD
movement and aggregation in-vivo and in real-time.The objectives of this study were to 1)
compare the spermiation response between intraperitoneal and intranasal administration of
GnRHa, 2) compare the spermiation response to GnRHa-QD conjugates following both routes,
and 3) map the real-time progression and bioaccumulation of GnRHa-QD conjugates s following
both IN administration and IP injection.
Materials and Methods
Study animals
Sexually mature male Anaxyrus fowleri toads were collected from Oktibbeha County in
Mississippi during the breeding season from April-July 2016 and 2017 (Permit #0728161),
March-April 2018 (Permit #0501181), and April 2021 (Permit #0504202). Males weight on
average 24.0 ± 0.8 grams. Toads were housed in accordance with IACUC protocols at
Mississippi State University (IACUC #16-406; #19-345). Briefly, males were housed in
polycarbonate tanks (30 cm L x 46 cm W x 66 cm H) in groups of 3-6 on a substrate of cocoa
fiber and soil cultured with springtails (Collembola), with terra cotta pots and PVC piping as
shelter options. Animals were fed a diverse diet of crickets, dubia roaches, and mealworms three
times a week on a rotating schedule. Prior to feeding, all insects were gut-loaded with vitamin
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supplements (Repashy Ventures Inc., CA, USA) and coated in Reptivite calcium powder
©

(ZooMed Laboratories Inc., Costa Mesa, CA, USA). Water was available ad libitum. Animal
housing areas were kept on a 12-hour day/night cycle and were maintained at 23 ± 2 °C.
Following this study, all subject animals were euthanized for additional experiments.
Hormone administration
Male toads were treated with a single 10 µg dose of GnRHa that was administered either
intraperitoneally (n = 12), intranasally (n = 13), or orally (n = 13). GnRHa was dissolved in a
vehicle of 200 µl phosphate buffered saline (PBS) and delivered by intraperitoneal injection into
the peritoneum of male toads using a 30-gauge insulin needle and syringe. For intranasal and oral
delivery, GnRHa in a vehicle of 10 µl of PBS was pipetted directly into the nares or mouth of
individuals while they were held upright and the fluid allowed to drain.
Quantum dot administration
Male A. fowleri were administered one of two types of quantum dot nanoparticles, each
measuring between 15-20 nm: an unconjugated QD(QTracker 655, excitation/emission: 455585/655, Fisher Scientific) or gonadotropin-releasing hormone (GnRHa) conjugated QD in
which GnRHa was conjugated to QTracker 655 (Conjugations were performed by Invitrogen
(Fisher Scientific). Exact ratios of hormone to QD conjugations were not made available.
As a control, the effects of quantum dots on physiological responses were determined for
both unconjugated QD and GnRHa-QDs. Males were administered 50 nM QD-GnRHa
conjugates as either IN (n = 3) or IP (n = 3) administration routes, and assessed for spermiation
response.
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Collection and analysis of spermic urine
To determine the response to GnRHa or QD administration, urine was collected from all
males to determine if sperm were released. Urine was collected by holding males upright over
sterile petri dishes and eliciting urination via a natural scare response. Urine was then analyzed
using an Olympus CX-41 for sperm presence, motility, and concentration. Sperm motility was
evaluated by assessing the number of motile sperm present in a count of 100 total sperm, and
sperm concentration was evaluated using a hemocytometer. The same analysis was performed to
determine the differences in spermiation response to GnRHa delivered through IP, In and oral
routes.
IVIS imaging
For imaging, male toads were anesthetized using ethyl 3-aminobenzoate
methanesulfonate (MS-222; Sigma-Aldrich E10521) at a concentration of 1 g/L for 30 minutes.
Once anesthetized (determined by pedal reflex tests and heart rate) all males were imaged for
baseline fluorescent measurements prior to the unconjugated-QD and GnRHa-QD treatments.
Males were given QDs either intranasally or intraperitoneally. For IN delivery, anesthetized
males (n = 2) were suspended upright and administered 50 nM of QDs in a vehicle volume of
170 µl distributed evenly into the nares. For IP delivery, anesthetized males (n = 2) were held on
their backs and injected with 170 µl of 50 nM QDs.
All males were imaged immediately after QD administration, and then at subsequent time
points as designated in two different experimental trials. In trial 1, imaging was conducted at 15,
30, 45, and 60 minutes post QD treatment, and in trial 2, males were imaged at 24 hours post-QD
administration. Measurements were taken both on the ventral side and dorsal side of the imaged
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animals. All imaging was performed using the In-Vivo-Imaging System (IVIS; Perkin-Elmer). In
order to determine the best excitation and emission filters, spectral unmixing was performed.
Euthanasia and histology
Following IVIS imaging, males were euthanized using an overdose of MS-222 at a
concentration of 3 g/L for 60 minutes. Once males were euthanized, they were prepared for
histology. In trial 1, males were sectioned in a “breadloaf” fashion (Figure 27) in order to
determine QD pathways following administration. Briefly, males were prepared by submerging
them in formalin for 48 hours and then undergoing a decalcification process using Kristensen’s
solution for 72 hours. Each toad was then sectioned by hand using a razor blade. In trial 2,
organs were excised at hours 1 and 24 for comparison of signal accumulation, specifically the
brain, heart, liver, stomach, kidneys, and testes. Histological samples were encased in paraffin
wax and sectioned at a thickness of 5 µm, which were then mounted onto slides for imaging and
comparison to fluorescent signal detected by IVIS imaging.

Figure 27

Breadloaf sectioning map
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Spectral analysis
For analysis, the brain, heart, liver, GI tract, kidney, and testes were excised from males
treated with nanoparticles, and analyzed for fluorescence signal using a Nikon 80i microscope.
Images were assessed at a 20x magnification first with a FITC/TRITC filter and then with a QDspecific filter cube using an excitation wavelength between 485 nm and 525 nm. Five images
were taken per slide of selected organs. Section images of organs were uploaded into ImageJ
software for Windows. From each section of interest, color channels were split to separate
monochrome images, and five regions on each section image were subsequently measured for
fluorescence intensity and background signal. Background signal was then subtracted from
measured fluorescence intensity and averaged across each organ. Spectral data was organized
and graphed in Microsoft Excel based on treatment and organ.
Statistical analysis
Spermiation responses were compared between intraperitoneal and intranasal spermiation
responses, oral and nasal administration. Assessed spermiation parameters included sperm
concentration (sperm/ml), forward progressive sperm motility (FPM), and total sperm motility
(TM). Prior to statistical analysis, percentage data (responders, FPM and TM) were ARCSIN
transformed in Microsoft Excel. For all data, normality and homogeneity of variance were tested
using Shapiro-Wilke’s and Levene’s test. Statistical tests were all performed using SAS Version
9.4 (Cary, North Carolina), and statistical significance was set at p ≤ 0.05. All values were
expressed as mean ± SEM.
Sperm parameters (FPM, TM and concentration) were examined with a Student’s t-test to
compare the efficacy of GnRHa when delivered through IN or IP administration. Comparison of
IN and oral routes of delivery were similarly assessed for spermiation response.
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Additional comparisons were made between the bioaccumulation of unconjugated and
GnRH conjugated Qdots in organs (kidney and GI tract). Spectral data of conjugated and
unconjugated Qdot bioaccumulation within the GI tract and kidney were compared between
nasal and intraperitoneal at 1 hour and 24 hours post-treatment using a Mann-Whitney U test for
non-parametric data.
Results
Intraperitoneal vs. intranasal administration of GnRHa
While forward progressive motility (FPM) did not differ (p = 0.119; t = 1.188) between
IP and IN administration of GnRHa, nasal administration resulted in significantly higher total
percentages of both motile sperm (p = 0.049; t = 1.669) and concentration of sperm/mL (p =
0.006; t = 2.572) than hormones given through intraperitoneal injection (Table 2). Sperm
production began as early as one hour and continued for each subsequent hour until collections
were stopped at hour eight post hormone collection (Figures 28 and 29).
Table 2

Average number of responders and sperm parameters following intranasal (IN) and
intraperitoneal (IP) administration of 10 µg GnRHa. Data are shown as mean ±
SEM, and significant differences are indicated by *.

Route Responders
IN
IP

14/15
7/12

Responders
(%)
93.3
58.3

Sperm/mL
(x105)
5.7 ± 0.8 *
2.0 ± 0.6
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FPM

TM

35.0 ± 3.4
25.0 ± 5.0

63.0 ± 3.6 *
51.0 ± 6.0

Figure 28

Average concentration sperm released over time for male toads administered 10 µg
GnRHa via IN administration (n = 15) (●), and IP injection (n = 12) (■). Data are
shown as mean + SEM.
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Figure 29

Forward progressive motility (A), and total motility (B) of sperm samples collected
from male toads given 10 µg GnRHa via IN administration (n = 15) (●), and IP
injection (n = 12) (■) over time. Data are shown as mean + SEM.
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Intraperitoneal vs. intranasal administration of GnRHa-Qdot
Intranasal administration of GnRHa-QDs did not result in sperm production from any
male toads, however, intraperitoneal injection of GnRHa-QD did elicit a spermiation response
from all three males. The average sperm motility was 47 ± 7 %, and the average concentration
was 3.84 x 104 ± 1.21 x 104 sperm/mL
IVIS imaging of Qdots
Fluorescence signal of both GnRHa-conjugated Qdots and unconjugated Qdots were
tracked using the In-Vivo Imaging (IVIS) system. In trial 1, Fluorescent signal obtained from the
IVIS system after IN administration indicates that QDs initially at the nares, migrate to the ear or
throat. I. After IN administration, QDs (both unconjugated and GnRHa conjugated QDs)can be
seen migrating from the nares to the tympanic membrane when viewed from the dorsal side at
both 1 hour and 24 hours post-treatment (Figure 30A). Ventrally, fluorescent signal is localized
near the mouth and throat after 1 hour, but is observed in the stomach after 24 hours (Figure
31).
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Figure 30

In-vivo imaging of QD fluorescent signal following (A) intranasal administration,
and (B) intraperitoneal injection of GnRHa-QDs and unconjugated QDs (Dorsal
View).

Figure 31

In-vivo imaging following intranasal administration of (A) GnRHa-QD and (B)
unconjugated QDs prior to treatment and at 1 hour and 24 hour post-treatment
(Ventral view).
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In contrast, intraperitoneal injection of QDs showed a dispersal across the abdomen from
the point of injection for both unconjugated QD and GnRHa-QDs. (Figure 32). Ventral imaging
further revealed that the GnRHa-QD signal remained visible in the lower abdomen, while
observable signal indicated unconjugated QDs migrated to the upper chest area after 24 hours.
GnRHa-QDs, along both sides of the abdomen after 1 hour., but after 24 hours GnRHa-QD
signal was no longer detectable. (Figure 30B). Dorsally, unconjugated QDs were not detected at
either 1 hour or 24 hours post-treatment (images not shown).

Figure 32

In-vivo imaging following intraperitoneal injection of (A) GnRHa-QD, and (B)
unconjugated QDs, prior to treatment and at 1 hour and 24 hour post-treatment.
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Histology
Histological analysis revealed that signal aggregation varied by both quantum dot type
and route of administration. Unconjugated QD fluorescent signal was detected only in the kidney
following IP injection at hour 24 (Figure 33). Intranasal administration of unconjugated QDs
showed no fluorescent signal at any of the imaging time points. However, IN administration of
GnRHa -QDs resulted in detectable fluorescent signal in the nares, mouth, tympanum, and GI
tract at 1 hour post-administration, consistent with signal shown from IVIS imaging (Figure 34).
At 24 hours post-treatment signal remained detectable only in the GI tract (Figure 35).
Intraperitoneal injection resulted in fewer organs with QD localization, as signal was only
detected in the kidneys, at both 1 hour and 24 hours (Figure 36).

Figure 33

Histological sectioning of toad kidney following IP injection of (A) unconjugated
QDs, and (B) GnRHa-QDs at 24 hours post-treatment. Yellow circles indicate
locations of QD concentration.
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Figure 34

Pathway of bio-accumulation of GnRHa-QD conjugates following nasal
administration. GnRH-QD signal (red) was observed within the nares (A), mouth
(B), tympanum (C), and GI tract (D).
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Figure 35

Histological sectioning of toad GI tract following IN administration of GnRHa QDs at (A) 1 hour, and (B) 24 hours post-treatment. Histological sections of the
kidney following IP injection at (C) 1 hour and (D) 24 hours post-treatment. Yellow
circles indicate locations of QD concentration. Average fluorescence intensity
within the GI tract and the kidney following IN (GI tract) and IP (kidney) treatments
(E). Significance is indicated with *. Data are shown as mean ± SEM.
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Fluorescence intensity was measured by organ following either IP or IN administration at
both 1 hour and 24 hours post-treatment. After 1 hour following IN administration, measurable
fluorescence intensity was found in the GI tract, mouth, nares, throat, heart, kidney, and ear. The
average fluorescence intensity (arbitrary units; a.u.) was 3.32 x 107 a.u. in the GI tract, 1.81 x 10

7

a.u. in the mouth, 1.57 x 10 a.u. in the nares, 9.20 x 106 a.u. in the throat, 3.16 x 107 a.u. in the
7

heart, 7.37 x 10 a.u. in the kidney, and 1.21 x 10 a.u. in the ear. Intraperitoneal injection
7

7

revealed localization in fewer areas, being detectable in only the kidney at 9.99 x 10 a.u. and the
7

lung at 7.90 x 10 a.u.
7

There was no significant difference between average fluorescence intensity after 1 hour
and 24 hours in the kidneys following IP injection (p = 0.42; Chi-square = 0.69). Within the GI
tract, significantly higher levels of average fluorescence intensity (p = 0.03; Chi-square = 4.52)
were found after 1 hour compared to 24 hours later. At 24 hours, GnRHa-QDs and unconjugated
QDs signal in the kidney was not significantly different (p = 0.13; Chi-square = 2.28) (Figure
36).
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Figure 36

Average fluorescence intensity in the kidney from GnRH-QDs and unconjugated
QDs at 24 hours post-exposure. Data are shown as mean ± SEM.

Oral vs. nasal administration of GnRHa
Nasal administration of GnRHa resulted in significantly higher (p < 0.01) percentages of
both total motile sperm (t = 2.56; 56%) and forward-progressive motile sperm (t = 2.19; 2.23 x
105) than oral administration. Neither the concentration of sperm/mL nor the percentage of
responders significantly differed between nasal and oral treatment groups (p > 0.05; Table 3,
Figures 37-39).
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Table 3

Male responders and average sperm parameters following intranasal and oral
treatments of 10 µg GnRHa. Significant differences are indicated with a *. Data are
shown as mean ± SEM.
Treatment Summary

Mean Sperm Characteristics

Forward
Treatment Treated Responding Latency to Sperm/mL Total
5
Males
Males
Spermiation
(x10
)
Motility
Progressive
Route
(hours)

(%)

Intranasal

13

12

1.7 ± 0.3

2.2 ± 0.7

Oral

13

10

1.9 ± 0.4

1.8 ± 0.4

Figure 37

56.0 ±
4.0*
41.0 ±
5.0

Motility
(%)
35.0 ± 4.0*
23.0 ± 4.0

Percentage of males responding to nasal (●) or oral (▲) GnRHa treatment over
time.
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Figure 38

Average concentration of sperm/mL over time following nasal (●) or oral (▲)
GnRHa treatment. Data are shown as mean ± SEM.
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Figure 39

Average percentage of motile sperm over time following nasal (●) or oral (▲)
GnRHa treatment. Data are shown as mean ± SEM.
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Discussion
In order to investigate the pathways taken by GnRHa following two routes of
administration, intranasal (IN) and intraperitoneal (IP), both spermiation responses and
conjugated nanoparticle accumulation were compared. Previous studies have shown that GnRHa,
when injected intraperitoneally, will cause anuran males to produce and release spermic urine
(Waggener and Carrel 2003; Uteshev et al. 2011; Kouba et al. 2012). A recent study by Julien et
al. (2019) found that GnRHa can also stimulate spermiation in A. fowleri following intranasal
administration. The concentration of sperm produced from GnRHa given through IN
administration was lower, at average magnitude of 10 sperm/mL compared to 10 sperm/mL as is
5

6

generally reported following IP injection (Kouba et al 2012; Julien et al. 2019; Della Togna et al.
2020). However, in the present study, intranasal administration resulted in significantly higher
concentrations of sperm/mL than intraperitoneal injection, as well as significantly higher
percentages of total sperm motility and caused more males to respond. This discrepancy in
spermiation responses necessitated an investigation into the pathways taken by GnRHa through
both intraperitoneal and nasal delivery.
The use of both in-vivo and ex-vivo imaging techniques facilitated our investigation into the
pathways taken by GenRHa after administration through the two tested delivery methods, In and
IP. By following fluorescence signal accumulation of GnRHa-QDs through the bodies of the
animals we were able to determine a general pathway of GnRHa flow from the point of
administration. IVIS imaging of live animals revealed the primary signal migration to and
accumulation of both unconjugated and GnRHa -QD within the peritoneum at 1- and 24-hour
time points following IP injection. After imaging, the animals were euthanized and their organs
removed and sectioned to provide further specificity of Qdot bioaccumulation. Both the
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unconjugated and GnRH-QDs were found only in the kidney of the animals. Owing to the lack
of GnRH receptors in kidney, the accumulation is likely due to QDs entering the bloodstream
and dispersing to the kidneys as they are filtered through urine and subsequently released from
the body rather than as an accumulation due to hormone binding.
The lack of GnRHa-QD aggregation in excised organs, suggested further validation of the
efficacy of GnRHa when conjugated to quantum dots. Once conjugated to QDots, the
concentration of GnRHa was not able to be determined, but was estimated to be0.16 µg/µl based
on the the lyophilized hormone to nanoparticle ratio used during synthesis. In the current study,
10 µg GnRHa was successful at stimulating spermiation in male toads using both IP and IN
routes of administration. To compensate for possible hormone loss during synthesis of GnRHaQD conjugates, we estimated 16 µg of GnRH-QD would be comparable to test spermiation
responses to Qdot conjugations. All males produced sperm when given GnRHa-QDs through IP
injection, but sperm concentrations were very low compared to GnRHa alone, averaging of only
3.84 x 104 sperm/mL compared to 2.00 x 105 sperm/ml
In-vivo imaging of GnRH-QDs following IN administration found that fluorescence signal
visibly moved throughout the body. QD signal was visualized starting at the nares and
continuing to the tympanum of the ear and down the throat. At 1-hour post administration,
GnRHa-QDs were detected in the abdomen. This migration is consistent with anuran anatomy;
the external nares open into the internal nares at the roof of the mouth, providing a direct
pathway to both the throat and to the ears via a cavity opening that plays a role in calling
behavior. There is also a direct opening of the tympanum into the mouth and throat of anuran
species, which could mean that Qdot solutions flowed into the throat from the tympanum. It is
therefore likely that a large portion of the administered QDs flow down through this pathway and
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the internal nares and subsequently down the throat and into the GI tract. At 24-hours postadministration, nearly all Qdot signal had moved from the mouth and throat and migrated to the
stomach. From these images we can conclude that QDs administered intranasally are largely
swallowed. Microscopy of excised organs following intranasal administration of GnRHa-QDs
revealed large accumulations of QDs within the GI tract. A method of organ sectioning known as
“breadloaf sectioning” was performed to further pinpoint the movement of fluorescence signal
throughout the body. Animals were sectioned from snout to vent (rostral to caudal; figure 1) to
follow the assumed pathway of QD flow thorough the body. Additional minor aggregations of
GnRHa-QDa were found in the nares and mouth, lending further support to the IVIS evidence
that IN-administered GnRHa-QDs are largely swallowed after flowing from the external to
internal nares. While the IVIS showed that unconjugated Qdot migrated in a similar pattern
sectioned organs did not reveal bioaccumulation of fluorescence signal at either the 1 hour or 24
hour time-points.
The localization of QDs the stomach following IN administration suggests a significant
portion of hormone was likely swallowed. In a separate experiment we compared spermiation
responses to GnRHa after intranasal and oral delivery. While sperm motility was higher when
GnRHa was given intranasally,, the percentage of responders and concentration of sperm/mL
was similar in oral administration of GnRHa . Combined with the patterns of bioaccumulation of
unconjugated and conjugated QDs majority of substances given intranasally travel through the
nares and are swallowed, rather than accessing the brain directly. However, intranasal delivery of
GnRHa-Qdots did not result in spermiation. Taken together, these results support the assumption
that it is the conjugation of GnRHa-QDs that impedes its efficacy in elicting spermiation when
delivered nasally. One potential explanation for both the lack of response in the IN group and
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low concentration of sperm produced in the IP group is that the conjugated GnRHa can not bind
to GnRH-receptors in large enough concentrations to be effective. As imaging revealedGnRHaQD accumulation occurred in the GI tract and that minimal accumulation was found in other
organs, particularly in areas associated with GnRH receptors (ie. the brain and gonads), it is also
possible that GnRH-QDs were unable to diffuse through the GI tract to access other organs
containing GnRH-receptors. The QDs used in this experiment, prior to conjugation, were
between 15-20 nm. Unfortunately, the exact size of the conjugate was unknown. The lack of
spermiation responses following nasal administration of GnRH-Qdot conjugates could also be
due to other digestive effects that could have broken down the conjugates within the GI tract.
Another possible explanation is that the conjugation concentrations were lower than anticipated,
as some hormone may have been lost in the purification process. The mechanisms that inhibit
GnRH-Qdot conjugates from inducing spermiation require further investigation.
While the current study cannot reliably determine the precise organs that nasally and
intraperitoneally administered GnRHa binds to induce sperm production and release, it is
possible to determine the general pathways taken by GnRHa using the GnRH-QDs as tracers.
Both IVIS imaging and histological analysis show that GnRHa-QDs show distinct differences in
signal migration and signal localization when given through IN or IP injection.

Conclusions
In the current study, the presence and migration of quantum dot fluorescent signal was
clearly visualized, despite skin tissue depth,validating the use of in-vivo imaging to observe the
movement of exogenous substances within a living amphibian. Through these observations, we
were able to determine that when administered using intraperitoneal injection, GnRHa-Qdot
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conjugates remain within the peritoneum for 24 hours where the GnRHa ilikely exhibits the
majority of its effects in eliciting spermiationm was shown to travel from the nares to the GI
tract, which was further supported by similarities in sperm parameters following oral
administration. The need for effective, minimally invasive hormone treatment procedures is
growing as captive breeding programs requiring assisted reproductive technologies become more
prevalent. The present study serves to validate alternative routes of hormone deliverywhich can
be used in these programs to increase reproductive output of endangered species.
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CHAPTER VI
NASAL ADMINISTRATION OF ARGININE VASOTOCIN (AVT) RESULTS IN WATER
UPTAKE AND RETENTION IN ANAXYRUS FOWLERI
Introduction
Across most of the animal kingdom, vasopressin and its related nonapeptide lineages are
associated with both physiological and behavioral functions. In mammals, the oxytocin
homologs mediate breeding-pair bonding, lactation, and smooth-muscle contraction while the
vasopressin homologs mediate osmoregulation and regulate blood pressure through smooth
muscle contraction and vascular what?(Norris and Carr 2013). Vasopressin has also been shown
to mediate pair-bonding in mammalian species such as the monogamous prairie vole (Winslow
et al. 1993). In non-mammals, the homologous hormones mesotocin (MET) and arginine
vasotocin (AVT) have been shown to perform similar functions to that of the mammalian
oxytocin and vasopressin, respectively. These behavioral differences induced by the hormones
can be sexually dimorphic; oxytocin and mesotocin are often associated with female behaviors
and functions, while vasopressin and vasotocin exact strong influences over male physiology and
behavior (Goodson, Lindberg and Johnson 2003).
In amphibians, which do not possess either oxytocin or vasopressin, AVT regulates
similar processes. In anurans, AVT generally stimulates calling and phonotaxis in both sexes. In
males, AVT has been shown to stimulate both amplectic-clasping during breeding, and calling
behaviors for attracting mates and deterring competitors as a demonstration of fitness (Moore,
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Boyd and Kelley 2005; Norris and Carr 2013). The release of AVT in male anurans is
predominantly triggered through social and environmental cues, such as conspecific calling,
visual detection of females, or changes in weather patterns like rain storms. In females, AVT
inhibits resistant vocalizations of unreceptive females and increases receptive phonotaxic
responses to male calls (Moore, Boyd and Kelley 2005; Boyd 2006). In urodeles, an surge in
AVT can increase the clasping propensity of males as well (Moore, Boyd and Kelley 2005).
There are three types of receptors for AVT, and they are located in a variety of areas
inside and outside of the brain. In amphibians, three different G-protein coupled AVT-receptor
subtypes have been found. (Acharjee et al. 2004). AVT binding to these receptors mediates
either reproductive events or other physiological effects, such as osmoregulation, and the
response depends on both the type of receptor and its location (Boyd 2006). AVT -receptors in
the brain are most closely associated with the aforementioned breeding behaviors. Within the
periphery tissues osmoregulation is the most well-known role of AVT-receptor mediation (Boyd
2006). Water uptake can be stimulated by administration of exogenous AVT both at the
periphery and directly into the brain (Uchiyama and Konno 2006; Maejima et al. 2015),
indicating both direct peripheral and neuromodulatory control of water absorption. An in-vitro
study by De Sousa and Grosso (1982) found that AVT can increase the effects of water
absorption by ventral pelvic skin in Anaxyrus marinus, while an in-vivo study by Viborg an
Rosenkilde (2004) found that intraperitoneal (IP) injection of AVT increased water uptake in
Bufo bufo.
In both the skin and the kidneys, AVT controls osmoregulatory functions (Boyd 1997;
Bentley 2002). Absorption of water is mediated by AVT via receptors in the skin (Ogushi et al.
2010). Toads, like other amphibians, have skin with a low resistance to water loss from
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evaporation, thus their skin is capable of water absorption, particularly through skin on their
ventral side, to facilitate hydration and water balance (Lillywhite 2006; Suzuki et al. 2015). This
ventral location of primary water absorption is between the back legs and called the seat patch or
drink patch (Hillman et al. 2009; Bentley and Yorio 1979; Suzuki et al. 2015). Internally,
osmoregulation is managed by the kidneys and urinary bladder (Warburg 1995).
Currently, over 30% of amphibian species are facing extinction and captive breeding
programs are becoming increasingly necessary to maintain and re-establish populations of
threatened species. Increasing reproductive output of animals is a key component for anuran
conservation outlined by the Amphibian Conservation Action Plan (Gascon et al. 2007). In many
programs, reproductive output is low or non-existent and some species may require additional
assistance to obtain breeding goals (Browne and Zippel 2007; Trudeau 2016). Vasotocin, with its
ability to elicit calling and amplexus behaviors, might be a useful tool in captive breeding
programs to stimulate reproductive behaviors as well as gamete production and release.
Hormone therapies in assisted reproduction fall into two general categories: 1) elicitation of
gamete production and release for in-vitro fertilization (IVF) and gamete storage, or 2)
stimulation of reproductive behaviors for natural breeding attempts (Kouba et al. 2012; Clulow et
al. 2019). In the majority of breeding programs, natural breeding is preferred to manual gamete
expression. Gamete expression and collection requires technical protocols and advanced training
as well as extensive animal handling. Hormones such as AVT, which stimulate natural breeding
behaviors may be an ideal solution. When personnel and advanced training are limited, or animal
handling should be minimized, breeding programs may want to stimulate breeding behaviors
rather than only gamete production.
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Several in-vivo and in-vitro studies have been conducted to determine the effects of
exogenous AVT treatment on anurans. Rowlison et al. (2012) found that intraperitoneal
administrations of AVT resulted in calling and amplexus behaviors in Anaxyrus fowleri. Boyd
(1994) demonstrated that intracranial administrations of AVT into the laryngeal motor nucleus
increased the number of calls in male anurans, albeit, the elicited calls were shorter. In many
studies across anuran species citing the effects of AVT on calling, a consistent theme has been
that AVT increases the male’s calling frequency (Choleris, Pfaff and Kavaliers 2013). In
contrast, AVT seem to decrease release calls, or calls indicating a lack in reproductive interest, in
females (Boyd, Tyler and de Vries 1992). Taken together, AVT increases advertisement calls in
males while decreasing female mate selectivity.
Before implementing hormone therapies as a means of assisted reproduction, animal safety
must be considered, particularly the route of hormone administration. The most common method
of exogenous hormone administration in assisted reproductive technologies (ART) is
intraperitoneal injection; an injection into the body cavity of focal animals (Kouba et al. 2012;).
However, many programs and institutions do not permit general animal personnel to administer
intraperitoneal injections out of concern for animal safety. In these cases, extensive training is
required and only permitted through veterinary personnel. In addition, there are numerous
species of amphibians that are small and stress easily, increasing both the difficulty of injections
and the handling stress of the individual animal. This can make breeding attempts limited, or
even impossible, if appropriately trained staff is not available. Therefore, alternative routes of
hormone delivery should be considered to overcome these challenges. A recent study
demonstrated that sperm can be obtained from male anurans by introducing small volumes of
GnRHa intranasally, thereby directing the hormone to the olfactory bulb (Julien et al. 2019). One
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of the areas of the amphibian brain that regulates calling behaviors, the amygdala pars lateralis,
receives direct projections from the olfactory bulb (Boyd 1994). A study by Moreno, Morona
and Mu (2005) detailed the olfactory and vomeronasal pathways transmitting signals to the
amygdala and then the hypothalamus. While the effects of intraperitoneal injection of AVT are
documented, that is, effects of osmoregulation, calling, and amplexus, the effects of intranasal
AVT administration are unknown. Due to the aforementioned pathways, it is possible that,
following nasal administration, reproductive calling behaviors will be invoked.
Osmoregulatory effects such as water absorption and retention, may accompany the desired
reproductive behaviors induced by AVT. In female amphibians, water absorption is necessary
for oviposition, contributing to the hydration of the egg jelly layer (Norris and Carr 2013). In
male amphibians, excessive water absorption is undesirable and may impede amplectic clasping.
Therefore, it is important to determine whether or not water retention results from intranasal
AVT treatment prior to recommendation for use in amphibian breeding.
In order to determine the effects of exogenous AVT on captive anurans, the
following study on AVT administration was conducted. I hypothesized that, due to the effects of
AVT on calling and osmoregulation in other amphibians, that both intraperitoneal and intranasal
AVT treatments would result in calling and water retention. Furthermore, intraperitoneal
injection would result in greater effects on osmoregulation than intranasal delivery due to the
proximity of intraperitoneal injection to the kidneys and that nasal delivery would maximize
reproductive effects while minimizing osmoregulatory effects. Male A. fowleri were
administered AVT via both intranasal and intraperitoneal routes. The objectives of this study are
to determine 1) the reproductive and osmoregulatory effects of AVT delivered intranasally to
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males, 2) the time course of action for AVT delivered intranasally, and 3) how AVT affects
males differently when administered by intranasal compared to intraperitoneal injection.
Materials and Methods
Study animals
Male Anaxyrus fowleri toads were collected from Oktibbeha County, Mississippi, during
the breeding season from April-July 2016 and 2017 (Permit #0728161) or March-April 2018
(Permit #0501181 and #19-345). All males were sexually mature (as determined by the presence
of dark chin patches and developed nuptial thumb pads) and the average weight was 21.6 ± 1.9
grams. All housing and animal maintenance was performed in accordance with Mississippi State
University IACUC protocols (IACUC #16-406 and #19-345). Males were housed in
polycarbonate tanks (30cm L x 46cm W x 66cm H) in groups of five or six on a substrate of
cocoa fiber and soil cultured with springtails (Collembola). Terra cotta pots and PVC piping
were offered as shelter options. Animals were fed a diverse diet of crickets, Dubia roaches, and
mealworms 3x a week on a rotating feed schedule. Prior to feeding, all insects were gut-loaded
with vitamin supplements (Repashy Ventures Inc., CA, USA) and coated in Reptivite© calcium
powder (ZooMed Laboratories, Inc., Costa Mesa, California, USA). Water was available ad
libitum. Animal housing areas were kept on a 12-hour day/night cycle and maintained at 23 ± 2
°C. Prior to hormone treatment, toads were fasted for 48 hours. Following Experiment 1, toads
were maintained at Mississippi State University until their natural deaths. After Experiments 2
and 3, animals were euthanized for histological analysis.
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Exogenous hormones
Vasotocin concentrations were chosen based on previous methods in A. fowleri from
Rowlison et al (2012). Arginine vasotocin (AVT; Sigma-Aldrich product #V0130) was
reconstituted in phosphate-buffered saline (PBS) at a concentration of 5 μg/μl, and was given on
a weight basis of 10 μg/g body weight. Using a sterile pipette tip, male toads were given AVT
intranasally by placing half of the hormone solution into each nare. During nasal administration,
toads were held upright to prevent overfilling and subsequent runoff out of the nasal passage.
Intraperitoneal injections were given to males into the abdominal cavity also in concentrations of
10 ug/g BW AVT. Each animal acted as its own control and was administered 50 ul of PBS 24
hours prior to AVT administration. Animals were treated nightly, with 3 males treated per
evening. On night one, males were treated with PBS, and then AVT the following evening.
Experiment 1: Water retention and calling behaviors following nasal administration of
AVT
Prior to both hormone or control treatment for each route of administration, each toad (n
= 10/trt) was removed from the holding tub and weighed. Toads were weighed in plastic petri
dishes which served as weigh dishes in the event that the toads released urine upon handling and
impacted weight measurements. Following each treatment, each toad was placed into a plastic
holding tub (Sterilite; 35.6cm L x 20.3cm W x 12.4cm H) with approximately 2 cm of water and
held overnight. At 12 hours post-treatment, toads were removed and weighed to determine water
retention weight. Weight gain was then compared between control and AVT treatments in each
toad. Animals were returned to housing tanks following treatment. Recording for mate-calling
was conducted using a Songmeter sound recorder (Wildlife Acoustics, Maynard, MA).
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Recording began directly prior to hormone treatment and continued overnight. Songmeter
recordings were only conducted for Experiment 1.
Experiment 2: Rate of water uptake following intranasal administration of AVT
Male toads (n = 5/trt) were selected to determine the water absorption rate of nasallyadministered AVT over time. Hormone treatments were the same as in Experiment 1 and
included a control group administered PBS and an AVT group. Males were weighed prior to
AVT administration and then placed into plastic holding tubs (Sterilite; 35.6cm L x 20.3cm W x
12.4cm H) with approximately 2 cm of water. Every two hours, males were weighed for up to 24
hours.
Experiment 3:Water retention following intranasal and intraperitoneal administration of
AVT
Male toads (n = 5/trt) were selected to determine the water absorption rate of nasallyadministered AVT over time. Hormone treatments were the same as in Experiment 1 and
included a control group administered PBS and an AVT group. Males were weighed prior to
AVT administration and then placed into plastic holding tubs (Sterilite; 35.6cm L x 20.3cm W x
12.4cm H) with approximately 2 cm of water. Every two hours, males were weighed for up to 24
hours.
Statistical analysis
Prior to further statistical analysis, weight gain data were tested for normality and
homogeneity of variance using a Shapiro-Wilk’s and Levene’s test, respectively. Weight gain
data from Experiment 1 were found to be normally distributed Comparisons between weight
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increase following AVT treatment were run against weight gain following control treatment
using a paired Student’s t-test.
In Experiment 2, data comparing weight increases over time following both AVT
treatment and control treatment were run as a linear mixed model analysis using the PROC
MIXED function. Time (2 hour intervals for 24 hours) and treatment (AVT vs. control) were set
as fixed effects. Time was set as a repeated factor by male. Male ID was set as a random effect.
A mixed models analysis was also run for data in Experiment 3 comparing weight gain increases
over time between intraperitoneal and intranasal AVT treatments. Similarly, male ID was set as a
random effect while administration route and time were fixed with time set as a repeated factor
by male. All statistical tests were all performed using SAS Version 9.4 (Cary, North Carolina),
and statistical significance was set at p ≤ 0.05. Values were expressed as mean ± SEM.
Results
Experiment 1: AVT-induced water retention and calling
Calling behavior was not detected in either control or AVT treated males when AVT was
given intranasally.s. After 12 hours, AVT treated male toads gained significantly more (df = 18;
P < 0.0001; t = 8.36) water weight than PBS treated males. The average weight gain following
intranasal administration of AVT was 10.33 ± 1.13 g, compared to an average of 0.02 ± 0.3 g
without AVT (Figure 40).
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Figure 40

Average male weights before and after control (PBS) and arginine vasotocin (AVT)
delivered intranasally. Letters indicate significant. Data are shown as mean ± SEM.

Experiment 2: AVT weight retention over time
Control males weighed an average of 26 ± 2.4 g and AVT-treated males weighed an
average of 17.5 ± 0.9 g prior to treatment. Twenty-four hours post-treatment, males weighed an
average of 26.5 ± 1.9 g and 20.9 ± 1.3 g in control and AVT groups, respectively. This is an
average difference of 0.5 g from time zero to the 24-hour time point in control males compared
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to an increase of 3.4 g in males given AVT. Overall, these constitute a 1.9% and 19% increase in
baseline body weight in control and AVT treated males, respectively. Over 24 hours, males
gained an overall average of 1.99 ± 0.21 g in the control treatment compared to 6.77 ± 0.52 g
following AVT treatment. Males treated with AVT gained significantly more weight (F =
112.71; p < 0.01) than control males. This difference in the increase in weight is consistent with
the results from Experiment 1 wherein AVT resulted in a greater water retention than those in the
control group.
In the AVT treatment group, weight gain began as early as two hours post-treatment, with
an initial weight gain of 4.8 ± 0.6 g (Figure 41). At hour 4, this increased to a weight gain of
7.77 ± 0.98 g and continued to rise until hour 8, where the average peak weight gain of 9.17 ±
1.59 g occurred. After hour 12, weights began to decrease. At hour 24, four out of the five males
returned to within 3 g of their baseline weights. However, one male remained 10.3 g heavier than
his baseline weight at the 24-hour time point. There was no significant effect (F = 0.8; p = 0.64)
of treatment by time across groups.
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Figure 41

Average weight gained over time between control (PBS) and intranasal AVTtreated males over 24 hours. Data are shown as mean ± SEM.

Experiment 3: Comparison of water retention between intranasal and intraperitoneal
routes
After 24 hours, intraperitoneal injection of AVT resulted in significantly greater (F = 5.28; p < 0.05) weight gain than intranasal administration. The average weight gain following
intranasal weight gain treatment was 6.77 ± 0.55 g. In comparison, IP injection resulted in an
average of 18 ± 1.69 g of water retained (Figure 42).
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Figure 42

Average weight change between AVT-treated males following intranasal (IN) and
intraperitoneal (IP) administration routes. Data are shown as mean ± SEM.

There was a significant interaction effect between time and route. At hours 14 to 24,
males given AVT via IP injection gained significantly more (F = 3.19; p < 0.05) weight from
water absorption than males treated nasally. Similar to IN treatment, weight gain following IP
treatment began at 2 hours with an average increase of 6.3 ± 0.8 g (Figure 43). In contrast to IN
administration, average peak weight gain was not seen until 16 hours post-treatment, with an
average weight of 21.6 ± 6.7 g. While this was the highest weight gain, an average weight gain of
21.1 ± 5.9 g was reached at hour 16 and did not vary by more than 1.5 g from 12 hours to 22
hours. At hour 24, average weights had decreased to 16.6 ± 5.1 g. At the end of the experiment
24 hours later, males weighed an average of 40.4 ± 7.4 g, which was 16.6 g higher than their
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average baseline weight of 23.8 g. By comparison, at 24 hours post-IN treatment, males only
weighed, on average, 3.4 g more than baseline. Because no calling was recorded from nasallytreated males in Experiment 1, call recordings were not made for Experiments 2 or 3. While calls
were not recorded, two out of the five males were observed calling at 30-mins post-IP treatment,
and ceased calling at 2-hours post-administration. Following IP treatment, two out of the five
males died; the first was found dead at 26 hours post-treatment while the second was found
deceased at 72 hours post-treatment. No males died following IN administration.

Figure 43

Average weight change over time between AVT-treated males following
intraperitoneal and intranasal administration routes over 24 hours. Data are shown
as mean ± SEM.
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Discussion
In this study, we administered arginine vasotocin (AVT) to male A. fowleri in an attempt
to determine and compare physiological effects following intraperitoneal and intranasal
administration routes. The effects of intraperitoneal injection of AVT have been documented in
anuran species. For example, Rowlison et al. (2012) found that IP treatment with exogenous
AVT resulted in amplexus and advertisement calling in A. fowleri. From an application
standpoint, the size of many smaller species of amphibians may restrict the use of intraperitoneal
injection and benefit from non-invasive methods of treatment. In addition, intraperitoneal
injection can be difficult for staff involved in breeding programs to perform due to lack of
training of personnel or inaccessibility to veterinary assistance in threatened anuran species. We
therefore chose to evaluate the effects of a minimally invasive intranasal route of administration.
Because intranasal administration requires only a pipette, training is easy and minimally
invasive. If intranasal administration of AVT is successful, it would be a valuable, easily
applicable delivery alternative to intraperitoneal injection for captive anuran breeding
programs.
Despite past studies reporting calling behavior following exogenous AVT treatment in
male anurans (Moore, Boyd and Kelley 2005; Boyd 2006; Rowlison et al. 2012), calling
behavior was not observed in the current study from IN treatments within twelve hours of
recording from Experiment 1. Water absorption, however, was observed following treatment
with AVT but not in the control.
Over the course of 24 hours, males began to absorb water quickly and increased in weight
until 8 and 16 hours, dependent upon delivery method. Thus, nasal administration showed peak
weight gain eight hours earlier than IP injection. The rate at which IP water uptake occurred was
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also faster than following IN delivery, with IP-treated males gaining much more water retention
weight within the first two hours than IN-treated males, a trend which continues over the 24-hour
time period. In addition, IP injection resulted in higher weight gain averages than IN. Both of
these results imply that the effects of AVT are greater when administered as an intraperitoneal
injection, and that those effects persist longer than those elicited by IN treatment. These greater
effects of IP-injected AVT on water retention may be due to the proximity of intraperitoneal
injection to the kidneys. Water regulation in most organisms is mediated through aquaporin
(AQP) water channels which control the permeability of cell membranes to water (Preston et al.
1992; Zardoya 2005). In anurans, AQPs are located in numerous areas such as the skin, urinary
bladder, and kidney (Kubota et al. 2006; Sasaki 2012). AVT stimulates osmotic permeability and
AQP expression in ventral skin, kidney, and urinary bladder (Ogushi et al. 2010). Therefore,
delivery of AVT directly into the abdominal cavity, in closer proximity to the kidneys, likely
exerts a stronger effect on osmoregulation than when it is delivered intranasally. These results
also suggest that the pathway of nasal administration limits dispersal of AVT throughout the
body and thus the concentration of AVT that reaches receptors in the kidneys is much lower.
Despite the observation that effects of water retention were significant, calling behaviors
were not observed when AVT was administered intranasally, The lack of calling was surprising,
considering receptors which modulate calling behaviors are located within the brain and can be
directly accessed by substances delivered nasally via diffusion across the olfactory mucosa
between nerves and into the subarachnoid space and circulating cerebrospinal fluid, by binding
to olfactory receptors, or by traveling along the trigeminal nerve. This suggests that AVT may
not pass through the blood brain barrier via the nasal passages as initially expected and does not
reach the bloodstream in high enough concentrations to reach the brain and stimulate calling
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behavior. Intraperitoneal injection, however, did result in calling from two of the five treated
males. A possible explanation for the elicitation of calling is that IP delivery allows AVT to enter
the bloodstream in large enough concentrations to reach receptors in the brain.
While intraperitoneal injection of AVT was successful in eliciting calling behaviors, it
also resulted in the deaths of two males; this was likely due to the increased osmoregulatory
effects, as the males that had retained the most water were the males that died. Further
investigation into the pathways of both intranasal and intraperitoneal delivery routes would aid in
determining the reason behind the differences in calling and osmoregulatory effects.
These outcomes demonstrate that neither intranasal nor intraperitoneal treatments of AVT
at the tested concentrations are likely to be of benefit for eliciting breeding behaviors in male A.
fowleri. The potential benefit of exogenous AVT treatment in females requires further
investigation, specifically to determine if AVT facilitates egg-jelly deposition and oviposition. In
fish, AVT has been shown to assist in oocyte maturation and oviposition (Joy and Chaube 2015).
Thus, while AVT causes excessive weight gain from water retention in male anurans, in fish,
water retention is beneficial for oocyte maturation. As shown in this study, intraperitoneal
injection of AVT results in significantly greater water retention than intranasal administration
using the same concentration. Therefore, it may be that IN treatment with AVT is preferable to
IP for reducing the undesirable effects of AVT while providing the benefits of oocyte maturation
and ovulation in females. This would be especially useful to stimulate ovulation and oviposition
in species that exhibit difficulty in ovipositing such as the Panamanian golden frog (Atelopus
zeteki), which can result in negative health effects such as egg binding and egg sepsis (Eustace et
al. 2018; Bronson et al. 2021).
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Because the concentration of hormones were the same when comparing In and IP
delivery of AVT, and the effects were observed at approximately the same time in both cases, the
pathways taken within the body from each administration point was the likely cause of the
differences in water absorption. It would be beneficial to determine what these pathways are to
better inform breeding programs of the mechanisms of action of this hormone.

Conclusion
In conclusion, the current study resulted in water retention following both intranasal
administration and intraperitoneal injection of AVT in male A. fowleri. Intranasal delivery
resulted in less weight gain due to water retention than intraperitoneal injections. In addition,
water retention increased for twice as long following intraperitoneal injection compared to nasal
delivery, with peak retention occurring at hour 8 in nasally-treated males compared to hour 16 in
intraperitoneal delivery. Despite routes from the nares to the brain, nasal administration did not
result in any calling behavior. In contrast, intraperitoneal injection of the same concentrations of
AVT caused much greater effects on water absorption over time and resulted in calling after only
30-minutes post-treatment. Unfortunately, intraperitoneal injection also resulted in the deaths of
two males from excessive water uptake and retention by the skin and kidneys. These results
suggest that AVT should not be used for assisted reproduction in male A. fowleri, as excessive
water retention would likely impede amplexus and therefore breeding attempts.
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CHAPTER VII
A COMPARISON OF NASAL AND INTRAPERITONEAL AVT TREATMENT PATHWAYS
USING QUANTUM DOT NANOPARTICLES
Introduction
The hormone arginine-vasotocin (AVT) is a neuropeptide, homologous to the
mammalian vasopressin and oxytocin, and is released from the posterior pituitary. Vasopressin
mediates fluid balance, smooth muscle contraction, and vasodilation (Ouden et al. 2005).
Oxytocin similarly controls smooth muscle contraction, lactation, and other reproductive
functions such as social -pair bonding (Norris and Carr 2013). Non-mammalian species such as
birds, reptiles, and amphibians lack these two hormones and instead have the homologs
mesotocin (MT) and aginine-vasotocin, which control both the osmoregulatory effects of
vasopressin and the sexual behaviors of oxytocin, such as breeding advertisement and mating
behaviors (Moore, Boyd and Kelley 2005; Norris and Carr 2013).
In both birds and anuran amphibians, the sexual behaviors controlled by AVT include
calling for sexual advertisement, receptivity, and mate competition (Marler et al. 1995; Choleris,
Pfaff and Kavaliers 2013). Following environmental or social stimulation, AVT is produced in
the hypothalamus and subsequently released from the posterior pituitary (Boyd 2006). To
stimulate calling, the reticular nuclei of the thalamus, which coordinates calling and breathing, is
activated, followed by the pre-trigeminal nucleus (PTN) which generates vocal patterns that are
sent to the motor nucleus and finally, to the larynx via cranial nerve 10 (Boyd 1997). In
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addition, AVT may also affect the auditory processing of calls from conspecifics. Penna and
colleagues (1992) found that AVT can change auditory processing within the torus semicircularis
in tree frogs. In females, it has been postulated that exogenous AVT may act on the torus
semicircularis to control phonotaxic responses to calling (Boyd 1997). Aggressive calls between
males, are also affected by AVT, though these seem to be context dependent and testosteronedependent (Marler et al. 1995). Depending on the binding location, endogenous and exogenous
AVT may affect different aspects of calling. If AVT binds in the amygdala, it may affect sensory
processing, while binding in the pretrigeminal nucleus (PTN) may alter motor output (Boyd
2006). The release of AVT is heavily influenced by environmental factors and interactions with
conspecifics and can affect both the stimulation and duration of calling (Moore, Boyd and Kelley
2005).
Studies by Boyd (1994) and Rowlison et al. (2012) have found that treatments of
exogenous AVT stimulate calling and amplexus in male anurans. Rowlison applied AVT by
intraperitoneal injection, while Boyd employed intracranial delivery of AVT directly into the
laryngeal motor nucleus. In both studies, exogenous AVT increased call frequency compared to
unstimulated natural call frequencies. (Choleris, Pfaff and Kavaliers 2013). The use of
exogenous AVT is of interest for amphibian breeding programs, wherein the goal is to increase
breeding behaviors and reproductive output. One point of concern, however, is the stimulation of
water absorption from the use of exogenous AVT. While water absorption is desirable for
ovipositing females, in males, bloating from excess water retention can negatively impact
breeding by causing males to retain water in volumes that inhibit movement and breeding
behaviors such as amplexus. There is also the potential for damage to the kidneys, which would
be particularly detrimental when used in endangered amphibian breeding programs. Peripheral
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and intracerebroventricular injection of exogenous AVT have both stimulated water absorption
(Uchiyama and Konno 2006; Maejima et al. 2015). Rowlison et al. (2012) observed the presence
of bloating in male anurans following AVT treatment, though this was not quantified or
recorded. In chapter 3 of this dissertation, I quantified rates of water uptake as stimulated by both
intraperitoneal and intranasal delivery of AVT. Both routes of administration resulted in rapid
water uptake and extended retention of water over time for up to 24 hours. Retention weight was
significantly lower following nasal administration than intraperitoneal injection of AVT. Calling
behaviors were observed following intraperitoneal delivery of AVT, but were not observed
following nasal administration. These results indicate that the effect of exogenous AVT is
specific to the route of its delivery and that there are likely both a peripheral and
neuromodulatory route of action, which is further supported by AVT-receptor localization in
anurans.
Systemically, Acharjee and colleagues (2004) localized one AVT-receptor within anuran
brains and peripheral tissue, as well as one form of mesotocin-receptor (MTR). Receptors for
MT were found in the forebrain, hypothalamus, pituitary, adrenal gland, kidneys and testes. They
also localized AVT receptors within the forebrain, specifically the hypothalamus. Receptor
localizations outside of the brain included the distal lobe of the pituitary, heart, and interrenal
(adrenal) gland, kidney, skin, and oviduct. It is therefore possible that exogenous AVT may bind
to receptors in one or all of these organs, and that delivery route may affect organ localization.
Depending on the delivery route, AVT may elicit reproductively desirable or undesirable
physiological effects.
In order to investigate the pathways taken by which AVT acts following intraperitoneal
injection and intranasal administration, I chose to implement both live in-vivo and histological
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ex-vivo techniques. Live-animal in-vivo imaging allows us to monitor the progression of
exogenous hormones in real-time, while histological analysis provides greater specificity of
hormone localization in the tissues. Some common methods of live imaging use equipment with
x-ray or positron emission tomography (PET)-like imaging capabilities, such as the In-Vivo
Imaging System (IVIS; Caliper Life Science (Perkin Elmer). The IVIS system can detect both
bioluminescent and fluorescent signal. However, traditional fluorescent dyes and proteins have
limited longevity and cannot be easily detected through deep tissue. A novel imaging tool that
has been gaining popularity in the past decade due to its fluorescent stability and ability to be
tailored to specific applications is the quantum dot nanoparticle. Quantum dots (Qdots) are
fluorescent nanoparticles that emit light (Burbach et al. 1995), and can be customized for color
and intensity by simply altering the size of the particle. Qdots are also significantly brighter (e.g.,
have a much higher extinction coefficient), emit light much longer than traditional fluorescent
probes, and they are resistant to photo-bleaching, all characteristics that are needed for deep
tissue imaging (Gao et al., 2011). Qdots can also be conjugated to a variety of biomolecules
making them ideal for visualizing hormone movement through living systems.
For this study, we administered arginine-vasotocin conjugated quantum dots (AVT-QD)
in order to visualize the movement of AVT in real time in living toads and identify subsequent
organs of bioaccumulation. Amphibians are ideal model species for this project as their skin is
thin and not obstructed by fur, and they are a taxa of interest in conservation programs where
AVT may be employed for assisted breeding. The objectives of this study were to 1) observe the
real-time pathways taken by AVT-QDs following intraperitoneal injection and intranasal
administration, and 2) determine in which tissues bioaccumulation of AVT-QD occurs following
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IN and IP delivery. We hypothesize that route of administration will show differences in AVTQD movement and subsequent aggregation that may affect AVT efficacy.
Materials and methods
All animal populations were housed and maintained in accordance with Mississippi State
University IACUC protocols (IACUC #16-406 and IACUC #19-345).
Study animals
In this study, sexually mature male toads (Anaxyrus fowleri) were collected during the
breeding seasons of April-July of 2016-2017 (Fish and Wildlife Service Permit #0728161) and
March-April 2018 (FWS Permit #0501181) in Oktibbeha County, Mississippi (USA). Sexual
maturity was determined by the presence of dark patches beneath the chin, nuptial pads on the
thumbs, and size with the average weight of males was 24.0 ± 0.8 grams. Male toads were
housed in polycarbonate tanks (30cm L x 46cm W x 66cm H) with substrate composed of cocoa
fiber and soil cultured with springtails (Collembola). Tank accoutrements included terra cotta
pots and PVC piping as shelter options. A rotated diet of crickets, Dubia roaches, and
mealworms was fed three times a week. All insects were gut-loaded with vitamin supplements
including vitamin A (Repashy Ventures Inc., CA, USA) and dusted with calcium supplement
powder (Reptivite© calcium powder, ZooMed Laboratories, Inc., Costa Mesa, CA, USA) prior
to feeding. Water was provided ad libitum. Laboratories where animals were housed were
maintained at 23 ± 2 °C and kept on a the natural day/night cycle of Oktibbeha County where the
animals were collected. In experiments involving euthanasia, males were euthanized following
experiments using an 4g/L of ethyl 3-aminobenzoate methanesulfonate (MS-222; Sigma-Aldrich
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E10521) for one hour. In non-fatal experiments, toads were maintained in Mississippi State
University collections until natural death.
Experiment 1: Determination of biological effects of AVT, QD, and AVT-QDs
Male toads were administered two types of quantum dot nanoparticles: an unconjugated
control (QD, QTracker 655, Fisher Scientific) or an arginine-vasotocin conjugate (AVT-QD;
Fisher Scientific). QDs measured between 15-20 nM. Conjugated QDs consisted of AVT
(Sigma-Aldrich product #V0130) to QD-655 (excitation/emission: 455/655 nm) (Fisher
Scientific) in a solution of phosphate buffered saline (PBS) Conjugations were performed as a
custom commission by Invitrogen (Fisher Scientific) with an approximate ratio of 0.15 μg AVT /
0.3 nM QDs /μl hormone to Qdot 655 conjugate. AVT alone (25.5 µg) was also administered for
comparison. In the control, unconjugated QD, and AVT-QD groups, 5 male toads were treated
while in the AVT alone group, 3 male toads were treated (Table 4).
Hormone treatments were given as either intranasal administration (IN) or intraperitoneal
injection (IP). Prior to treatments, males were anesthetized using 4 g MS-222 in 1 liter of water
for approximately 30 minutes. IN administrations were performed by suspending males upright
while solutions were slowly pipetted into the nares with a sterile pipette tip in a vehicle of 170 µl
of PBS. For IP injections, males were given an injection of treatment in a 170 µl PBS vehicle
into the abdomen.
To test the efficacy of the AVT when conjugated to QDs, and determine whether or not
the AVT-QDs caused water uptake and retention, or calling, male toads (n=3/treatment) were
recorded for sound and weighed in response to treatment. Treatments of either AVT (25.5 µg),
50 nM of unconjugated QDs, or 50nM AVT-QDs (approximately 25.5 μg AVT), were given by
IN or IP administration routes and toads were subsequently weighed every two hours for 24
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hours. Weight gain due to water uptake and retention over time was compared between
treatments. Calling behaviors were recorded using Windows Audio Recorder.
Experiment 2: In-vivo tracking of QDs and AVT-QDs
Following treatment, anesthetized males were placed into the In-Vivo-Imaging System
(IVIS; Perkin-Elmer) for fluorescence intensity imaging. A baseline image was taken prior to
QD treatment. Males were imaged immediately after treatment (0 hour) and subsequently at the
0.5 hour, 1 hour, 3 hour, 5 hour, 12 hour, and 24 hour time points. Toads were imaged on both
the ventral and dorsal side using the Spectral Unmixing function on the IVIS Living Image
Software under the QD fluorescence setting at excitement wavelengths of between 485 and 525
nm. Following imaging, toads were euthanized with an overdose of MS-222 at a 250mg/kg BW
in a water bath for approximately one hour (Florida Atlantic University protocol).
Experiment 3: Bioaccumulation of QDs and AVT-QDs
In preparation of histological analysis, toads or excised organs were stored in
formaldehyde for 48 hours, and then placed into a decalcifying solution (Kristensen’s solution)
for 72 hours. In the initial trial, toads were breadloaf sectioned (Figure 44) and placed into
paraffin blocks to determine QD presence throughout all of the body. Only the brain, heart,
kidneys, testes, liver, and a section of stomach were removed from males for QD
bioaccumulation analysis. All histological samples were sectioned and mounted onto slides. Deparaffinizing was completed following two 100% xylenes washes followed by washes in
decreasing concentrations of ethanol in duplicate. A fluorescent DAPI mounting media
(VECTASHIELD) was used to mount slide coverslips. Slides were then incubated at
approximately 4 C overnight and then imaged using a Nikon Eclipse 80i. Quantum dot signal
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was determined at an excitation wavelength of 455 nm and emission at 655 nm, and DAPI was
analyzed at 480nm. Images were taken using NIS Elements Version 4.1 (NIKON Instruments
Inc.). Five images were taken per slide at 20x magnification.

Figure 44

Diagram of sectioned regions of toads for breadloaf imaging

Spectral analysis was performed in FIJI (FijiisjustImageJ; NIH). From each slide, five
measurements of fluorescence intensity were taken from different regions. Background signal
was subtracted from each measurement, and then subsequently averaged across each organ. Data
were then organized and graphed in Microsoft Excel. Quantified spectral analysis was performed
for the the heart, liver, kidney, testes, and GI tract. These were compared across hours 1, 12, and
24. Average fluorescence accumulation in brain sections were compared between IP and IN
treatment groups at 24-hour time points only.
Statistical analysis
All data were tested for normality and homogeneity of variance using a Shapiro-Wilkes
test and Levene’s test, respectively, prior to analysis. All statistical tests were all performed
using SAS Version 9.4 (Cary, North Carolina), and statistical significance was set at p ≤ 0.05.
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All values were expressed as mean ± SEM. Comparisons of 1 hour time-points were included
only following intranasal administration of AVT-QDs, as signal was not detected at 1 hour postIP injection or at any time for unconjugated QD treatments.
Physiological data were run as a repeated measures ANOVA to investigate the water retention
rates following treatments (PBS, AVT, QDs, and AVT-QDs) in repeated collections over 24
hours.
Comparisons of fluorescence intensity across organs and treatment route following both
AVT-QD and QD treatment were run as a two way ANOVA. Analyses of fluorescence
intensity of AVT-QDs compared to QDs when delivered by IP injection were performed for
each organ as either a Student’s t-Test or a Mann-Whitney U test as determined by preliminary
normality tests. The same analysis of fluorescence intensity for the heart, liver, kidney, GI tract,
interrenal glands, and testes at 24 hours post- treatment was performed between IN and IP routes
of quantum dot administration. Time points of 12 hours and 24 hours were compared using
Student’s t-test or Mann-Whitney U between organs, and for IP and IN delivery.
An additional two-way ANOVA was run to determine differences in organ aggregation
of AVT-QD signal at 1 hour, 12 hours, and 24 hours post-IP treatment. A Tukey’s post-hoc
analysis was performed for differences in means across organs and routes. Comparisons between
IP injection of AVT-QDs at 12 hours post-treatment were run as a Mann-Whitney U test, as
signal was detected only within the GI tract in this delivery mode.
Results
Experiment 1: Determination of physiological effects of AVT-QDs
Toads receiving treatments of AVT-QDs gained significantly more water weight (p <
0.05) than those receiving just QDs. Toads receiving AVT-QDs by IN administration gained an
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average of 0.13 g in water retention weight, while those treated with unconjugated QDs did not
gain weight, but instead lost an average of 0.5 g/toad. IP injection resulted in a higher weight
gain (3.94 ± 0.32 g/toad) following QD-AVT than IN delivery of AVT-QD (0.29 ± 0.12 g/toad).
The highest water retention weight gain occurred in groups given AVT alone, with an average
weight gain of 3.57 ± 0.41 g/toad following IN administration and 15.59 ± 0.75 g/toad following
IP injection (Table 4). Calling was observed from 1 male in the group receiving AVT by IP
injection, but quantification of calling was not recorded.
Weight gain peaked at different times across both administration routes and treatments.
Following IN delivery of AVT alone, water retention peaked much earlier at 2 hours posttreatment. Water retention weight following IP injection of AVT alone reached a maximum at 8
hours post-injection. A similar trend was seen in AVT-QD groups wherein IN delivery resulted
in a maximum water retention weight at 2 hours while water retention weight peaked at 6 hours
following IP delivery (Figure 45).
Table 4

Water retention following IN and IP administration of control (PBS), unconjugated
quantum dots (QD), arginine-vasotocin conjugated quantum dots (AVT-QD) and
arginine vasotocin alone (AVT).
Average Water Retention (g)
Treatment Male (n)
IN
IP
Control
5/trt
1.87 ± 0.32 0.97 ± 0.14
QD
5/trt
0.13 ± 0.17 0.75 ± 0.20
AVT-QD
5/trt
0.29 ± 0.12 3.94 ± 0.32
AVT
3/trt
3.57 ± 0.41 15.59 ± 0.75
a

a

a

b

c

d

de

187

f

Figure 45

Average water retention across treatments. Weights collected every two hours for
24 hours. Data shown as mean ± SEM.

Experiment 2: In-vivo tracking of AVT-conjugated QDs
IVIS imaging revealed that fluorescent signal from both AVT-QDs and unconjugated
QDs is visible in route-dependent locations throughout the body of treated toads. IN
administered QDs show fluorescent signal initially at the nares, and then migrate to either the
tympanic membrane or down the throat, indicating that a majority of the AVT-QDs are likely
swallowed, or migrate too deep for visible detection (Figures 46, 47, and 49). It is possible that
some AVT-QDs make it into the brain and bloodstream or spinal fluid. This migration is
consistent with anuran anatomy in which the external nares open into the internal nares at the
roof of the mouth, providing a direct pathway for fluid flow to both the throat and to the ears
through a cavity opening that plays a role in calling behavior. AVT-QDs administered by IP
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injection appeared to radiate from the site of injection and circulate throughout the abdomen
(Figures 46, 48, and 49). At hours 12 and 24 post-treatment, fluorescent signal could be
observed in the renal arteries, indicating that the AVT-QDs had entered the bloodstream.

Figure 46

IVIS imaging of AVT-conjugated quantum dot visualization over time following
(A) IN administration, and (B) IP injection.

Figure 47

IVIS imaging comparison of quantum dot movement over time following IN
administration of (A) AVT-QDs, and (B) unconjugated QDs.
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Figure 48

IVIS imaging comparison of quantum dot movement over time following IP
administration of (A) AVT-QDs, and (B) unconjugated QDs.

Figure 49

Dorsal view of QD AVT IVIS signal at 1 hour and 24 hours after IN and IP
administration.
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Experiment 3: Bioaccumulation of AVT-conjugated QDs
Fluorescence imaging revealed AVT-Qdot signal following nasal administration was
localized within the nare, mouth, esophagus, GI tract, lung, kidney, and testes at 1 hour posttreatment. This is consistent with the fluorescence signal visualized using the IVIS system which
suggests that nasally-administered hormone-QDs are largely swallowed.
Across all organs and both treatment groups following treatment with AVT-QDs, the kidney
exhibited the highest fluorescence intensity (p = 0.0003; F = 5.61). Across all time points and
organs, intraperitoneal injection exhibited a higher average fluorescence intensity (p = 0.033; F =
4.61). There was no difference (p = 0.865; F = 0.24) found between organs following
unconjugated QD treatment, and no fluorescence signal was detected within sectioned organs
following IN administration of unconjugated QDs.
Between unconjugated and AVT-QDs, only the heart, GI tract, and kidney demonstrated
QD signal from both treatments. While fluorescence intensity within the GI tract was not
signicantly different (p = 0.0824; t = 1.78), AVT-QDs exhibited a higher fluorescence intensity
(p < 0.01) than unconjugated QDs within the heart and kidney.
There were significant differences between routes of administration of AVT-QDs over
time. Following intranasal administration, the kidney exhibited greater fluorescence intensity
than the GI tract at both 1 hour and 24 hours post-treatment than at 12 hours post-treatment (p <
0.01; F = 15.96). In organs treated intraperitoneally, there were several more differences between
organs. Fluroescence intensity was significantly higher (p < 0.01) within the testes, kidney, GI
tract, and heart at 24 hours post-treatment than at 12 hours post-treatment. There was no
significant difference in fluorescence intensity between the liver and interrenal gland (p > 0.05).
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There was no fluorescence signal detected at 1 hour post-treatment of intraperitoneal
AVT-QDs. Between routes at 12 hours post-treatment, intraperitoneal injection resulted in a
significantly higher (p = 0.0069; Chi-Square = 7.3007) fluorescence intensity than intranasal
administration within the only organ in which both routes resulted in aggregation: the GI tract.
Between the two routes at 24 hours post-treatment, there were no significant differences in
fluorescence intensity within any organs (p > 0.05).
While QD-AVT signal was found to accumulate in the brain, brain sections were only
acquired for time 24 and therefore compared between routes at 24-hours. We found that QD
signal was higher (7.6 ± 6.8 x 10 ) in IP QD-AVT sections compared to IN sections (1.67 ±
6

1.19x 10 ), though this result was not significant (p = 0.9168; chi-square = 0.0109). No
6

fluorescent signal was observed in the control group organs or unconjugated QDs.
Table 5

Quantum dot concentrations and dosage volumes by treatment and route.
Treatments included control (PBS), unconjugated quantum dots (QD Alone),
vasotocin-conjugated quantum dots (QD AVT) and vasotocin alone (AVT).
TRT Group IN IP AVT (µg) Vol. (µl)
Control

3

0

0

170

QD Alone

3

3

0

170

QD AVT

3

1

25.5

170

AVT

3

3

25.5

170
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Figure 50

AVT-conjugated quantum dot bioaccumulation across organs at 1 hour, 12 hours,
and 24 hours post intranasal administration. Quantum dots visualized in red with
DAPI blue staining.

Figure 51

AVT-conjugated quantum dot bioaccumulation across organs at 1 hour, 12 hours,
and 24 hours post intraperitoneal injection. Quantum dots visualized in red with
DAPI blue staining.
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Figure 52

Fluorescence intensity across organs at 1 hour, 12 hours, and 24 hours of
accumulation following intraperitoneal injection. Data are shown as mean ± SEM.
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Figure 53

Fluorescence intensity across organs at 1 hour, 12 hours, and 24 hours of
accumulation following intranasal administration. There was no signal detected
from nasally-administered unconjugated QDs. Data are shown as mean ± SEM.
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Figure 54

AVT-conjugated quantum dots bioaccumulated in sections of a) the interrenal
gland, b) the kidney, and c) the testes at 12 hours post intraperitoneal injection.
Images on right, from top to bottom, were taken from Anatomy of the Human Body
(Gray, H. 1918), FertilityPedia, and Notes on Zoology (Bhavya, S).
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Discussion
Determination of biological effects of AVT-conjugated QDs
In this study, we compared the physiological effects and fluorescence movemen and
bioaccumulation of AVT-conjugated QDs within a male toad model. Determining the
physiological effects of conjugated QDs, if any, was necessary prior fluorescence imaging to
provide evidence of successful AVT-QD conjugations. Toads were therefore treated with a
control, unconjugated QDs, AVT-conjugated QDs, and a concentration of AVT comparable to
the AVT-QD conjugations. Across treatments, AVT exhibited the highest weight gain.
In the previous chapter, it was found that IP injection resulted in greater water retention
in male toads treated with AVT than in IN-treated males. The same result was seen here, as both
AVT and AVT-QD treatments resulted in greater water retention following IP treatment than IN.
Interestingly, there was a much greater difference in weight gain following AVT only treatments
compared to AVT-QDs than AVT-QDs compared to unconjugated QDs. The exact concentration
of AVT conjugated to QDs was not able to be determined, though conjugations were considered
to have been approximately 0.3 µg/µl, making it 25.5 µg for this study. This may indicate that
the conjugations impeded the binding capabilities by obstruction of the binding sites of AVT
molecules.
In-vivo tracking of AVT-conjugated QDs
In order to follow the fluorescent signal of both conjugated and unconjugated quantum
dot nanoparticles through toad bodies following both intraperitoneal and inranasal treatment,
animals were imaged using an in-vivo imaging system (IVIS). Following IN administration,
fluorescent was detected along the top of the skull, as well as the tympanum of the ear and the
throat after 1 hour. At 12 hours, signal was found in the stomach but was no longer observable at
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24 hours. This appears to indicate that QDs, when administered intranasally, are largely
swallowed and follow the GI tract for uptake and excretion. There is a direct opening of the
tympanum into the mouth and throat of anuran species, which supports the visualization of QDs
moving from the nares to the tympanum. Similarly, toads have both internal and external nares.
The internal nares open into the mouth, which is likely why QD signal migrate from the nares to
the throat to the stomach. Unconjugated QDs followed a similar route, but were observed in the
stomach as soon as 1 hour post-administration. This may indicate that they are more swiftly
passed through the various stages of the GI tract than larger, conjugated QDs. From the GI tract,
hormones and QDs could easily enter the bloodstream for peripheral effects on the gonads or
other systemic areas.
QDs that were injected intraperitoneally, on the other hand, appear to disperse throughout
the abdomen. By 12 hours, fluorescence signal appeared within the renal arteries. This indicates
that QDs likely diffuse into the bloodstream following intraperitoneal injection and subsequently
circulate throughout the body. Prominent signal as still observed at 24 hours post-treatment,
which is likely due to QD aggregation in various organs following transfer through the
bloodstream.
While the routes show distinct differences in dispersal and QD movement, there is not
much distinction between treatment groups. In order to determine more specificity of QD
hormone movement, we took histological samples from treated toads to explore areas of
bioaccumulation.
Bioaccumulation of AVT-conjugated QDs
Across toads and routes, histological analysis revealed accumulation of AVT-QDs within
the brain, heart, liver, GI tract, kidney, interrenal gland, and testes. All of these are areas that
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have been reported to contain AVT receptors. Due to the potential pathways from the nares to
the brain in amphibians, it was expected that AVT-QDs, when administered nasally, would reach
the brain. However, while AVT-QDs were detected following nasal administration, there was
greater presence following IP injection. Signal was only detected within the brain after 24 hours
post-treatment. Taken together, it may indicate that progression of QDs into the brain is achieved
by QDs entering the bloodstream and filtering back through to the brain as opposed to QDs
reaching the brain through a direct pathway from the nares. Travel into the bloodstream from two
routes of administration would require more time to reach the brain, which is supported by the
presence of QDs within the brain being observed at only 24 hours post-exposure.
The presence of AVT-QDs within the heart was also expected. Le Mevel et al. 1993
found that, in trout, exogenous AVT increases both diastolic and systolic blood pressure as well
as bradycardia. They speculated that these effects were likely from action by V1 type receptors.
While both AVT-QDs and unconjugated QDs were found within the heart, there was a
significantly greater resulting fluorescence intensity from AVT-QDs than from unconjugated
QDs. Bioaccumulation of AVT-QDs was also detected in the liver in histological sections. In
mammals, vasopressin stimulates glycogenolysis in the liver, and in amphibians, AVT performs
a similar function (Ade, Segner and Hanke 1995). Janssens et al. 1985 found that exogenous
AVT increases the breakdown of glycogen and glucose release in axolotl liver sections in-vitro.
Therefore, the presence of AVT-QDs within the liver could be a result of hormone binding.
Literature of the effects of AVT on the GI tract are limited compared to the other organs
discussed here. Robinzon et al. 1988 found high concentrations of immunoreactive AVT in
chicken GI tracts. Considering the localization of QDs in toad GI tracts in IP vs. IN routes of
administration, it is more likely that AVT-QDs being passively absorbed rather than binding in a
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particular area of action. This is further supported by a study by Hunt et al. (2020) which
reported rapid uptake of silver nanoparticles within and subsequent diffusion from the small
intestine following oral administration.
Of all of the organs discussed here, kidney was the organ most expected to demonstrate
AVT-QD binding. Receptors for AVT have been found in the kidneys of numerous amphibian
species where it decreases filtration in the glomerulus and increases water reabsorption in the
renal tubules. These antidiuretic effects lead to water retention (Henderson et al. 1972; Pang et
al. 1982; Suzuki et al year). Additionally, AVT-QDs were observed in collecting ducts, which is
where AVT receptors for AQP expression and subsequent water absorption is mediated.
However, cadmium QDs, such as those reported here, have been reported to aggregate within the
kidney and remain there for up to 30 days (Liang et al. 2016). The increase of water uptake
following AVT-QD administration in experiment 1, however, support the hypothesis that AVTQDs within the kidneys are binding to receptors to stimulate this uptake.
While the kidney was expected to be a site for AVT-QD localization, its adjacent organ,
the interrenal gland, was a surpise. The interrenal glands are the equivalent of mammalian
adrenal glands. The adrenal and interrenal glands are glands adjacent to the kidneys which
produce a variety of steroid hormones such as aldosterone and corticosterone (Hanke 1978;
Milano and Accordi 1983; Gupta and Hanke 1994). Unlike mammalian adrenal glands,
amphibian interrenal glands more closely interact with the kidney due to its proximity and shared
blood supply. From the dorsal aorta, both the interrenal gland and kidneys receive blood which
subsequently exits through the renal veins (Hanke 1978). In the interrenal gland, AVT is found
in chromaffin cells and is likely released with catecholamines following stressful stimuli
(Larcher et al. 1989 and Lesouhaitier et al. 1995). In-vitro, AVT has also been shown to
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stimulate corticosterone and aldosterone secretion from the interrenal gland (Larcher et al. 1989
Lesouhaitier et al. 1995). Larcher et al. 1992 found that the interrenal AVT receptors are those of
the V2 type. As seen in the IVIS images in figure 4, AVT QDs appear to move through the renal
veins, thus having passed through both the interrenal gland and kidneys. This is likely the reason
why both the kidney and interrenal gland contained such high fluorescence intensity from AVTQD aggregates. Histological analysis appeared to reveal aggregation of AVT-QDs within the
chromaffin cells of the interrenal gland (Fig. 54a), which is consistent with the binding sites of
AVT reported by Larcher et al. (1989).
Maggi et al. 1989 found that receptors for vasopressin, a homolog for vasotocin, have
been identified in the cloned murine Leydig cells of the testes and identified these receptors as
the V1 type. Meidan and Hsueh (1985) also identified V1 vasopressin receptors in interstitial
Leydig cells in rat testes and that testicular AVP inhibits steroidogenesis. They did not find high
levels of binding on cells within the seminiferous tubules. This is consistent with the results
presented here in figure 12b, which shows AVT-QDs appearing to bind to Leydig cells
surrounding the seminiferous tubules, but not within the tubules themselves. Taken together,
these data indicate that AVT-QDs are found within areas containing traditionally reported AVT
receptors, though precise binding could not be determined.
The aggregation of QDs was more pronounced following IP injection, and greater
fluorescence intensity was observed at 24 hours post-treatment across all organs following IP
injection. Coupled with IVIS imaging demonstrating QDs entering the bloodstream, it is likely
that over 24 hours QDs circulate through the body through the bloodstream to enter and
aggregate within numerous organs. Following IN administration, however, hour 1 post-treatment
resulted in higher fluorescence intensity compared to 24 hours post-treatment. This was
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especially pronounced in the GI tract. As mentioned, IVIS and histological imaging support the
hypothesis that IN-administered substances are largely swallowed. This results in a greater
aggregation of QDs within the GI tract earlier, and over time, these QDs are filtered out of the
tract and diffuse into the bloodstream for circulation.
The largest limitation of the current study was that the conjugations of AVT
concentration to quantum dot nanoparticles could not be determined. While many of the
locations of bioaccumulation of AVT-QDs are consistent with receptor locations in previous
literature, the lack of this definitive synthesis concentrations should be considered when
interpreting the results presented here. In addition, images were taken and analyzed at 20x. This
low magnification prevented specific imaging cellular imaging. Therefore, it possible that the
observed aggregation within organs, despite containing receptors, could be the result of passive
integration of QDs from the bloodstream rather than binding. However, it should be noted that
AVT-QDs were found at significantly greater aggregated intensities and number of organs than
unconjugated QDs, which supports possible binding. Finally, exact localization in the brain was
impossible due to inconsistent brain sectioning which made it impossible to determine
orientation and complete anatomy of brains in this study.
Conclusions
For this study, we used quantum dot nanoparticles (QDs) conjugated to AVT
administered intranasally in order to investigate its pathways in the male anuran Anaxyrus
fowleri. The presence and migration of quantum dot fluorescent signal was clearly visualized,
despite skin tissue depth. In-vivo imaging revealed that intranasal administration appeared to
flow from the nares into the throat, to be swallowed and absorbed by the GI tract. Intraperitoneal
injection, alnternatively, dispersed throughout the abdomen and slowly entered the blood stream
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to reach numerous organs such as the kidneys, interrenal glands, and testes. This was confirmed
by histological analysis. While fluorescence imaging supports the location of AVT receptors in
previous studies, the physiological response of water retention was following AVT-QD
administration by both routes was significantly less than comparable treatments of AVT alone.
These results suggest that either conjugations were much lower than assumed, or that
conjugations impacted binding capabilities and reduced the effects of AVT. However, while
physiological effects were lower in AVT-QD groups, the organ bioaccumulation is compelling
as an indicator of receptor binding, particularly in the Leydig cells of the testes and the
chromaffin cells within the interrenal glands. In addition, the lack of similar accumulation for
unconjugated QDs further supports the potential of binding. Overall, this study demonstrates the
routes taken by AVT-QDs following two routes of administration and their respective organ
accumulation and possibly binding. These results can be used to inform researchers of best
routes for administration of AVT, and possibly other hormones, and as support for the use of
quantum dots as a tool for in-vivo imaging in living systems.
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CHAPTER VIII
CONCLUDING REMARKS
In 2021, the loss of amphibian species has continued to show a rapid decline. As threats
rise, so, to, do new methods of assisted reproduction in amphibian species. However, it is
important that due diligence is performed to ensure that methods are successful not just in the
short term, but in the long term as well in regards to animal health. In this dissertation, I have
shown that a new, minimally invasive method of hormone administration, intranasal delivery, is
capable of affecting the physiology of anuran amphibians. Intranasal administration of
gonadotropin-releasing hormone (GnRHa), for example, stimulates sperm production and
release. Intranasal delivery of arginine vasotocin (AVT) however, while effective at eliciting a
physiological response, results in excess water retention. This effect is more exaggerated
following intraperitoneal injection, indicating that there are clear differences in the efficacy of
hormones by the route of administration.
The in-vivo imaging reported here makes this clear: these two delivery routes, traditional
IP and novel IN, both follow different pathways throughout the body. These different pathways
affect the body in different or more exaggerated ways, which is an important key aspect in
tailoring our assisted reproductive techniques for each hormone in each species or sex. While invivo imaging and the use of quantum dot nanoparticles in living systems has previously
proceeded at a cautious rate, it is my hope that the success in using live imaging to differentiate
hormone pathways, and the lack of negative physical effect, reported here will help push this
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imaging forward. It is more important now than ever to be cognizant of the effects technological
advances have on the species we share our world with, and to be sure we temper progress with
ecological understandin.
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APPENDIX A
COMPARISON OF INTRANASAL GNRHA ADMINISTRATION IN A RANID SPECIES
(LITHOBATES CHIRICAHUENSIS) AND A BUFONID SPECIES (ANAXYRUS FOWLERI)
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Materials and Methods
An experiment was conducted to compare the efficacy of intranasal GnRHa in eliciting
sperm in a bufonid species (Anaxyrus fowleri) and a ranid species (Lithobates chiricahuensis).
Male were given treatments of 10 µg GnRHa (LHRHa; Sigma-Aldrich) in a 10 µl PBS solution.
Hormones were administered into the nares via a pipette. Males were suspended until solution
drained. Spermic urine samples were taken 0.5, 1, 2, and 3 hrs post-administration and samples
were analyzed for forward progressive motility, total motility and concentration to be compared
between families (ranidae and bufonidae).
Results
Results
While forward progressive motility (FPM) did not differ (p = 0.119; t = 1.188) between
IP and IN treatments, nasal administration resulted in significantly higher total percentages of
both motile sperm (p = 0.049; t = 1.669) and concentration of sperm/mL (p = 0.006; t = 2.572)
than intraperitoneal injection (Table 6).

Across treatments, route (IP vs. IN) was not significantly different for forward
progressive motility (FPM) or total motility over time. However, the effects of time were
significant (p = 0.0023; F = 3.43) for FPM with 7 hours post-treatment resulting in higher
percentrages of forward progressing sperm than hours 2 and 3 (Figure 57).
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Table 6

Average weights and sperm parameters between ranid and bufonid species
Species

Responders
Avg. Weight n#
(%)

Latency
(hours)

Avg. T. Avg. Conc.
6
Mot
(x10 )
(%)

L. chiricahuensis

29.4 ± 2.9

13

85

0.9 ± 0.07

56 ± 4 3.51 ± 0.87*

A. fowleri

24.7 ± 1.6

15

93

2.8 ± 0.5*

49 ± 7

Figure 55

0.52 ± 0.15

Demonstration of nasal administration in a) the ranid L. chiricahuensis and b) the
bufonid A. fowleri
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Figure 56

Distribution of sperm motility between a bufonid species (blue) and a ranid species
(orange)

Figure 57

Concentration of sperm/mL distributions between a bufonid species (blue) and ranid
species (orange)
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Figure 58

Percentage of sperm total motility between a bufonid and ranid over time
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Figure 59

Concentrations of sperm/mL over time between a bufonid and ranid
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APPENDIX B
COMPARISON OF INTRANASAL GNRHA ADMINISTRATION TO TRADITIONAL
INTRAPERITONEAL HCG AND GNRHA COCKTAIL INJECTIONS IN
LITHOBATES CHIRICHAUENSIS

214

Materials and Methods
An experiment was conducted in male Chiricahua leopard frogs (Lithobates
chiricahuensis) to compare novel nasal administration of 10 µg GnRHa to tradition
intraperitoneal injections of a cocktail of hCG and GnRHa. Male L. chiricahuensis were injected
intraperitoneally with either 200 - 300 IU hCG + 15 µg GnRHa or GnRH alone. Treatments of
10 µg GnRHa (LHRHa; Sigma-Aldrich) in 10 µl PBS solution administered into nare via pipette.
Males were suspended until solution drained. Spermic urine samples were taken 0.5, 1, 2, and 3
hrs post-administration and samples were analyzed for forward progressive motility, total
motility and concentration to be compared between treatments.
Table 7

Average weight, percentage of responders, motility and concentration between IP
and IN treatments
6

Route

Avg. Weight

Responders (%)

Avg. T. Mot

Avg. Conc. (x10 )

IN

29.4 ± 2.9

85

56 ± 4

3.51 ± 0.87

IP

34.3 ± 2.4

83

58 ± 3

2.8 ± 0.4
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Figure 60

Sperm motility distributions (A) and concentration of sperm/mL (B) between IP and
IN routes in L. chiricahuensis
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Figure 61

Average percentage of sperm motility over time
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Figure 62

Average concentration of sperm/mL over time between IP and IN routes of
hormone administration
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APPENDIX C
EFFECTS OF WILD, SEMI-CAPTIVE, AND CAPTIVE MANAGEMENT ON MALE
REPRODUCTIVE TRAITS FROM THE THREATENED CHIRICAHUA
LEOPARD FROG (LITHOBATES CHIRICAHUENSIS)
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Introduction
The Chiricahua leopard frog, Lithobates chiricahuensis, is a federally listed ranid species
endemic to the southwestern United States and parts of Mexico which breeds from March
through September in small ponds, cienagas and streams (Stebbins, 2003). Because of their
dependence on water in arid environments, factors such as water pollution, invasive aquatic
species, and drought have had a substantial deleterious effect on wild populations (Rosen,
Schwalbe, Parizek, Holm, & Lowe, 1994). The accessibility to viable water sources for breeding
has been further hampered by the reduction of historical habitat for farming, leaving streams and
marshes polluted, destroyed, or converted to cattle ponds (Southwest Endangered Species Act
Team 2008). The biggest threat to L. chiricahuensis in New Mexico is chytridiomycosis, a
disease caused by the fungal pathogen Batrachochytrium dendrobatidis (Bd), which has a
reported mortality rate of 90-100% in various anuran species (Longcore, Pessier, & Nichols,
1999); (Berger, Marantelli, Skerratt, & Speare, 2005). Outbreaks of chytridiomycosis have been
found in several populations of wild L. chiricahuensis and have contributed heavily to the
species’ decline (Berger, Speare, & Hyatt, 1999); (Sigafus, Schwalbe, Hossack, & Muths, 2014);
(Christman and Jennings 2018). In an attempt to salvage the remaining habitat and circumvent
the effects of Bd on wild populations, the federal government issued a recommendation for
protection and captive breeding efforts following federal listing of the species in 2002 by the
U.S. Fish and Wildlife Department under the Endangered Species Act (Fish and Wildlife Service
2005); Brennen and Holycross 2009). Unfortunately, continuing loss of critical habitat, spread of
invasive species, and the continued threat of chytridiomycosis impede the re-establishment of the
species into historic habitats (Southwest Endangered Species Act Team 2009).
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As a way to increase populations of L. chiricahuensis, captive breeding programs have
been established across several institutions including: Turner Enterprise’s Ladder Ranch, the Fort
Worth Zoo, and the Phoenix Zoo. These institutions have spearheaded L. chiricahuensis
conservation efforts through the reintroduction of egg masses, tadpoles, and head-started
metamorphic froglets into native and historic locations across the southwestern United States.
Since 1995, the Phoenix Zoo has released 26 egg masses, 15,562 tadpoles, 11,119 juveniles, and
140 adult frogs (T. Harris, Personal Communication, Sept. 24, 2020) while he Fort Worth Zoo
has released 1600 captive-bred tadpoles since 2015. The Ladder Ranch has released 69 egg
masses, 94,000 tadpoles, and 493 metamorphic froglets from semi-captive breeding events since
2011 (D. Barber, Personal Communication, Sept. 22,2020). Despite the reported reproductive
success, natural breeding of L. chiricahuensis within these programs has been sporadic and far
below targeted reintroduction numbers needed for recovery efforts. In addition, breeding events
are heavily based upon seasonal factors such as spring rains and summer temperature changes ,
limiting both the number of attempted breeding events and subsequent production of offspring.
One strategy for bolstering low reproductive output for amphibian assurance colonies is through
the use of assisted reproductive technologies (ART), such as hormone therapy and in-vitro
fertilization (IVF). For example, increases in gamete production can be achieved through the
application of exogenous hormones such as human chorionic gonadotropin (hCG) or
gonadotropin-releasing hormone (GnRH), which stimulate a natural hormone cascade that results
in enhanced breeding behaviors followed by gamete production and release (A. J. Kouba, Vance,
& Willis, 2009); (A. Kouba et al., 2012); (Vu & Trudeau, 2016). Exogenous hormone treatment
has been successful in a variety of amphibian species such as Anaxyrus baxteri (Browne, Seratt,
Vance, & Kouba, 2006), Atelopus zeteki (Della Togna et al., 2017), Lithobates sevosa (Kouba,
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A.J., Willis, E., Vance, C.K., Hasenstab, S., Reichling, S., Krebs, 2011), Litoria booroolongis
(Silla, McFadden, & Byrne, 2019), Rhaebo guttatus (Hinkson, Baecher, & Poo, 2019), and
several newt species (Guy et al., 2020), but has yet to be applied to L. chiricahuensis.
When establishing breeding recommendations and repopulation efforts for threatened
species, it is important to determine the reproductive potential of animals that have been kept in
captivity for extended periods and how the captive environment may have impacted reproductive
output compared to their wild counterparts. For example, the extent of differences in fecundity
between wild and captive amphibians, and whether lower fecundity in captivity is due to lower
gamete expression and quality. Another concern for reproductive output when moving animals
into captivity for breeding is the risk of premature senescence. Premature or early onset
senescence has been observed most commonly in large, long-lived mammals such as
rhinoceroses and elephants, particularly in females (Hermes, Hildebrandt, & Göritz, 2004);
(Tidière et al., 2016). There have been several studies in various species examining the effects of
captivity on physiological and reproductive parameters; however, the definitions of captivity
have varied widely, creating uncertainty in what specific features of a captive environment affect
physiology. For example, captive conditions for large megafauna are commonly indoor paddocks
linked to outdoor enclosures with exposure to natural environmental cues, but which are limited
in space (Bobe & Labbé, 2010). In comparison, non-farmed fish and herpetofauna are more often
housed in entirely man-made indoor enclosures away from natural environmental cues required
for reproduction. In addition, it is often unclear in published studies whether captive animals
were born in captivity or in the wild (Farquharson, Hogg, & Grueber, 2018). While the issue is
complex and understudied, it has been suggested that lack of frequent breeding events
contributes to poor reproductive fitness (Hermes et al., 2004). Many captive amphibians are
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housed in separated sex-biased groupings and only exposed to opposite-sex conspecifics during
short breeding periods based on recommended pairings. Thus, many animals within captive
collections can go several years without being paired for breeding until their genetic value
becomes of greater import for recruitment or retention. A lack of exposure to social,
physiological, and environmental cues necessary for annual reproductive cyclicity may impact
natural reproductive hormone cascades and gamete development. In the absence of annual
environmental cues, captive animals are at a higher risk of higher reproductive failure, possibly
due to premature senescence. Studying reproductive senescence can be challenging, as captive
animals tend to have longer lifespans compared to their wild counterparts, making it difficult to
determine exactly when natural age-related senescence occurs and whether or not it is impacted
by conditions in captivity (Tidière et al., 2016).
In studies that have differentiated between animals born in captivity and those born in the
wild and taken into captivity, wild-born captive animals have significantly greater reproductive
success as measured by higher gamete quality, more successful breeding events, and more
healthy offspring than those born in captivity, particularly in aquaculture settings (Farquharson et
al., 2018). A direct comparison of gamete quality between captive, semi-captive, and wild
populations of threatened amphibians has not been conducted and would help elucidate whether
low reproductive output in captive amphibian populations is due to suboptimal gamete quality or
quantity compared to their wild counterparts. Furthermore, determining whether male frogs held
in captivity for many years can still produce gametes at a comparable quantity and quality as
their wild counterparts provides assurance that they can be relied upon for breeding efforts
without necessitating frequent capture and replenishment with wild animals.
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Due to the critical importance of bolstering L. chiricahuensis reproductive output in the
captive population to support recovery efforts and poor reproductive performance under current
conditions, it is imperative that hormone therapy strategies be developed for long-term
sustainability management. It is likewise critical to determine whether captivity has a deleterious
effect on gamete quality or quantity in threatened amphibians. Thus, we investigated the effects
of exogenous hormone treatments on male L. chiricahuensis sperm production across three
populations: captive, semi-captive, and wild. The objectives of this study were to determine
whether captive, semi-captive, and wild male L. chiricahuensis, spermiate in response to
hormone treatment, and whether environment affects sperm quantity and quality. Overall, L.
chiricahuensis spermiate in response to exogenous hormone treatment regardless of population
origin and characteristics differ only in quality, not quanitity, providing evidence that captivity
does not significantly impair spermatogenesis in this species.

Materials and Methods
Animals
Captive males were either wild-caught at sexual maturity (n = 8) or born in captivity (n =
2) and housed at the Fort Worth Zoo in Fort Worth, TX in an indoor artificial habitat for at least
one year. Briefly, animals were housed in 66 x 46 x 23 cm polycarbonate tanks set at a tilt to
provide a dry level and an aquatic level. All tanks include hides on the dry portion and artificial
plants in the aquatic side. Water temperature was controlled to mimic the natural environmental
fluctuations across seasons. UV lighting was provided to all tanks via fluorescent bulbs over
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each enclosure. Frogs received a primary diet of crickets four times a week, and an addition of
waxworms and earthworms weekly. Insects were gut-loaded with Repashy Superload with an
additional vitamin supplement of NektonRep and calcium carbonate. Captive males had an
average weight of 35.6 ± 4.1 g and age of 5.4 ± 0.5 years (Table 1). Husbandry guidelines and
research protocols were approved by the Institutional Animal Care and Use Committee (IACUC)
for both the Ladder Ranch and Fort Worth Zoo (#17-H001).
Semi-captive males (n=11) were housed in 2.4 m3 outdoor ranarium equipped with aviary
netting at the Ladder Ranch in Caballo, NM for a minimum of one year. Each enclosure
consisted of a 416 L water tank for breeding with an adjacent land access containing native
vegetation. Housing groups consisted of at least two male conspecifics with two female and diets
were foraged native insects with a supplement of crickets. For sperm collection, males were held
in plastic tubs with cool water inside the ranch building for approximately four to five hours
before being returned to their outdoor enclosures. Male CLFs held under semi-captive conditions
had an average weight of 43.6 ± 1.3 g and average age of 7.2 ± 0.3 years (Table 1).
Wild males (n=25) were collected from several field sites in New Mexico during the
breeding season. Males were located at night, placed in buckets of shallow water obtained from
streams where they were caught, held until morning, and separated into individual plastic tubs
with cool stream water for the duration of sperm collection. Males were held no more than 16
hours from time of capture, with all frogs returned to the locations from which they were
obtained following sperm collection. Wild male frogs averaged 25.9 ± 1.7 g (Table 1). Males
were sexually mature, as determined by the presence of vocal sacs and enlarged thumb pads. All
collections were approved under U.S. Fish and Wildlife permit #TE43754A-2 through the Turner
Endangered Species Fund at the Ladder Ranch.
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Exogenous hormone, sperm collection, and analysis
Sperm collections were conducted during April and May of 2017 and 2018, within the
natural breeding season of L. chiricahuensis. Males from all three population groups (n = 46)
were given a combination of human chorionic gonadotropin (hCG; Millipore Sigma, CG5) and a
gonadotropin-releasing hormone agonist (GnRHa; Millipore Sigma, L1898). All males were
treated with an average of 8.6 ± 0.3 IU hCG/g body weight (BW) and an average of 0.5 ± 0.04
μg/g BW GnRHa in phosphate buffered saline (PBS) delivered intraperitoneally.
A baseline urine sample was taken from each male prior to hormone treatment to
determine the background level of sperm production. No animals were producing spermic urine
prior to hormone administration Spermic urine samples were collected at 1, 2, and 3 hours
following hormone treatment. Urine samples were obtained using a sterile vinyl catheter to drain
the cloacal contents into a petri dish and then analyzed for the presence of sperm. Frogs were
handled for sperm collection no longer than two minutes to reduce handling stress. Sperm
concentration was measured using a hemacytometer (Hausser Scientific #3200) and manual cell
counter. Sperm motility parameters are reported as the percentage of 100 spermatozoa that were
sub-classified as: 1) forward progressively motile (FPM), defined as spermatozoa moving
forward through flagellar movement; 2) motile (M), defined as spermatozoa exhibiting flagellar
movement but not progressing forward; and 3) non-motile (NM), defined as spermatozoa
exhibiting no observable movement. Sperm sample total motility (TM) is the sum of FPM and
M. All sperm samples were analyzed using an Olympus CX43 phase-contrast microscope.
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Statistical analysis
A generalized linear mixed-effects model (GLMM) with fit by restricted maximum
likelihood using the Mixed procedure from SAS (Proc GLIMMIX, Statistical Analysis System v.
9.4; Cary, North Carolina, USA), was used to detect differences among populations (captive,
semi-captive, and wild) in sperm concentration and motility parameters with relation to sperm
collection time points. The GLMM was generated with captive, semi-captive and wild status,
animal weight, years spent under each condition, and collection time points set as the fixed
factors and male ID set as a random effect. We utilized a Poisson distribution with a logarithmic
link for count data (sperm/mL, total sperm) and a logit link for proportional (total motility, FPM)
data. Data are reported as mean ± SEM and were considered significant at α ≤ 0.05.
Data were tested for normality and homogeneity of variance using the Shapiro-Wilkes
test and Levene’s test, respectively. Normal data (sperm/mL) were analyzed using a one-way
ANOVA followed by a Tukey’s range test as a post hoc analysis. Data that did not meet the
criteria for normality (responders, years in captivity, weight, forward progressive motility, total
motility, and total sperm) were analyzed using a Kruskal-Wallis H test followed by Dunn’s
multiple comparison test for specific differences between groups. For the ANOVA and KruskalWallis H test, all percentage data (total motility, forward progressive motility) were arcsine
transformed using Microsoft Excel.
Results
At 1-hour post-hormone treatment, males from each group had begun producing sperm
(Figure 1). Overall, 80%, 100%, and 96% of captive, semi-captive, and wild males, respectively,
produced sperm during the experimental period and there were no significant differences in the
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number of responders across groups (Table 8) or over time (Figure 63). The percent of semicaptive males peaked at 1-hour post treatment, while captive and wild male response to treatment
peaked at 2 hours post-treatment. Sperm production began to decline in frogs from all three
groups at three hours post-treatment. Weights differed significantly only between semi-captive
(43.6 ± 1.3 g) and wild (25.9 ± 1.7 g) males (H = 20.2, df = 2, p < 0.05). Despite differences in
weight between semi-captive and wild males, weight did not contribute to differences in
response to hormone treatment. Furthermore, the number of years spent in captivity, semicaptivity, or the wild did not significantly affect (p > 0.05) any of the measured sperm
parameters.
Captive males demonstrated a sharp peak in sperm concentration one hour post-hormone
treatment followed by a steep decline in concentration after two hours (Figure 64). Wild males
showed a similar peak in sperm concentration (4.28 x 106 sperm/mL) at hour one, followed by
subsequent decline in sperm concentration at hours two (1.92 x 106 sperm/mL) and three (3.02 x
105 sperm/mL). Semi-captive males had a peak sperm concentration (4.29 x 106 sperm/mL) at
hour two post-treatment, which declined by hour three (1.44 x 106 sperm/mL). The peak in total
sperm released from wild males (2.52 x 105 sperm) was released at hour one but declined
substantially by hour two (6.04 x 104 sperm) and hour three (4.39 x 104 sperm). Neither sperm
concentration (sperm/mL) nor total sperm differed significantly differed between groups.
However, while not significant, semi-captive males tended to have higher (H = 4.8, df = 2, p =
0.08) amounts of total sperm compared to wild males.
The percentage of total motile sperm was similar (H = 0.79, df = 2, p > 0.05) across the
three populations and remained high across all time points. Total sperm motility from both
captive (72%) and wild (67%) males peaked at one hour post-treatment while sperm motility in
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samples from semi-captive males (58%) peaked at two hours (Figure 65). At hour three, total
sperm motility from captive males began to decline (51%) from its levels in hour one and two. In
contrast, semi-captive males did not show any decline in total sperm motility over time. Wild
males exhibited a slight decrease in sperm motility at hour two, which subsequently remained
steady through hour three (56%). Sperm quality remained fairly consistent across the three-hour
collection interval. Interestingly, captive males produced significantly less (H = 14.5, df = 2, p <
0.01) sperm with forward progressive motility than either semi-captive or wild males, which
were otherwise similar (p > 0.05). Overall, peak FPM occurred at one hour post-treatment in all
groups (captive = 19%, semi-captive = 38%, and wild = 50%) and subsequently declined for
semi-captive (33%) and wild males (30%) three hours post-treatment while captive males’ sperm
FPM varied from 9 - 13% from hour two to three.
Individual weight affected forward progressive sperm motility (H = 37.2, df = 24, p <
0.05), with males between 30 g and 41 g producing significantly lower average percentages of
forward progressively motile sperm than males either under 30 g and or over 41 g. However,
weight did not correspond to differences in total sperm motility (F = 1.41, df = 24, p > 0.05),
sperm concentration (F = 1.22, df = 22, p > 0.05), or total sperm (F = 0.5, df = 20, p > 0.05).
Furthermore, a generalized linear mixed models analysis determined that there were no
significant interaction effects between individual weight and population on forward progressive
sperm motility (F = 0.4, df = 3, p > 0.05), total motility (F = 0.26, df =3, p > 0.05), sperm/mL (F
= 1.55, df = 4, p > 0.05), or total sperm (F = 1.36, df = 4, p > 0.05). Thus, animal weight,
irrespective of population, was shown to significantly impact forward progressive sperm
motility.
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Table 8

Male L. chiricahuensis physiological and response parameters based on population
groups. Parameters include percentage of responders, forward progressive sperm
motility, total motility, and sperm concentration following intraperitoneal (IP)

Forward
Total
Sperm/mL
Years in Weight Responders Progressive
Population Animals
Motility
6
Captivity
(g)
(%)
Motility
(x10 )
(%)
(%)
3.7 ±
35.6 ±
63.0 ±
a
Captive
10
80
1.7 ± 0.9
a
ab
14.0 ± 3.0
6.0
0.5
4.1
5.2 ±
43.6 ±
Semi57.0 ±
b
11
100
3.4 ± 0.8
a
a
36.0 ± 5.0
Captive
5.0
0.3
1.3
0.0 ±
25.9 ±
60.0 ±
b
Wild
25
96
2.5 ± 0.5
b
b
39.0 ± 3.0
4.0
0.0
1.7

Responders (%)

Captive

Semi-Captive

100
90
80
70
60
50
40
30
20
10
0

Wild

1

2

3

Time (hours)
Figure 63

Percentage of males responding to hormone treatments over time between wild,
semi-captive and captive males
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Figure 64

Average sperm concentration/mL (Panel A) and total sperm collected (Panel B)
across the three population groups, Captive, Semi-Captive, and Wild, over time.
Data are shown as mean ± SEM
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Figure 65

Average total sperm motility (Panel A) and forward progressive sperm (Panel B)
across the three population groups, Captive, Semi-Captive, and Wild, over time.
Data are shown as mean ± SEM.
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Figure 66

Images of population housing locations. A) Captive, The Fort Worth Zoo; B) semicaptive, The Ladder Ranch; and C) wild, New Mexico field site

Discussion
In this study we have shown that captive, semi-captive, and wild male L. chiricahuensis
produce sperm in response to intraperitoneal injection (IP) of the reproductive hormones human
chorionic gonadotropin (HCG) and gonadotropin-releasing hormone (GnRH). This is the first
time that a direct comparison of the efficacy of hormone treatment on reproductive parameters
has been made in this species or across three levels of environmental conditions in a threatened
amphibian. Captive amphibians are often kept in indoor enclosures, away from environmental
cues required for the natural initiation of reproductive hormone cascades, gamete maturation, and
subsequent stimulation of breeding behaviors (A. J. Kouba et al., 2009). In addition, the lack of
232

environmental cues has also been previously cited as a factor in premature senescence in captive
animals (Hermes et al., 2004). In this study, however, we found little negative effect on sperm
parameters among populations.
Nearly all (80%) of the animals classified as “captive” in the current study were
originally wild-born. It has been previously reported that wild-born animals across varying
aquatic taxa are more reproductively successful in captivity than captive-born animals in
aquaculture systems, from breeding behaviors to gamete quality, and this trend was also seen in
conservation and research environments (Farquharson et al., 2018). A study by Araki et al.
(2007) found that subsequent generations of captive-born and reared trout resulted in a 40%
reduction in reproductive success than previous generations. Wild born animals may have
already established epigenetic cyclical patterns in hormone expression due to previous exposure
to environmental factors during development and as wild adults.
The majority of the captive and semi-captive males in this study were caught in the wild
at sexual maturity, and had spent an average of 3.7 and 5.2 years at the Fort Worth Zoo and
Ladder Ranch. We estimated that the average approximate ages of the captive and semi-captive
males in this study were 5.4 and 7.2 years. Based on size and sperm production, wild males were
assumed to be close to sexual maturity at approximately two or three years of age. Because the
exact age of animals in each group, particularly the wild group, was impossible to determine, we
unfortunately cannot definitively compare response by age. However, the lack of significant
differences in the majority of sperm parameters measured in this study despite differences in
approximate ages and time in captivity indicate that captivity does not affect sperm production in
wild-born L. chiricahuensis following hormone treatment and has little effect on the quality of
sperm. Epigenetic modifications in DNA over time in subsequent captive generations of frogs
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may display reproductive abnormalities, which are not currently observed in wild-caught stock
males. Following future generations of captive-born offspring will be valuable to see if longterm absence of environmental factors influences gene expression, which in turn may lead to
reproductive disorders or certain disease states.
Across captive, semi-captive, and wild populations, males responded to treatment at a
rate of 80%, 100%, and 96%, respectively. This is consistent with reports for several other
amphibian species when administered exogenous hormones. For example, Lithobates sevosa
respond to the same treatment of hCG and GnRHa at an average rate of 83% (Kouba, A.J.,
Willis, E., Vance, C.K., Hasenstab, S., Reichling, S., Krebs, 2011). Moreover, in response to
hCG alone, 80% of Anaxyrus baxteri (Browne et al., 2006), between 83%-100% of male Rhaebo
guttatus (Hinkson et al., 2019) and 100% of Litoria booroolongensis (Silla et al., 2019) produced
sperm. When GnRHa has been given alone, the hormone elicited a spermiation response rate of
82% L. booroolongensis (Silla et al., 2019) but only 20% in R. guttatus (Hinkson et al., 2019).
Despite the production of captive and semi-captive offspring, the difficulty remains that
natural breeding attempts of captive L. chiricahuensis are below sustainability levels, are not
reflective of wild fecundity, and do not produce enough animals to establish a successful
reintroduction program. While natural breeding rates in captivity have been low, we report here
that gamete quality does not differ greatly between populations. Interestingly, the only
significant difference found between population status groups was in sperm quality, specifically
forward progressive motility, and it was not a function of individual weight, which is generally
associated with nutritional health. Sperm quality from semi-captive and wild males did not
differ, but captive males produced significantly lower proportions of forward progressive sperm
on average than both semi-captive and wild males. Lower progressive sperm motility would be
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consistent with reports that captivity has a deleterious effect on reproductive parameters such as
gamete quality (Farquharson et al., 2018), but it is surprising that no further differences were
found between population groups. It is therefore possible that captivity may only negatively
impact reproductive behaviors in L. chiricahuensis while gamete production and quality remains
minimally affected. Deleterious effects on the initiation and completion of breeding events have
been reported in many mammals and fish in captive environments (Farquharson et al., 2018).
Differences in exposure of L. chiricahuensis individuals to abiotic and biotic environmental cues
such as weather, barometric pressure, temperature, and diet have likely negatively contributed to
the lower reproductive success in captive animals compared to natural reproduction in wild
animals (Hermes et al., 2004); (Araki et al., 2007).
The effects of captivity on other taxa, primarily large mammals, have been studied.
However, little is known about the effects of captivity on amphibian fecundity. Mimicking
environmental cues and more naturalistic housing is necessary for eliciting natural breeding
behaviors in many captive animals, especially amphibians (A. J. Kouba et al., 2009). Moreover,
when favorable breeding conditions or nutritional needs are not met, anurans may not undergo
proper gametogenesis or attempt to breed in future breeding years (Cayuela et al., 2014). In order
to artificially stimulate reproductive cyclicity in captive amphibians, many zoological institutions
and breeding facilities put their animals through a period of artificial hibernation (Calatayud et
al., 2015). However, this process can pose a risk to animal health and its success is variable with
high risk of mortality (Kouba et al., 2009). In addition, despite the attempted replication of
environmental cues, many species still do not readily or sufficiently reproduce in captivity (e.g.
L. sevosa, or A. zeteki) or breeding attempts are minimally effective, as reported for L.
chiricahuensis. For these species, the use of artificial reproductive technologies (ART) may be
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necessary to reproduce these animals and to bypass the need for environmental cues. There has
been little investigation, however, into how differences in exposure to environmental cues affect
the success rate of ART. Our results indicate there are minimal differences in the quality and
production of gametes between captive, semi-captive, and wild L. chiricahuensis. Although, we
do recognize the limitations of this study as such that we only compared captive founder stock
and understanding these differences over future generations will be valuable to understand the
long-term impacts on reproductive traits. Due to their dwindling populations and low natural
breeding success in captivity, the use of ART in this species will be an important means for
increasing offspring numbers to meet recovery goals as well as transferring genetic material
between institutions for genetic management.
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